var title_f17_11_17584="Basic knee anatomy PI";
var content_f17_11_17584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17584=[""].join("\n");
var outline_f17_11_17584=null;
var title_f17_11_17585="North American yellow jackets";
var content_f17_11_17585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    North American yellow jackets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from American Academy of Allergy and Immunology, Monograph on Insect Allergy, 3rd edition, Levine MI, Lockey RF (Eds), 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17585=[""].join("\n");
var outline_f17_11_17585=null;
var title_f17_11_17586="Sulfasalazine and the 5-aminosalicylates";
var content_f17_11_17586=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/11/17586/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17586/contributors\" id=\"au2816\">",
"       Adam S Cheifetz, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17586/contributors\" id=\"au8358\">",
"       Garret J Cullen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/11/17586/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17586/contributors\" id=\"se6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/11/17586/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17586/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?17/11/17586?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Sulfasalazine (Azulfidine&reg;) and the 5-aminosalicylate drugs (Asacol&reg;, Asacol HD&reg;, Pentasa&reg;, Salofalk&reg;, Dipentum&reg;, Colazal&reg;, Apriso&trade; and Lialda&trade;) are commonly used to treat inflammatory bowel disease. These drugs have anti-inflammatory actions, and they are effective for inducing and maintaining remission in mild to moderate ulcerative colitis. Their efficacy in Crohn&rsquo;s disease is more controversial. Sulfasalazine appears to be effective in controlling active Crohn&rsquo;s colitis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      \"Patient information: Crohn's disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Sulfasalazine is also used to treat rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathic arthritis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"      \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"      \"Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=see_link\">",
"      \"Patient information: Psoriatic arthritis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"      \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In many cases, sulfasalazine or a 5-aminosalicylates must be taken for a long period of time. These medications can have side effects ranging from mild to serious. Many of the mild side effects can be avoided by using lower doses of these drugs; the serious side effects are uncommon or rare, and usually resolve when the medication is stopped. In most cases, the potential benefits of these drugs outweigh the potential risks. Nonetheless, it is important to be aware of the possible side effects before starting treatment.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SULFASALAZINE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      How it works",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sulfasalazine acts locally in the colon to decrease inflammation. It also works throughout the body by inhibiting the formation of a chemical known as prostaglandins. Prostaglandins have several important functions in the body, one of which is control of pain and inflammation.",
"    </p>",
"    <p>",
"     Sulfasalazine is a",
"     <span class=\"nowrap\">",
"      yellow/orange",
"     </span>",
"     color; patients who take it may notice that their urine, tears, and sweat develop an orange tinge, which can stain clothing and contact lenses. Patients should drink plenty of fluids while on therapy and avoid taking the drug on an empty stomach or with antacids. Sulfasalazine can affect folate absorption, so patients should take folic acid (1",
"     <span class=\"nowrap\">",
"      mg/day)",
"     </span>",
"     while taking the medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The major side effects of sulfasalazine can be classified according to how frequently the side effect occurs: commonly, uncommonly, and rarely.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Common side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effects of sulfasalazine are headache, nausea, fever, rash, and reversible infertility in men.",
"    </p>",
"    <p>",
"     Headache is one of the most common complaints, affecting up to one-third of people. Headaches are more likely with higher doses of the drug, and are less likely to occur if the dose is gradually increased. Loss of appetite, nausea, sensitivity to sunlight, and nervousness are also common when starting therapy. Sperm count may be reduced in men who take sulfasalazine, although this is reversible once the drug is stopped.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Uncommon side effect",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inflammation of the pancreas (pancreatitis) is an uncommon side effect of sulfasalazine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Rare side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rare and potentially serious side effects of sulfasalazine (affecting less than 1 percent of people who take this drug) include inflammation of the liver (hepatitis), inflammation of the lung (pneumonitis), a serious skin reaction called Stevens-Johnson syndrome, and destruction of red blood cells (hemolysis).",
"    </p>",
"    <p>",
"     Rarely, there is a decrease in the number of infection fighting white blood cells. In some cases, the bone marrow completely stops producing a specific type of white blood cells, a condition called agranulocytosis. Agranulocytosis usually occurs within two months of starting sulfasalazine and is usually accompanied by a fever and rash. In most people, agranulocytosis resolves within one or two weeks of stopping the medication. Testing to monitor the blood count is recommended in all patients on sulfasalazine. This should be performed every one to two weeks for the first six weeks, monthly for three months, and then every three months.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Sulfasalazine and sulfa allergies",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are allergic to sulfa drugs may have a cross reaction to sulfasalazine and should therefore not take it. If sulfasalazine produces mild allergic symptoms but very effectively controls symptoms, desensitization, a method to reduce or eliminate the allergic reaction, may be attempted. Desensitization uses very small dose of sulfasalazine initially, and gradually increases the dose over time. This strategy is not commonly done for people with inflammatory bowel disease since other treatments are available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Sulfasalazine during pregnancy and breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who wish to become pregnant can continue taking sulfasalazine during pregnancy and while breastfeeding. Sulfasalazine does not increase the risk of any complications of pregnancy or the risk of birth defects. Pregnant patients taking sulfasalazine should increase their folate supplementation to&nbsp;2",
"     <span class=\"nowrap\">",
"      mg/",
"     </span>",
"     day.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      5-AMINOSALICYLATES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      How they work",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sulfasalazine is a molecule that has two components: 5-aminosalicylate (5-ASA) and sulfapyridine. The sulfapyridine is responsible for many of the side effects of sulfasalazine, while the 5-ASA is responsible for many of its beneficial effects in patients with inflammatory bowel disease. This discovery provided a rationale for the development of a drug that contains only the 5-ASA component. Unfortunately, the sulfapyridine component is necessary for the beneficial effects of sulfasalazine in patients with rheumatoid arthritis; thus the 5-ASA drugs are not suitable for those patients.",
"    </p>",
"    <p>",
"     Several formulations of the 5-ASA drugs are available (eg, Asacol&reg;, Asacol HD&reg;, Pentasa&reg;, Dipentum&reg;, Colazal&reg;, Apriso&trade;, and Lialda&trade;). &nbsp;These differ in the specific formulation of 5-ASA, how many times per day they are taken, and the way the pills dissolve in particular parts of the bowel.",
"    </p>",
"    <p>",
"     Overall, the 5-ASA drugs have fewer side effects than sulfasalazine. However, about 20 percent of people who have side effects while taking sulfasalazine will have similar side effects while taking 5-ASA drugs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Common side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effects of the 5-ASA drugs (occurring in more than 10 percent of people) include headache and malaise (a vague feeling of illness), cramps and gas. Watery diarrhea is fairly common with one of the 5-ASA formulations (Dipentum&reg;), occurring in about 15 percent of people.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Uncommon side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Uncommon side effects include hair loss and skin rash; these occur in 1 to 10 percent of people.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Rare side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rare side effects affect less than 1 percent of people, but are potentially serious. They include inflammation of the lung (pneumonitis), inflammation of the tissue surrounding the heart (pericarditis), inflammation of the pancreas (pancreatitis), and a worsening of inflammation of the colon (colitis). Inflammation of the kidney (interstitial nephritis) can also occur, although this can usually be detected with routine blood tests performed at six weeks and at six months after starting a 5-ASA medication, and yearly thereafter.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      5-aminosalicylates during pregnancy and breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;5-ASA drugs appear to be safe during pregnancy and breastfeeding. Studies suggest that they are safe when taken during pregnancy and that women should continue taking these drugs during pregnancy. However, women who take 5-ASA medications should speak to their clinician before trying to conceive. The US Food and Drug Administration has changed Asacol&reg; and Asacol HD&reg; from pregnancy category B to category C because of concerns over the presence of a chemical called dibutyl phthalate (DBP) in the coating of these drugs",
"     <em>",
"      .",
"     </em>",
"     Because the remaining 5-ASA drugs remain pregnancy category B, physicians may consider switching pregnant patients taking Asacol&reg; or Asacol HD&reg; to an alternative 5-ASA.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32163991\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32163998\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164022\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1785007300\">",
"     <span class=\"h2\">",
"      Patient Level Information:",
"     </span>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=see_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164037\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=see_link\">",
"      Anti-tumor necrosis factor therapy in ulcerative colitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=see_link\">",
"      Fertility, pregnancy, and nursing in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Food and Drug Administration",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.fda.gov/\">",
"      www.fda.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Crohn's and Colitis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ccfa.org/\">",
"      www.ccfa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?17/11/17586/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12142779\">",
"     <span class=\"h1\">",
"      ACKNOWLEDGMENT",
"     </span>",
"    </p>",
"    <p>",
"     The authors and editors would like to acknowledge Dr. A Christopher Stevens, who contributed to earlier versions of this topic review.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?17/11/17586?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17586/abstract/1\">",
"      Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2000; :CD000543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17586/abstract/2\">",
"      Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17586/abstract/3\">",
"      Bell CM, Habal FM. Safety of topical 5-aminosalicylic acid in pregnancy. Am J Gastroenterol 1997; 92:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17586/abstract/4\">",
"      Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114:23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f17_11_17586=[""].join("\n");
var outline_f17_11_17586=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SULFASALAZINE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           5-AMINOSALICYLATES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12142779\">",
"           ACKNOWLEDGMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f17_11_17587="Pyoderma gangrenosum - ulcer";
var content_f17_11_17587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This purulent ulcer with a ragged and violaceous border is consistent with pyoderma gangrenosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17587=[""].join("\n");
var outline_f17_11_17587=null;
var title_f17_11_17588="Vaginscopy findings";
var content_f17_11_17588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Commonly observed findings on vaginoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 404px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGUAZcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK434i+UDpj3Go6bbxK8hNpqVw0EFz8o6uP4l6gEEck4yAR2VVNT1CDTYFluROVZtiiGB5mJwT91AT0B7UAebS+JNUj0eefTHfT4LDSEv0tpf8ASPMfzZV2mR/maIhBgjaSCCCOlW9V8RX+nT32l3GqukseoLDDfSmG3UKbZZSsjtGyj5icYQsQMeprrdP8UaZqGtHTLOR5ZTaQ3qSqhMUkcvmbcMO/7snnHUYycgW7nWrG21GKxuJJI55GCKWhfyyx6L5mNm49hnJoA8vttWu9Xu7C/u2C3Fza+H5JBGSF3NeXO7A9DXaeK9Yks9ctLObV49FsntpJxdSKhEsqsoEeXBHQklR8x7EYNaUHirRJ/O2ahGFiiaZndWVSinazKxADBWIB2k4JAOCRUlv4k0mcJi8WIu7x7Z0aFldU3srBwCp2fNg4O3npzQBwb+L9bWfWpGu7CKS2S/8A9AllTzYhErmJ1j2h+QqklmKkNkY4rS1LWvEGkmxtZbmK8udZgWKylS12LDclhuyoJyojcvgnpA3PNdlJq9jHpCanJcKti6q6ykH5gxAXAxkliQAAMkkY61jXnjGzF7pFppyfaptQkdBvDxiIRlQ4YbCyuCwG1gPcigDlb/xVqemwy/YpoXZr6+imSRGk+ywpMV+1nHOxOAV4B3DGMGvT4CGgjKyeapUESDHz8deOOfaqOpa1Y6bcRQ3skkRk24fyXaNdzbRucDamTwNxFaNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFYvjK8udP8ADd3c2Nza2s6GPE1y4RFUuob5iCA20kKWGNxGeM0AbVYXirQpNbWzCXMMaQSF3guYDPBOCpGHQMucZyMkj2PGOR/4S3VRpOnTWRmuf7U83T7WSeKMlbwSkI7GM7GjKb23LwRFnjdgWf7V1qfWLaFdUaKG51mfStqQRnZGlvLKJASD+8zFjnK4b7pPNAGv4V8Jy+Hbi0eC/jlij06DT5ka3wXELSsjIQ3yczNkEN0GMVDq/gyTUfEa6nJfQsi3dvdos1qZJYfK25jjk3gIjbckBc5Zjkjgc2/ivXZdGnu0vY45LHSUvmAgUi4kE0qENnopEYyFwcngirGs+I9Z028utOa/XyYtQWB9Rm8qExI1ssoUsUMa5ckAsvTC/eINAEun+A7zUdAgttfukhaGCaK3hhhGYS8yyBnbewk/1acAKMFge2L134BXUNHk0y9uLGK0mn8+cWNj5JkZVATl3fowBPXIAXpuDc/c+JNWs113UZ9ZtvtMXhlLy2t4nV7eeZPtZZ48/extjZtvYrngCtTXNW1XRtYmguNQjJNvaeffeTsS3SS4lVn2ElQFAABOccFiQDQB1uqaRcaloVvaT3iC/heGdblIcIZYnVwTHu+6SvK7uhOCDg1R0vwu9prMGqXF6s12GuJJ9kJRJGlEQ+UFjtCrCoxk5znNTTXV4/g6a60K/j1a8jR3gnwhFwUYnZ8ny5IBTIHXnHauQ1LxpeXWmxX1lffYbbUZJ5NNklMcEZiiVFw7yI5LO5ZlVVyy9CME0Ab/AIu8GSeIdQedr6FYXjiQR3FqZjCyOW3xHeAjNkAnBOAORXY15fbeMtQuptPlnv4bOea406NNPCp/pEU6RNJKNwLkBpHQFTgeWc5qvP4l1iHRNSuLS8EA0/Tr/Ugvlh/NeG4lCoxbJCkLg4wfQigD1iivPbjxVdjx/b2Fvdr9ma/+xTWc7xhwPIL+YkYTft3AfOz4OcBehr0KgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK1xY29zeWl1PHvmtSzQkscIWUqTjpnBIz1AJx1NWaKKACiimyyLFE8khwiKWY+gFAFSzuJJ72+GR5ELLEgx/Ftyx/wDHgPwq7WfoMbJpcLyAiWbM7g9mcliPwzj8K0KACigkAZJwKiiuIZiRFNG5BwQrA4oApXOi2N1qUV9cLPJNEyuiNcyGIMM4byt2zcM9duc4PYVpUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFU9Y1O00bS7nUdRl8q0t0LyPgk49ABySegA5JOKuVyXxFdRbaFHIN0Uur2ysvZsFmUH23KtAA2sa3JZQ38q6bo9rOV8qG+DyS/N0D7SoRsdvmx61cg8QSwQrLq1si2rLuF9ZOZ4CPVsAMg9yCv8AtVjfFLTtJnHh+910stpb6lHHIRK0YIkVkUMVI4Dsh/CqkvgLUdBn+1+BdamtgOum6g7TWzjAGA3LpwB/eHtQB6DbzxXMEc1vKksMihkkjYMrA9CCOoqSvGE8TLo0yx+J9K1XwnqDuQ9xYMDZSt/eG4GI59xu9ajufHXhS5kUXeq6zrk8mEhh88RqWOcARwbSxJx/Cx5ouB7XRXknhbXZp4YJ/CIjDC4e3u9Lvb11SJRx5mHDOrKc7gMDggjJBG9H4g1N9RFrZ69oeoahsMn2FbV4lcDqqy+Y20+hIP0oA72s3XyXsBbKfmupFg/4Cx+b/wAdDVV0XxRpmqWzMZltLqL5bizumEc1u3911z+RGQeoJFcz4v8AHemaffWxsri2vHhWQ7xKPIhcgDdLIMhQqlsjqSwAHNAHaaxq1hotn9p1O5jtoMhFLdWY9FVRyzHsACTXAaj411rVCRoloumWRbaLi8Aa4cYzuEOf3Y93BPP3a4NfHfhhroatrXjLT7zUiSPN8p2SBP7kcaIyqPUliT3NbWm+LPBWoRB4/EnksSfNkmtZFiznjaRtCqPc4+lK4E8Ph8eJbyzZtbttRSdsy/aNSNwQmCcxxglQ2ccAKMZ9Ks+IvA2h2enrMlgsjRsIXaJysjylsDaNuScEdGHT2Ndvb2c+oRWtzaXum31tHtaGVN+wkdGwHKsffrUc3hvVZZp5P7XiQznMgNsJV68AK5IApgefLpWuaI4l8Oa7c2YQY8m5bzLZ/YpKQe3VSp967G28dS6ZHD/wlVvDHC+AL+x3PCW9ChG5eeAVLj3FYXjG28L+HoGbxBr1y92FGbazWNJZOeP3cajGc4ycD1NcW2v6tqNuJtF8KahPZvxH/aVzDE0g6gnMe3HuGakB9AaVq2n6vC0umXtvdRqcMYnDFD6MOoPseau18t6lqWrWutaWsvhXVLLU57mNRfWOqw3DIpPOTEAcAZzvBAAyc4r13w54u1+20HTbjW9Nl1dbmPzFutOhIYqWIUshwmSMHhh1+6KYHo9UdR1fTdMKDUtQs7Qv9z7RMse76ZIzXEeJfEWpXmlmcmTwxo+ds13eMoum4ztijBOCegIJb0A61zfh+5SCCTVdK8Fy32kOAn2udRLPOCeZGOSxHT7qN9TzgA9laaJYDO0iCELvMhYbQuM5z6Y71zz+MbM7ZLSw1W9syNwura0Z4yv95f4nHuoIry221SzKraaNouo6iJJDILK6uvNtrZs5OIIxg8knaQADzx1rZtYfGmi+LG1zU7eW/tr2EoLeEFxaAE4TamcZG3kBhwcnoaAO+fxZpkixDTGl1SaWNZUisV8w7G6MxJCoD/tEVkQeMr+6v2tLTTdLa4Gf3LauvmH2wsbLu9t1YmhaBr17pyWkNqND05pGklEmBJMzHLO6ryxJz1KDp8pAxVrVPhFo17pjW6ahqkFyq5huIZVjaNx91sIozg+tAG7o/jfT73xDL4f1COTTNejUP9juCD5qkE5jcEq/AJx14PHFdXXh+qi9vfhdDrWum3bVtOuPM0u+jBLjynJ3s5H3W2Hjuu3ucD2mxuBd2NvcqComjWQA9sjP9aAJ6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivLfEXiXV9L1LxSxvWFkL6GxtPlX/AEaT7PbS4zjkOJJeT0KqB96gD1KiuHm8X38LtcmC1azkur2yihG4TRvbpM29znG1vJPGBgOnJzxWvPFmvwWEczW2lpKdKm1dlBkkXZGEIjB+Xk7z83Qeh6UAeg0VwkvivUop57GQWv8AaEjW5tBFbtJ5nmpK/l7S65ZVhc7iyjAzx0p/g/xBea5rlrLcq0Cvpshktw2UEqXLRlgASOdp7nrjJ60AdxXL/EmyluvC001vG8lxYSx3qIn3m8tgzAe5XcB711FFAHPWNzpfjbwo0chS5tLyAJPGDgjcOR7H/CsDR5PE/hOYaTLpVzr+kLn7Jd280YmiQdI5FcqDgdDnoMcms/VNPk8Ba0usWSTS6M58t40JPlKzcRlR2DH5G7Z2njbXaXOrS3lklx4fWHUYSMSKkux8EAgqTxnBzg0Acv4i1DxTeXkV3oOmXltFDbyJcWuqeQttIWKhWOHLfLlmJBxhSOpFUPDnxD8FPbNeQWca6hAGW4ew015FV1ba+2RU5XPO4nGCCa2pdRWXStRuJrq+njhh/wBJ0e4tY5pwpBGPL4J3cYzwcHrXjvha+uG/tWCXVY8MfNbTZtM+y3VywGBlV+SMbUACZwwBU4yaQHc+J9N8FajO2v3kWt6FNc4LX1tbP5c+7GGbCvHzgfNwTxzSaT4E8JatavL4d166m14hZYby5lLSKoOQDD8g8sk84UdjnIFLPqFzrFpcDwXpkHkLti1O3ZlhgVlKupAAIJYZDAfwkZ7VseKWttWt7PWb2KziCEQ2hWQyTruILPGy/dOADleSAOccEGcn4lTx1Fpr2Ws+H7bVLqONoodTt7RbktkkbhxvTAYHG0H5ep782uhaVdyWmrav4Z1COzsYFEdtqEbpp0IIB3SKsZDMvIOWVARhivUdjY+NPEsT3FhL/bF3fWUot7mX+zY2iUkKQxddoXKspK4JHPB4zHqV34jOnxQXvhPxNqdrEFYWsjW8UDEHo6RsXkA64YkHuKYjbFhoj3EyWeiWVxZvbmRf+JVA0KY25+UKD3IwWzjnpzXOaj8M7e4T+1fBMdvpOrRqWn0oMWtLggcKP+eR5yOMcj/eql8LNZe+1vxHpkkUtq8TC4Www0JgDEloVVuVwVLL6EADjivRLWS7ZbWG3lhS7SIwi5CAJK38LFewzggdt6Y4JFIZ454OvILkz3Fs13o91uKyfY/NiZHXgrIRkZznjB6cg1s6ld3s4kiXxxqVxbFdm0u4wc8ndGFOfY/lVPxhYTWXxHln06KEpqiR3jeUxwJgzLKFOAx+aNvrurVvhJJpsqzx3Re3OHW5lzkMeAuTkc/X147giv4X8NWUKw635H2ieZJGtI3VdpCZ3XMq9WJIIRTwep9tm81fUNN0i6luvMutUvWjS2SKQkFmz8zbcbjjnAGMDIB4Faum28cPhbw7O0iw211p2nWaZfhd3JPTrkLjnuayfE+m61qPiTQo/DNrC91bl9QJklVEhIjURk55IAmZRgH7ooA63S/h14b1bR4Z9UkbXHuIlJuvOaONxj+BEYKB+Z9SajPgXVNIlI8NapKlpu3RwSXTxGP1BIDK4+qg+pNV7Wx8ZadPJcR6TaQSysZJv7Kvg8cjepgmVV3HuVZSe5p//CyJ9Ou4rPXLKCC7k+7HOzWbsP8AZEgMbdD92U0wLlv4DuNV1Fb7xnqDaiIs+TZK37lM9SThd2fQBR65rvkVURURQqqMAAYAFcWfGs97qVvpOlaUy6pcRNOpu7iLyEjB2li0TOSc8BQMnnoATWFqCX0+svpev3F7qd467wNPuza20O4/KpQFWzyMBnfPUkcCgD1FmCqWY4AGTXB+JfiXo9hos9zpNx9tuPLDxFYJWiJ3YKl1XAYc/KSDxjjNVtG0LwteaJHb6Vpthe6nH+6uBcTlbiNwcOZHOZAQwP8ATiuH1bQItNn1CTGoW6RzFbgXp+0Rsowco7DLf7Jcc4Gc0gPd7O7gu7KG7tpklt5UEiSqflZSM5zXDeL/ABDNrsn/AAjPhCSSa6u28m81K2IKWER++wboZNpwoHQkE9MHD0/SxqFul5b6VqLkxi5MutpbWsMi5/iEcbYPGeVBxzmu00AW2j6S1zLd2sFjBE08iRAqihjndz820BSFz1H4AMDkPiTaWmn6BpPh7T8t9lhEcUTyEs4KmNVPqckH8OnNepWkC21rDAn3YkVB9AMV5X4TtpvFfjdtcmbFlHi4MW0HP/Pupb6fvMYGMJnrXrNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVTn0ywuI7iO4sbWVLiRZpleJWEjqFCswI5YBEwTyNq+gq5RQBR/sfTPtk93/Z1n9qnUpLN5C75FIwQzYyRgDg1I+nWMihZLO2ZfJNtgxKR5RxmPp904Hy9OBVqigChd6Npd4kiXmm2VwkgQOssCuGCZ2ZyOduTj0ycVianrXhvwtcRWsUEP9pGNlgsNOtg9wyk7iFRBkAkk5OBk5zWL4r8U3upTz6Z4anS2hjVvtGpnnZjgiP2B4L8+igscjkrfTH0h57HQLBzqEm2a9ubqdoY1VQW829lUliMEkQqeQTvOScAHV2Xirxf4imuI9D0XTNLSJcmTVLrznz2DRQn5T/wLtTPtfixXU3OvIDg7li0RkUnsQGctj2/WuVt40vrV4o7XxN4yjOXD2P/ABK9MAIPyxKrIHGc8/P1+9WjY6Tfgf6B8JdA01yu37RqN9CcDHfYjsf880hmveav4ms7WUXs2j6jaOu1472xms2kU8FctlDxniuV0HxBL4a16cxWV3Z6Kw88qjG6hcZ+YK6jKkDnLgDHU8ZN+/j8R2W6VfD+n3FvECD/AGFqFxbSYA4xsJB6cBwo+lXtN8++SO70PURqV1GoMukaw8aXQI5JjuI/mDYwOdy9ckc4BHP/ALQl5p3iHQdJk0aWDUnCG7H2aaJi8LZCvtYfOm4N91l24z9HfCOSxnkstK8SWA+2pbCVCXQxXPlkfvXReGKZAycgHJ4PNLeaRZjVX1Tw9byXFh5jwXHhq/hKRyO2DIq7yVEnG4LwSRkZFdho3g7wRr8Capomn/2ddxkqJLQtbzWr8bl2g4U8DIxg8dRQBl3/AIpW28XX9xp6RjTBbFBKsA8udhj5WIOTxu2NjnkDiuffUtS8QeIbqzt7K9mvEEflxldqnJOJJiAViKgFTnDMOQD37LTPhHo1tdNJfX+p6jbFiwtJ3RIQSd33Y0XIB5C9B2Fd1pOlWGj2xt9Ls4LWIsXZYkC7mPVie5PqeaYGRa6Z/Z9npumPL9ouJ7g3N3MVx5rg+Y747AvtAHYYHaukrNg/f69cydVtolgHszfO36eXWlQBwnxJtYotQ0PUCAkjz/YWlHBG/wCZCT7MgA/3qo2VzbXmmQappnmu0bsXdATGUUgr9OQnI6hD6VofGOLzfBygEB1vLdlOeQRIORUeqltMsYrKFmee4k8piuVUHyo8rjowIHXtk0gPPfi3axJ4m8NS2rSRswvYSWlaMkLOCfmB6Et+vTtREjiFgLs3ELArLG88bsF9MqM/mQM4qf41SiW88LXbxNHClxPbhtnmbw6RMGGRxnBP4VzWvXIsNMMlvN5pG9mLYRlUDPQ9fyHQUMZ6N4fl3eCfDRu9PaW2gtLWQMDv8tlLAArnnIC4IHvW/oCeX41hXIJGmMD+Atqp29m9npPhpHURSWcFrbuoYYLLGGORjPHbJ7nirWl2smj+NtMtbm5a5kksJIvNYYLt8h/lEfypiO6qtqVhaanZyWmo2sN1ayDDxTIHVvqDVmigDwvxR4Xtfh34qtdW0RXtdGv0EFwZZGeOB0JKpuY/IkgZhk5HGOMiptO1nQpvEUIujfabAUKm43iOGCYko0aSHlQR8wAPGWxXtVzbw3VvJBdRRzQSKVeORQysD2IPBFcDq/wr0i4iuP7Gu77R5JMELA4lhDAgg+VICAMgcLt9sUAVfEmr6XaX8BGbPT7CEC2lil8lbkvgMFkU52qvOONxyRnYaxPGmt2WrX1jc6ZbxXN8lpsaWSWSXyxu5EUeNjtwSXHzYA6DkaQ8D+LTe7m1LRzESu4skx3YXafkzjBBPGeMnmpdJ+GV6HgbXdcF0bfzfLe2haJ23jHzEuRtwB8mMcd8nKAz/D13JrFpFbXit/Zulsj29lbxsiXc+fkWaTlSdx3GNc44LYxitrXjstT4fVoNU13U51e4VyxijPDDco/5Zoqg7cjIAyMuMstfBWqaLfG606ZLuSMyC3kmlYtAHj2gIjkqqhiWPJJBwMcg2vDXhnV9E8SLfzR2d39paUXEyvtZN+ws/T5iTGvGOgAzxmgDrtA0mHRdNS1hZpGyXlmbG6aQ/edsdz6dAAAOAK0aK5v4hXtzYeGvOspZ4pmvbKHdAFMhWS6iRwu7jJVmA+tMDpKK81v/ABNr+haVc742uLqBLi+S3uokaY2ibdpkdHVEOdwz8zY2/KSGrVHiu/bVZtkFr/Z8Wp2+mmPDec/nW8Mu8HOBtMvIwcqCcjHIB2tFeT2XiHUryayl+13CrNb6HIU8zvLd3CydAB8yqoPHIAq9/wAJ9qCxXU0dpBc28tj9vsJihgSVPNRBn53YgiRTuKr/ALpoA9KorjZ/E+pWOsQaLf2todVu3hNr5LN5ckZLeccnnMaozHpncg712VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFct411Cb9xpFkSLi7wJCHKEITgKGHILEHkchVcjkCupJwMnpXlGqXdzLcXWtW7K1zFZzXlvxlUeRvJt8/7sayHHq7UAR2KvcXuow6R5Kx29yllHcuoCG4UEyzhehWEDai9Ack5PJgs5LDVNCuIEaKPwkZ/IADiSfV5mOMktjO8j7zYyOQNoDVFqtqbf4a+E/DekQSXF3rMQaXBw7wbRLPuYZPzZVSe+6tG/v8AQbDw1rFzf2Yfw/4eLQAltov7oYDgKOCN5EfOQSWGMA5QHNeLvHUlhpcEuq6jp2naVIfKjjjEkkIUDHlwJHte5YdC5KQjoN1JoGpWGpy250/w29yCAwe6ht7XzfTEQicgN2GfrWb8O7F9X8fWut+LJrebVp3UQQhBIsA2BwsfZQAQN3UDpjOK921HR9HvJVv7u2haW2bzBOmQyFTnqvPGOlAzyRtf8LW18Y73T9Q8GXkbuqzxohtVcE7svHygPcHZnr712sF1Ldw2qXr2uqWtyV8iQOjLL7xToBhx1AYAnHDcGqkvhu28Trd3t+gsoLqZkhWaMKZgSQMqTkE/h16evkkc9x8MNeQwSzXPh+7d4r6yCBSADtWZF4CyKxTOMZDDv0BHsd9pOm6iJ/tPkz/2giwR6i5K+aEbIjlIxtlXna+M59wQeZF1ceCPEkknl/abrPm3whG0XNqWK+aB0MiNgNjHLdBuJMdzci/u5RZr+51e1bUBHG5AtdQhIV2B6cHBOeG9xW5qE513w/ouvWcUjyeYzSwAmNjcKDHJAQchQ+HQjH39hoGel280dzbxTwOJIZVDo69GUjII/CpCQASTgDvXF/Cy9Emj3Gn7962Un7k4IzBIN8fX0yR/wGuk192GlyxRnElwRboR1Bc7c/gCT+FMQ3QAW08XLD5rp2uD9GPy/wDju0fhWlTY0WONUQYVQAB6CnUAcP8AEZku73R9MlyYWMt3KAcHaiY/k7fiKnIPn6Ql+/2oFzGCvWMjylPJ6/ODn2NZevpJqfjO/wDLkCx2kUFq6hNxdXYF0HIwSsoGfar+qILSCGS3FxHgNdr54+ZHll80g9ht2tx2xQBynxY0/wC3fDjVPIRnk0kQ6hDyob90zRuDjkfIj8/4YrkbeZ/E76XplxFcf6XcwYbasiBcgud6kj7gevVYrSabz4borINTtbq1dguAxGOSPcmU4968b/Z9mutW1zw+LsW5EFpNIrxx7HXC+X83Y/f6jikB6hq90mr6Y1/5qy20jGdQOAmZYo1H1Crn6tVvXlu4ZLJtmdQslQ2q9DI67sJn/bEUqj/rqKwtBRptDnt5HmiiR5rQxAnaz5ZRx0Pzwrz259TW7cSz3enKZJiGuGSAyHrDv2lHH+7KjEf71Azu9OvIdQsLa8tW3QXEayoemVIyKsVy3ga4IW/sGUKIZFuYlAwAkw3kfhJ5q/RRXU0xBRRRQAUUUUAFFFRzzR28LyzuscSDLMxwAKAHsQqksQAOST2qtemyexMt8bZrNCs++baY12kOr5PAwQGB7EA1REUusMHukaHThykDcNN7uOy/7Pfv6VD4z0WfW9GjtrOVY5YbiK4VWdkWTY4baWUEr04IBwQDg4xQBNeW2ga7HDNew6XqMaxmSJ5UjmAjPVlJz8pwMkccVQs9P8Maf4hvb4Sad/a92Rd7pWi82ONYUj/dnG4R7YwfTJbtwOd1HwLfX1jawxxWFqYJZrpw93LcfaHcgmCRiqnyZCCXGOoXg4zVzVvC+rXWleKNOhh0pk1iO4ZLmWZxJDJJbeUFI8s5APG7IOw428cgHR7PDlvJbRbdIieRkhgTEaljExKIg7lGZiAPuljjGahtrHwolzfx21roa3Eak3ixxxBlBIYmQDkDIB57gGsHXfA7T6vNLp1vanTp7WK2a1F09msXlu7AgRowYHfnHy4K9eeILjwXq0j6hFBJZ2+nyP58do8zTpLJ9qSc5JjDRo+1w6hnB8zgDbyAdM8+hTapYa2+qWjsY3tLRjcR+WS7KX2Hu52KOp4HAGTnV/tGy+3Cy+2W32wgkQeavmEDr8uc1xPiDwnqesXz3s9rY4uLR7Oeyj1CWJNpOd3mLFltw4YFR0Xnip5fB13JNK6zQRNJqxvfNRm8xYzaGDg4+8CSeuMd+1AHU/23pXkXM39p2Pk2rbJ3+0JtibOMOc/Kc9jUj6pp6T2sL31qs10N0EZmUNMPVBn5h9K4qTwpq82k6LbmHTLebSGi8sWt1JGLkLFJGcsI8xY37lAD/wAQzzmiz8H6jY32my6bHa2CxmEXLC9ecPGkruYyjxYbh22uChBbOMKAQD0GiiigAooooAKKKKACiiigAooooAKKKKACiiigDP8AEMpg0HUZFOGW3fB9DtOK868MW8d1HdwwJuhjNpp0jLz8yROzj0yHk59zXf8Ai1S3hnU8drd2/ADNcR8M9VRLu50d7WONbm91N3YKcmWO5wynPHKOhHqBQBHeWN5oN14U1a7VWa2tLXSY4o1BKSySKJT04G1AMjtn61wPiy0jvvDvhDQBCklq14k10+7Pmt5P2uQkY5DNIg+uK7q6nvNZtdKu5yIbODXLlIoo5OAIo5I4l/F0xgd2Fc58SYF0jUdC1mLbPZWN5byXEcbYAhltxAwJ/h5WI/RgaQzrfCmjx3EmoXtlvt9WNo0EcpjHlhj/ABr6NnjHpiuH8SfEXUvAhTRjPam/+zfaSzHckK+Y6+WiKPmcFfmJPJbtjn0fTPF8CT4tYy2mmFHjRFAaMkAkH16nOe/0JrgPHHgzRNY8M3mr+IIpGu2nMdpPEzQTMCfmI7EHrjB6HmgDH8GfFOfx5c3Fhr97Hp4toDcQz2oOWYYUxupIG4k5XH5nNbvxQuvD+p2d9b/anWe6kNujtD8nmFDllIzwSAc4xn65rmPD/wAPtK0fwxnT7c2t/JMJXkvrndNdxAEhVRecg9PlGc1i+JNRszE5NzEGtFaQxyHZ846IwPOc8kdsYoA6X4P6qbvw/ax3Ziifz5zwQRIJ7Us5XsMOg49GPpXfWSyLPqunRxhUutSuWgiU4XzGto5MnsD5rZz/AHjXh3wM1S7mtNMsxDEQCIFYDa2HV1zjuAHbJ7cGvX/7Sz4lnls0zM8rTSTMm0JCJkKuOvBjjcj/AHe3YA6fw/dxQ/Eae1jVIzcWUiSRq2QJIJsA+vKSA47V1t5+/wBasYP4YVe5b642L/6Ex/CvLvAV1JqfxEt7ySIQzyw3txPDv3GIloVCH3H9a9R0v99f6jdHkGQW6f7qDn/x5npoRpUUUjHapPoM0AeaeEJ/tOs3t3cEst7qksinGSUjYpGPpjyz+Fbt7PJfSafpt+zGSPH2uRVABdk2YA6felT2rjPDJkTw3pVxGshnmieMIo/jaNED57De45rp79lgdEsnkaSZwUl24TBZtp9eCIl/L1pAPsZoX17R4Io8XRAu5X3E5Ro5wcjsASvPfcK8m/Z21CB/ElnApIZLe8hUFcAnzY3AH/Aea9L/ALQt9IvfFmtKjNDpGmiNQT1WMP8AKD9Y/wDx4V86fCPVLfQNT0PVF1GVljuCksMce9j5iEH5QcnJAHGQBk9qAPf4ZYLXSTashF5DcJJNzkfKdrj2JbzD78mtWOxS60S+jikYyTQxuiAckARglR7MjdO5rN1+yT/hI1uoWY2l/bNcQvGMq/ALJn1wWZfeQ1qeGLmRbJBtH2qIywQlz8iSbMjp1Rgufqp9aYE2gh7bxikUhG97OaKQA9WjljcfX/j4au1rhdBkkm8SaRdXBzNcQXrMR0yPsyn9VruqACiiigAooqpqF9HZqgKtLPIcRQp95z7e3qTwKAJL27hs4DLO2FzgADLMewA6k+1Ure0mvZkutTXaEO6G1zkR/wC03Zm/QdvWn2VjIZxeagyyXeMKq/chB7J7+p6n2HFaNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEV3Al1azW8ozHKhRh7EYNeNa3qUGjHSdQmVk8i9H2+VTgbXT7LcBvcMgk9wK9qrh/GGgxXtxc2c237LqqnYH5iF0oGA69CHVAP+At3agDltDa6g07xRo7Bftel38GqxFw20jzFeTn03xyHjs4OOap61p1pqFvqWm3MNxLaaq4tp7Kc4dWiyvlLIvG7Co0Tc52MvJOKwbPV7rw34sfU/La5jsbZbG9tnUNM9qGJ+b/bjBVTnqFB55ra8X6XPZQR6r4dL6ppzrvktlkJuREjA+ZFnO8pwrIRnaAOcCkByWgamnhG8uvD+sm8udUhV/7PkMYVZVz8kjZOCRn5kGeRnpzV9Br3im8SC5CXk0g2okcP7qPAHTJKqOOnFS+JLLQ/FFtp+qmKK6WRjEl2j74GJPcsccnnJIbPQtgsc5/h34ptZzGL+80mzuOLlYJp/Lk54ChNyxg8dTx60DTsbOoGz8FWTXF/q8VvqBJDvbThFiQD7mQoyxP93075ry/XL2X4hXcFppbTNotowN1M0TRi6wQSjORzj1PPX8ehn+GV14dlJvbZdRNxjJuOI40U5x+8lX0BICnOOtb8FuyyW9i8+ny6gULWNrGytukx96O2RVUEDgO25QOV6bqAJtF8LWtjFJeXWnwS3t3Ds0+EIq4UZHmHoERRnBJ+Y5PQA02DQRpfhB7mZry3v7uRPuXMgOJG2xpgnH+q3nBH/LYd67KO1urNrKw1C4hvNRMPm3udz/KONrv1f5iFwOo+QYySYPENy0egwx/vr/UHm+0tKwGZbmVTEoVBxhdxVB6pnkITQA34QaBfPdazq0WqzJLNIVWR40kDbjkg8A9BGeD3r1zTrX7HZRQby5UEs+MbmJyTj3JJrM8FaGvh3w1ZacAgkjQGUr0Lnrj2HQewFblMQUycZgkA67T/ACp9NkdY42eRlVFBLMxwAB1JoA8m8EXUQ0PSbeKDy/8AR7Jd+4n5v3cjNg+pIGO22tjRL1nshLft5kFsZIowuAUCqkg/WJgTXPeGGaLQ3aOMGLDxWV0R8jrFMUjkU9wUXd7gg9Oa1JbB5w8+mRs9nLKZF80YH70nKH0+Ziv0FIZyvjC6lPw31OIPdo9zaSX93J9kE8Tq6t5Icq2+PhVIIH8WTkZryLRLv7HpkUrztYst3bvHqGwL5KiZQz7ypK8Enjg4PavdPHFrf2+hmW7YW2mtbW0cbQW8ImVhEyNE5eVTIvzOduCRk4B5r578G2jXhitlivpFlubX/UxG4ZPn3ZVM7WBCt97POc96BH04skWo/D/TZrGTdPYXalZpblp9rhj/AMtZAjMGDAA46sBjFaOnambAac8duUN3E8YRxjaI5sDPvtcjP0qbQLmGLwnq11fG8ntAjyN9tRkLx+XnA3EqRjgFT9ecmsmytJ4YNLMbyXq2qop242+YxXMaE4zyM56cnNAzY0oiTxlZoP8AljaXz8dPnukA/wDQDXZVxnh/Za+Nrq2vXWK9bTYDCjNgy5kmeUp6gMyg46ceors6YgoorIutTknvGsNKUSTqcTTnmO3+v95vRR+OKALN/fmGRba1QT3rjKx5wFH95z2X+fal0+wFszzTyGe8kGJJiMcf3VHZR6fnk0+wsorKNljLPI53SSuctI3qT/kDtVNPEGnPq+oaYk5a9sYlmnjCnhSM8HoTgqSO25c9RQBrUVlaT4g0vVdLjv7S9tzAyRu2ZVzFvAKq/PytyODUzazpi2MV62o2Qs5W2xzmdfLc5xgNnBOQRQBfoqvLfWkMmyW6gR8Z2tIAcYz0+nNQQa1pdxJDHb6lZSyTMyxKk6sXK/eCgHkjvjpQBforHu/EmlW9jeXUd5DdJZlVnS2kWRoyW2gEA8HPr6GreqajFpsULSrJJJPMsEUUYBd3bsMkdACxPYKT2oAu0Vk6r4i0zTUuvOu4nmtlVpbeJ1aVQxABKZyB8wq4uo2TXM9st5bG4gXfNEJV3Rr6sM5A+tAFqis7+3NJ+wLff2pYfYmfy1uPtCeWW/uhs4z7VfkkSONpJHVI1GSzHAA+tADqKrXN9aWscj3N1BCkZw7SSBQpxnnPTjn6VAur2r39paoxYXcJnt51IaKUDGQrA9cEH3GSM4OADQooooAKKKKACiiigAooooAKKKKACiiigAooooAKralZQ6jZSWtyGMb45VirKQchgR0IIBB9RVmigDxnxnFc2Hi2wnvLVJ76SKSFplj2LdRqoYMxUZIAVtyj5kJ3DK8Vl2yWelWY1TRNTW10tZM3djdudltJ08wMnzIR03ocYxlcV654xs4LuwtDdJvjhvIX6kFcts3AjkEb8gjmuR1XwZfaffNe6aiXfPLLhJHXBBWRAQr/AO8pU/7JPNIDkLfS/t96NT8PXtzbSXBZ5RZqk8dyOQxaJcRTp0ywCtxyGPI6izuNXNpFYqNDW9jYi3idruyIyBwqnkjrhQQBxXHQ6ZYzXsgudPu/D+qqCSLC8EYcsMbkR1BPuGiz0O41u3A1gxWmn3/iXVY4Qhed20qQyLDnhWdGKuWI2j5em70FAzKgh1DWdRZbvQIbYhj5t5cZghBHYuX3N6fxflW/odrYaM6x+HVsJ7+4JV7q3XahIIJUysTJL/up6HJFYmpWOlmO5t7zXr1LPqWZxA0qj+EJHDHgf7PmD3zU3htNSKtbeCNEuYLR1MbXcpWMyDsfPIJA68AyN0wRQBpa+JoJp7OS4hi1K5XfNIqlI7dTkb25yFAJwOMnIGeSO18NaR580OoXNu9vBDzZ28qgSdNvnSDsxXhV/gU44JwIPCngtdOdL3WbgX+pZDAAEQxHsVByWb/bclj14rsqYgooooAK46RF8XancG7IPhnT5Cnltwl7Ov3mfsYkPGOjMCTwozqeMb64tNJFvp5I1G/lWztiP4HfOX/4AoZ/+A1578Sb3yLW08I6IjjT7SOMXhR0G4Y+SFiSOCPmf1G0Z+Y0AbF7478P6pex6WLS/a1JKW9z5GyG4YoR5ceSCdylgpICk9CeKmmtLmOxnWw3EpHsmjjXgkEfMB23Ahxj/bHXGOLh0eG9tNjaJqd1cyEMslpcrE8ZHIZSeMggEEH0q3ofizY66Rrw+xa0VxHJn5ZsMGJjCnJGcsUHzoS20MtIZ1mm2T69pdxbyuYNk0V0baMr8ivGjgp/dbdv9QTu+o+ePh/4cvE+JFvoEaXFvffaIryO/VuYYwrOSBk5Y/Mh6qT6ivpXwrFNJrZmFusVrbWn2ZXVnO7JVlUsyqWIwxzjjzMdc1wejeJdMvv2gbqa3nilt3tzp0Myn5WlVQxweh5DqCOpBpiN7xbqeo3epwaDk3FtDEDdPEmwzyKUJOMnCjcvyjqxAJwCDe0gwRXVs9zfi2hsYpLuTL/J5Y4yc8AfebPHylfU07xPoupw6tJf2sVrPZsWdnkuzatErBd6sdpBHy5DdRuIxkBh5pq2o3mruYbCKKeGaUSz3NpFsgnw6mKGPdy8Y4beRhyBgY6gHpVn4h8NfEMy6ZG89nq9ti5thOgiuYh/BcQ9flOR07HDDnFdJ4Y1Wa9iubPUgiatYOIbpU4VsjKyqP7rjkehyP4TXz3JYT2U0eoWVxHFqkEpuIpXlRysgJyCV25yQykdxuBr1G/ujrcdh4pls3s9K8tLW8HmbZZIWcbt+P4Eft1xv6ZxQB10t7ca5I1vpEphsVO2a+Xq3qsXqf8Aa6Dt2rYsLOCwtkt7SMRxL2Hc+pPc+9SwxpDEkUSKkaDaqqMAD0FPoAK4K18G6nBqUeqnUhJfTT3bXULFfJEU642owjDkr5dv944xGenGO9ooA82tfBGqS6bZQ3yaZC9rDplr5cMrSJMltcpK7MTGvJCkKuCMk5PPGgfC+pW2qPf20em3ZM96RbXMjLHsuDGdxIRvmHlkEYwQ7c813Nc74q8X6X4biP2t5J7njFtAAznPTOSAuf8AaIoA5xfh9LHoWr2ZazuLu40y30+C6mX5/wB3D5bFjtJAJ54z1rTu/Ck76lf3MH2RBPqllep1BEcKxhlOB1+RsDpz1FcRJ4+1/XLyYRXdv4f0xMqGt4Uu7lm9MyFUH4Kw7Zrfg8FSXlul5feOvEc0T9HFybYEk9CowB34AFAEQ8D69cea99c2j3L2P2V5jdyuJn86OTeI9gWJcI3yrnBI5PWuz8SJJHd6NfJDJPFa3f71I0LsqvG8e8KAScF1z6KWPaueTRNI09reJfEPiBidxEv9pyyDG3PzEkg9j68jsapy65runXa/YbtL+04Pk6iqiRgVzgSRgbTzjlW70AXpvC+qNomo6QsWmNHLcTXEV40r+axkn83DLs4ODtJDHO0cDPENx4LvbmOS0uYdPmso3vpFbz3SS6FyXPlyYT5AN/LKWJKKcDpW5oXjHT9TuYrOcPYajICUt5yP3mMZ8thw2M/X1ArpaAPN38Ha9I1rdXN1DczQSXAW3a8aP91KsQ5nSIF2Bjbkx/dkKk8ZO3feEEm8ITaZavLBdNposkVryaWBCIwo+UnB6D5tu48nqTXW0UAecapo2uLqcF/JYWU9zc63DdCCKeR44lS0aPLyeVkfMAc7epFamlaTc2U/h/Tnj3Pa3V1qk8kaN5EXm+cBEjEDODcYA4O2PJAyM9nRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVUfULZNTXT3fbctA1wqkEAorBWIPTgsuf94UAW6KyrDxDpN8liYL+3El9Es9vDI4SSRGGQwQ/NgjnpUk+t6bEt9i9gllso2luIYnDyIqjJyg5z/jQAzxRGZPDuobfvJC0i/7yjcP1ArRgkWaGOVDlHUMD7Hmq0l9YSXR09ru2N06n/R/NXzCMc/LnNZseuaPp2jA2l7FeW9k0No/kSrKyMzLGobB4OSM596ANLV/sSadPLqUUUlrEhkcSIGGAM9DXPaJ4O0f7M91f6Jp63l03nOnkJ+6B+7GMD+EYB98nvW/qkFpdLFFfSAJGwudhfaGCEHLDuoJUntnGaW+1bTbBd19qFpbDcEzNMqfMRkDk9cc4oA8+1uRNE8W3NnoGlacs0FnaXEFvFphd7h5JZlZTIv+rAWJfmPAyScgEVZ1P4jSDSNbu9M01nFrZXdxazSByjNAD/rBtAUHBIwxJAwdprom1XSbbxTOBFN/adw1vp8kg5VhsmljHXGADLyBnLDrxix/wiukYu0NvKbe6WVZbY3MvkMJM7/3W7YN2WyQB1PqaAMi/wDGr2Wqiwl0uV54hEbpYWaQx+YxChMJh8AbjkrgHjJ4qDVfFWpyaINR0ywVLR7+1t4JWmBeYNexQuChXChlZ8HJwOTtPFb3/CL6X50coW8EyIsZkW+nDSKpJAkIfMgBJxvzwSOhpB4U0dXci3mCNMtx5X2mXylkWZZgyx7tqnzEVjgDJznIJyAZX/CYlXh+1RRWjxyXcVyrSgxhoF3ZEpxhSMHJXvyBiqa/ERBG8UunMmo/aVt0jzKIm3RGQPuMQfbtVuRGecYyDkbOteGrKa3kMGlQXjySTPLFNcPGG81dshB5GSAOOAO2KyUsdAgjf+1dO1SwmeRJmuLq4nkZXVSoYXCu23CllzuHBIPHFAC6LrI1/wARNqclvNBb6Xp24wSoQ6TSs2/rjOEiGD3D+9edabaXN4ZL3UjCLm/ZbxkjV3dDJ82DkrjqABt6KMZ613ugyWEPh7xpe2jNNaieceb57TNIscCL99iS3IbknvXKeB4FiQSa1dwWVjZyi2uEMhhCZRFjCyJ/GWJDIzkjPRcYoA6C0tNeUqrXWsiDhdkaxwIgxxgeWMfnUmq+E3v7eWLVNQtrtZAAY7m5Uh17gt5efTkc1rDR9E1iUm1ktpoImaFmdFum3ryRucsFxnoQD36VFe2tvbxCTS7e91JGOPMtobfanbg7OefQHGKAOR8QfDrUNQ0f+zNF8ZajptptKG3bVWuUK/3SWTeV7Y34xXIXnwY8R21lClx42023gDDyxHbiEJjpsbdxjAIx6V6hK9wcLLompSBuD+4gYD674gP1rVktNFsIo5dWhsmdtrxqlsiSp652Eg89xSGePa3Drd/p6WOp6nqeqwRTeU8+oXVqtrM38IESlC3qC24cA1H4d8NTafpV7PcRtNDd27xuxYG1RcjbKuSEOW/iU5XngHmvU9a0/QtUvjqemX/kakQAUM7pHMo42lCdp4yMYIPcHrXIXGrwRXksOtx3lpfCUyRtcyOyKTwYpDFhVLDJYp0AVjuBoEZa6DPd6dLqF+YAqoJIGjj2RAlwpjJwoDZcYY9A+Ruw+ex+D8Ct4Z1rwxqkU0Eiyyn7JcKRItvKMbjyRhmEhGGNYKPtt5I476Kw1IIyCzlKBZ4DwTLgkb0IYeYyqSVBb5ayvg1q81j8T7zQ4JUjsZ0lkFrNu8yMjnCrEDEAMcFm+7wtMD2rwRevf+FdPln3faI0NvNu6+ZExjf/AMeQ1uVz3hfbb6l4hsgeI77z1H+zLGjn/wAfL10NABRRWL4v1o6HozTxR+dezOttaQjrLM5wq/1PsDQBkeNfEtxZiSy0kYnUqs90RlYC33UUfxStkYXBwDk9s854X06wsbK/1HWUaXz2McUwYtI7EnciHOSxIOWAye7cYF2G1tnWH7R5hggO8zF/nd3zuYc8ySfMd38MYyMZyOd8e/EI2d7DYeHp7Sx8kBI2lgVgIyAQ6nOFGBwOOOTjK0hnPfEfXbjRLmS0git7B5gsps4G8t4oiCMyyBg5Y8HapVQM5yaf8DfFF14n0TxJYeIblm0mCaCKBwpLRvtLsgzyBiMcep968H1u+v8AxL4nSz0uOe81K9mCxRl90kkhJyx7L1P0APQc19HaD4eg8F+HNP8AD9qyyTQuZrq4Tgz3Jx5j/ReEBPX5vSgR1dzo1hbWrJZanFKIFZ5EK8BBtDcrwCFIwO5xTG083Ej/AGfULae9kWJxCARjcpIGfcBjj0FZ85W300xScLKFeYKnRFxsQDqCcg+vMeehqnE84maVn8qZ2LSMhIALAArkdFCgL9BkcZoGVJQqf8JRNOhMOmaG4kV0HyzsfMB5xhlx1yMEdq7Pwv4pNnfWWiatNNM0tpBPHdSfM0bSDAhmYfxk/db+LoefvYHiSN7zTYNLil82bxDfIsrgAMbONwpc+m48g/7QX0rY08217aePdUuIFaGSdrRQwODHBEqjjqMOXPbHXjrQB6JRXL/D3VrvUdBhi1bP9pwRxmUtjMiMuY5OP7w6/wC0GrqKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAK5bx74evtdtrU6RdRWl2jPDJK+R/o8qFJQpH8X3XXtuRc8V1NFAHCa/4U1S+1aD7LJbDTILqwmgT7TJD5CQSozp5SqVkJCtgs3GQMDGa5yLw9qmqQ3eiw26osGhappa300U0Syy3DxbGffGMk+W7EoXHU55GfXqKAONbwtd/2o93FJao7a1/aIfksI/sphx05bJ6Zxjv2rEg8Ea5Kzy309o1w1vawySfa5ZRK0VwkrOFKBYwQGwijAJ/GvTaKAOa8Z+G38QPpnlyRokUxS6D5/e2rjEsXA/iwg+ma5yPwVrVvpcdst3b3HmvP9rX7VJbmUbI4oHMiqWJEUShk4BLdcKM+kUUAcBpHg3UbO50qSae1b7LJZvJtdiT5Nq8TYyvdmBHtnp0rv6KKACiiigAooooA8t1Gw0ubwBqepXUMcBk1C4E11GTC/ktesj5dcHGzNeO3U17e6Pq0ZkNvo1vevHb2cNvG9nKS6RgCZlUmVVGQXVs+xr1/xJNMvwg0+G2yJ9RuIUU7Sx+ebzCQoBJyAeg75rF+H+n3114at3021jjtdOaeO4022XY0l5vGSsj/AHVHDEcg9BxSA5C3bVLLWdQttNGoxFjdzRQywJHnaqoWS3UeXIMdC7YGMDHWu10HTfGNrrECWdxomn3VxEkiW8iT7o7cDAVo1by8qSxyOp4OMqa7PRbdn0P7FZRz65HGQn27U59qzNE+Mk7NxIx1ClTtHzEk1v6fc6gmrS2d5a2kdp5XmW0kEpJIBAKspAxjI5GR9KAOc0/xFqY017bVLW3mnUMhuDIhjmGSASvy4yM5Xt6msmQxXUgb+z7GJz0FtdwqD24U5x+FeoEAjB5BrCuNBRnJaS4u0kY+ZHPKAp+UjJIXJ7Dr79qYHB+bLaamtpc6ZLJHJG07zTKyGJRhQN4A3ZLf7OAvfNah1ZDHbpdXavC00cR5aVQX+X+IK4GTjIZ+DkjGadH4Xmj1zUDpUTWcaLEo+z6rIgLYJJK7CM8jr2xVjU47m1aze50+9a6+0IUljZZchQWZS6ASbSBg5U/rQBifELwUhjFz4Yvjo+recD5k8rIl04G5cyYJJycAE4OXHcmuJ+GdtJP8Sba31i0l0OdHkn+xrfbkmuE+ZxGiEbVyS+HByo2+ufXJfF1tNFNHcabJNCwAKAq+4fxBlOMHrwefUCuKsU0r/hN9HvrS3ntEW6CtCCXT5kZEKk8qNxUFewxjjigD0awHl+N9ZUf8tLK0l/HdOv8AQVv1hW3PjrUcdtOtgf8Av7PW7QAVxmseTqnj22tbiUrb6dZyy4BwRLINu7PqqZwe2+uzrx/xDPLP4i1bbNKAbgjavAGwKoOeP7nTOD+FAHL/ABVvtaLxjQIftuj3ALg2AM8keCQAUX+EosfOONuD3z5lY+EvGHimVbLRdCngCsfMvbyFreJOS24s/U7jkhQen5fSXw9t7XUNM1KxntbUFW4kFuA5DZ5O4EEg5xVrxLpX9nW9qEmE9quEWK5AIQjoQP8AVj8VH1pAcn8GfhzpPga5QWs1trHiKYF73Um+7FH0KQj68Ej8ey1ranaC312+lcAqkmyFCOCcZC/Qbsn64P3ga0/CuofZL6V7uRRHMuXdzjaFzgnvjsM/L/dPasbxVepc+ILpLeYTxIqfKnbeOF46EnPv1/AApXDPdXCBSZPm3KScl2z9/nsCSB6ks3FSafbLqF+NKtmLTvjzJFHCKeWIPTIBB9sp/fIBMTaQzI0iCcr5lzI2BHAg4xx2/hwOv3RnLZ0NLv5vDklvHZ6fa3d7qMKTKs96IZSHchQF2HPPLHsW7gZAMmgs00fUZby8SEazOjXLQLIP3MMSMlvAufck8DlgxxxUGr6eNC+FtpoEYV9R1B/s5WMnL3EjlnORn+InJJHc+1U4BDceKFsrzUVj1iZhfatNAxIttpxHCsgIC42FSSD26FhnTsb6LVNUFybu0M1hLcpbRxJtgto9xV7lsnLtjKA8DduwDy1AjV1S/isvGOim2G7BOnXkgUAfOu6JMnqwZc4HQMf7wrs6891VLdPD7a5lxa2rxNZ7x87EzoXlbPO5yAPYfXA9CpgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFeb2fiu8n8YalE8twNLuftNpZg2zpGktuoyVlK7WLFbg8McCJeOtAHpFFeaaX4t1my0HTIroWl5dz2emSRyneuPtE6QHzeSSfmLBhjOGGBjnTtvE2rXN0mmRjTo79ZLxZLmVHEDC3aMYC7sqWEq9WOArHnGKAO4orzweOdUuNJ1DVbXT7SOztNNgvjHPI/mlpYfMCYAwMHgn9Kt/wDCS6zbanNBeJp8kVrqNvYymJHVpBOqFWXLHbtMgBzndj+HpQB3FFeW6h401G70+8WL5Le4slv7G9hjMJaPzo14BdmIIcHcQnfiu38RyTPdaPYxTSQJdXWJnjYqxREaTaCOm4qoP+zuoA26K8/1jXtWu/C+qalBNbW1qs8lvCke4ToY7jyyS2cc7Wyu0YBHJqWTxbq20zW1ja3K3Ml7b2lqrlJRJblwPMcnbhjGR0G0soyc5oA7uivOv+E11OV7XT7OGOfVZJLhZc2UkfleUsTbDE8gO4iZDkORt+YZ6Vt6l4mvrLwxcanNolxBJDYC7bzJYmiV9gYx5V9xIJIztxx16UAdVRXH6j4nvF1ebTrKK2Eg1OLT1ll3MFD23nFyoIyQeMZGfUdabper3d5PoN/I2xrm6utLuYUYmFzF5xEyA9Mm3OPVZOScCgDsqZM4jhdz0VSfyp9VdVO3S7w9MQuf/HTQB5nrq2s/wq8Jx3889rBdQxQtJCX8xRJayDC7PmJOcADrmtjwcuoalZbrJriwigC24uL0CWdwAucIDsQ8AEnc3ryK53xCob4W+AVk+1MNtr+6tMebIfsj4C5IA579vfpWqslxazWtrr3iOPRLdIgkGkafIhlKgYzJIVLe2V2jNAG54a0yysYtTtNSv0vXlu2iaKeX5AM70QRkBVOHUnaOSc81raoot9Z0SZPIRC8lqcqd2GTcFXHA5jHX0rl/DM3h2z1jUjZrLdzuYp1LwvNKvyYJ8w5J5X14PtitvUNdtp449rXMBhnidn8oONu9QQcHgEHGT0pAdKWAIBIBJwMnqaWqN5Ps1HT4RnEjOeMdlPt7+1XqYGRapPcLqL201tDI9yQssab+FCqdwz97Kke3FZ19aak2q2cAvrW5kWKWYedH5cifdTKlTgcORkqasaVPqR0yGa0tbSZJi03zu1ux3OW5XY2DgjPPJrKlvfEA1i8mbRtPcxWwjb7JftJOgJZujRgcgAgYPPrQBkeLZtStLIvrWlpPCuVN0i+YyLych0AIAwCcoB9a5nwtNBqXiLRLi3vobmw+1KXmVgSTtJjBxnOXCjPY4B6jO3rHiXybZIdcnv7X5gVF3aeYVyMjcUXgcddmR2NZOnx28Gv2F5Z7XtZ7u3jkFs4eJ/3g2g/xLhiGG7HTHQ4pAeo6f8/jHWWxwtrax598zH/2YVuVgaLk+KfER/2rcf8AkP8A+vW/TAK8d1pZLXxJrsX3ibrzBGRkMGRDngHnn0P19PYq8v8AiTaGz8QxX6PBEl1CA3mNt8x0ONoPqQw79FNAFXw7qkFneMTfR2KEjcUtd8h47HY3GR3Nb3jm933VtG0xSBI/MUo2TJu9VwAOn97ueK4Iam6yiJbl938ISSYgn04bFal/rAa7Cw3LXF2UQSIJFnlVwOcmMkLz2LCkMElZoEcRTMgY7XY7I19wTxn2G6rN8BJpmm3FuqLcB3hLCQhARg7lTOWYDjHHuUUZrFtf7U1d7ljbm2WIbTPqBL55OWCRbumP4mx7VLYbrqKVtCsL++IkVRfxBQZOMgKjptVWZWG58quM4BIAALxQ2sSySQJc3G37TDayv8hIB/0ibAG5FA4wAD91BjltD7Pd6lfahZrp7XMuo+W7yXkTqpi353Hc+9Ix+8CxgZ55I3AVmst3dapPHrGnkat5kdnat8zwFyY2Z2kU79+OdpYAKcDOSK09WumbV431dpN93JElwlrcboIYTKUWFgvzSMcOCcYBb0oERf8ACNXCWNxZtfyCzuNVCyWy28CRssaByQm35cmLAOehDnJ5MpvzjSYYtJtrC41kq1lpttsJizzJczbQAdgOQORkDueKDwWVj4eeTUbKRoHneW1t1lM09yDNuSOOJflQEBVLDHbqOTJZaPqKXMs+oCKyvb6KOGeK1cs9jbA5S0gIx+8fqzZx1OMDJALnigDXZYrWwMraNpjRRbtpEckzOI1UE4LMu7PcDHqePUa4HS4omv8AQ9F0yC3tdLtM3TQw8hth4IJ5I8xl+Y/eKse3PfUwCiiigAooooAKKKKACiiigAooooAKKKKACqv9nWXkQwfY7byIW3RR+Uu2M4IyoxgHk9PU1aooAzbPQNHsbdoLLSdPt4WdJDHFbIil0IZGwBjKkAg9iBinXeiaVeRGK80yxnjaQzFJYEYGQ9XwR97361oUUAVZNOspEuEks7Z0uFCTK0SkSqBgBuOQBxzSvYWbu7vaW7O8iTMxjBLOuNrHjlhgYPUYFWaKAMuHw7osLTNDo+nRtNnzClqgL5YMc8c5IB57gGpNasYL23ha4me3a1lW4jnQqGiZc5OWBGCpZTkdGNY3i3xhb6LIbGzjF7rDJuW3BwsYPR5G/hXg+pOOBXn88lzq+q79euzfpwyQsNsMZHPEY49OW3Nz1oA6nVvE3ge1vbiVLS21K8mDee9hYfaWcKNx3uqkH7o6nsPSjUNc0ezZ7y78G3inUE2zTNaW26VCOkhL5xgfdbn2rzvWWjlRhLZmaaCcSpCpAxMkkWAc8Hr0PFdt4BntbrwrqN3qQtb20+2ubeJIwA7li2ApA+YsxXHoqnuaQDbTxp8Pru1TTLrTrezsw5kSC605fJ3Dq3ygqDz1OOtegadLpep6Sqac9ldaa0fkhYCrxFMY2YHGMcYqj5Vh9kj0+6XSrHUZYtwt02Pt7ZVWA3D8K5rU/BUdtdNf2cYsbsAZvtIUwPx/z0hBKyL9OfY0wOjvPB2g3Nva2/8AZlpDawXIujBDbxrHK4RkG9duCMN+gq8mjWqX9ncxgxx2cTRW9sgVYYs4ywUD72Bt64AJAAyc8zoviu8srqOx8ULDslx9m1OE/upQcAb+ykk4DD5SSAdpIB7igAqjrozomoA9Dbyf+gmr1Z/iL/kX9Tz0+yy/+gGgDz/VCR8MPBrLcyWkkcNtL5sL+WyhbVmYBj03AFf+BVZ8C+DLG70i31DVrWcTSkukDzMEAPRtoxknrk5PP4VR8Q+RB8L/AAZLfQyyRRLaK8Ue3ewNuVONxCjGc5JwADWl4evvFWq29tHYRWemaaEwk0qvcvtHT5iVBP0GKANyDw5pFn4iVotMTEtqwJMQaNSrjueQx3/iF9qTxIurxWc0WlW9nbW53L5sZYyBfLY5CgKFO4DHJ/Xjl7rRdZj8d6eb7XrqRJlePdGfKCB0JG0Dr80R4/2xXW32lpp9t9pa5up0iMTuskhOSrg7snOO5460AV7h9Wn1DRLndYFXLlF2up5iJ55PpWxqN1eWulXM8lsJHjhdytvJliQMgLuA5NZ1m6Onh4ZuD5U0sAM5+clI5EJb1+6ateMA0miPbqsTG6lit9sjlQweRVYcEfwlu9AFi2hurXS7SK12OY4o0KXDEMcDBywzz07VzVr4jn0++1e41PRZo4TcbBcWv74OFRF5PTIO4dumMZBrobma1msYZby4kCSOWikh8yPg525xz09eKyNBa8tdAS4s5oZiVa4ktJnUkb2Ln94OmQ2ckHr6UAUPEN3o3iEpHbaiE1FYi6WsiEPInOdqMVJ6dVP58V5vpsAtfHWhP9neJpb+NXKj5XPJyeOueeeeK6DWJ7fUnmuriFLcTvve2nIIRQMKQjfLkjDZBVju9qzvCunTt4v0WO2unNmt15jrI5kChY3YBCfmwSOj5x1BPQIZ6togx4n8R+8kB/8AIQ/wrfrC0BQde8Sy9zdxJ+VvEf8A2Y1u0xBWD400Ma7ojQRpA93CwnthcRiSMyKDgMp4KsCVPsxreooA8vtNBtdXsd8HhfSRbSnazQWccMgIOGUnzAUYEFTjuKg1+yuLCB4Idc0TwzpYA3QzshMadDwCoYkjq5YexrX8deCIb+9bVLZ9SEchzfWdhctC0+BgSLjq4AHH8QHqBWBY6V4R01EmstH1vUgp3x3MViZyZAe7IoYMD1BIx7GgCtdaVaahoF0kmoanqVpcMsUVzqdw1tBNKzHCQQfIpU8fN0AwVzis+WBbi6stK0uxdtTkudt5qCXTiy+0pGVyuflEg5ZQE+8v1zKbW88RS3M0wuNN03DRTX2sNGspVSDIlrCSV+bAUyOxK9BzmryldPtIVi1XyLB0+zwRWcbvY20RwWLlV2zSHoAuByc5GSUMl0DSZ7LyIdFtL21V/M22qzqXMeAHuCzqMSO5PdCVBwcYxSu7gaZDLNNYJBPNOfsWnWdyUMjQqYi7LEmT/ESwcDBwTxk6Wn/2Df30Uei2Gsz2CN5gmeZraKHauB5bFldSBlQpIAViOeBVzRL7SbW5vLXwv4aF3enaontz5kWU+6JLhyM7SOgJxjjJoEakd0+l6XHdeJNRtINSA/cW8cRMdoCpwqIOWfarYzySSB7xSRslmt9qita+f5kq2UhwYojyzztyc4HzY9QgPrkyWBsfFNprGraol3fedI8u9sWGn4if7vq/TqdxA7V0ukaa2uXK398JTp4ZXjEylHu2U5V3X+GMHlI/X5m5xQBqeF7SQpPql3CYbq+2kREYMEK58uPHYgEsR/eZq3aKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcx498RyaBpRXT4kudYuEkNrbs2N2xSzufUKoJx1JwO+a6evFNZ1WLU59O8f2sh+y2erTaY0h+ZI7TLQF8ehk+Yn0YDtQBm6Ysu+3uHeSa5mc+e7cvJIxwS3HXkAegx2GK7KLRdw0q9kcfZZpgkmcLtXnqfQ8j649a5y5jgs0jFu8dxHkRymFunQYyew6o/Rh8pw4GesGtfb9HYQwq1qYvIkjYHBKttLheMENwR/tIaQx9vOuk6xqzQ2CNKSkZVm+8iZy+cfeIYMf8AdqF7dNN0+OOOAK1jdLd7FTGdp2yjjjIBDj2ar+hRnUpbSdWVp7dlWbdySAPlbjrkcE99qnpxVy41CKK9aS6tDub93cRYDAOMjI4zkoSR/eUEdRggjwu61n+yfjp4ttdeIX7XNG8T3H3VhEY8sq3ULgHoRznkYr1HR/EOowyODdSzxlmjDXABYY5GegPXhhjII3Y4Yc38b/h3/wALC0e21/wswj8R6UhjWLdj7RGPm8okd+cqeh3ehyPIPAvxGkgkg0nxNbtbS2lwBOZ4337kIwhO4FWGOOnTvwKAPo3VtQjvIzbfY4FilJZwy5zIQQSMnAB5BBHqD/FibwFr8kdwmh6j5gJUtaSSNuJxy0Wep2jBUnkr15U54pfEWmztaRGfYtzNFBE8nIDOSFUleM8Dp1XHHAA2/EGk3awXQt2j/tG1ZHidZMYlI3Ic+7ce5bkYNAz1eq2qRefpl3FjO+F1x65UiqvhvVBrOhWV/tCNNGDIg/gccMv4MCK0yAQQehpiPJfEs8SfCrwVdSLCSn2R1E24pn7O2QQpBPGe45xUGnaRr3iWOK6uL6/Gnz4Vd9wYIlHTiJCCR6ZJ+pqbU7WSf4L+H5ImjLWDWxwwO0gN5J7HoGJ6HpXReGtVfV9Kk0qPSZIPswVFdp1AYYysiHk5BA4IBBxwOKQHO+IPh5a6BZWWr6UYzqNrcxvI00SujgsAQBt3DPAzngE5716VfFNT8PztDylzbMUz/tLxSCNdW0mez1BULsphuFXOA2Ooz9QRWd4HuHbTZ7G4x59lM0TD2zkfhnI/CmBDZXCzzWDkzt/xMGZGlPUSW7SfL/sjfgfSr3iq6ltLWCSLeNrPISIwynbG5AY/w5bbg9c4HesLSIBbXtkVD5eeOMgsu0GJZosgdc4Rc5GOR71seJIvtWo6Xbsm5HlGc47Mr46Z6RnofrQBevt1l4emBmjDxWxQSTsdpbbgFj1xnGazdU0q1uIrPSFiWNnjVZXh+RlgTGVDDkAkKuPTPpVzUpjNpKNK2xJZ0GfLDAR+YDyOQAVHJPTOeKk0NGnWXUpgRJd4KKf4Ih9xfyJY+7GgDA8S6DfSWTGJU1CSMfu5SqpcD2J4Vx/3z+NedfDlVHxMsXhSRCIZoZrVsBbchc524yrZwv0bp3PrvibWhplv5duPMvJOFUf8swcjzGHoD271wngC2tY/iJc3UcQ+1XVlK00hznd5qMTg9CS3P0HYCgDufDpzqniQ9vt6j8reGt2sDwny2tv3bUpv0Cj+lb9ABRRUN3cw2dtJcXUqxQxjLOxwBQBJLIkUbySuqRoCzMxwFA6kn0rgdf8ADJ8ZtLc6fd32gwuMfbLRjHLecYBdOhjwepG4g8FR16KK1n1xkuNTjeHTwQ0Vi4wZMdHl/mE6Dvk8DeoA8qXw3c+GbePyfCNtrNzEpRL37WZAo7MYnGV6D5Uz061JqPiC8a3Qahr9zYuWGYrPRmhdPo1xkY7ZxXqNFAHjEH/COeazTW3iPxNdRkSRm+lMyM3+yicD8UxW7G3i/W7dbe20yHR9NZQvknEWF5yCcbhxgYCD616VRQBwsHhWKy1TQ5NQnN7It0zRxFSsEJEMhBRCT83A+ZiTxxjpXdVlav8A8hHRW7C6b/0TJWrQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBieNr86Z4S1a7UkNHbvtIOCCRgH8zXnOpSWXhyzvGtrJbvQLq5SS9s0yVCGDZLtGPnBUxzDjkByORXc/ExbV/Bd8moqzWTvCs+3rsMyAkVzfglcvceGfEO0ajbRp9lu0fm6tVLeTIjdNy+oyRz70Ac5a2dro9xb6df3IvfC2qnbpd9MgmiVmHEMpHIOPlDhgTgDPUVpX2n3XhKa2trRJZ43BEdpO5lEgA5WGUgFztyPKkJYr90naALU/h/UNFlvbOzt4dR0WYF7zRmBAeNiS0tt6Nk5MZ6HG0jKirmhT6b4i8NS6FLqDalpk2YbS9cMJYzgMkcucESqCMNxnbzhgcgGppWrR2umQ3emxx3Fg7ASt/wAtEbnIZhwe2GPpg4zkM8UPFdst5Y3YJ2qroUJ+XOQCAMlSQQcfMrDK/MCDw2zVdH1a60u5Y3mqQwCaVUGDqcC/8tUHa4Tgn+97kHO5pd3Be2UV9YSrPaSp5qsmOF4ywB6jGNyk8cZ4CuEBZ0e9mlWO6s5WtZZOqqUlOCx4IB2tkhumA3JUhtynF+IPg7wh4zlE+vxnTtaKeWuqWA+/2CupBOePuuMjoDWdLAnh3VzdW8N7qctyZ5IRLIHZSQrNApbjYVBbDenzEcSV2dney5mikjtI7pgIoReoWDhsbQDyzDJxj514OHIFAHD+CfgVfaJ4ksLzU/E63ul2k4uY7WK28vzXU7k3ZY4AbJ4yeSOM12WvxXVrrt5dafOyQagiyyuoR0k2A4K8dQq9fX6iufu7bUopZJIYEncDk21uYUYnjHKqPwPH1rpvCMguNFii1lVa5TMhaAq4gCnftZgzAnKrxnJI+7gUxlj4X3dy0viKyu38wwXxljfaFyrjBGB6Oj8967qvNvhkzjxNq8II8iKyt0Ck/P8A6yY7mGeCxZj+XpXpNAjzK7tDcfCgMjMo027knZd23Kw3L7gT2+VSfYgVzc3iCe2hsk8P6ffXNzaStOs1sjm3k3DG0yPwwI4ODjoR0GOsjBb4feMbUK3+jXmoAgMQWUyNKcEc/dfFU9GtP7dvWNsYNka+b80hZ2U524A2ls9MsaQyaz8a6peTnUrTwxcQWyEW921xcxIFbOATjJ+Unr0w2a0I7rUtN8bxtJp8UUerKEZDccB0HLAhefQDjOe1Zmo313oOotfXWlNHp7Rpa3iFR/pCYwCTuKllGccnIyPerWrTLdeGi9tKt1daN5eo2c6tkz23VWB75UMp9Sue4oAv3Y+za9afMQF1RoeD/wA9EEoz+O786v8AiiWSTVLK1tmAnZdqnGdpkYKW+oQTH8KpXjQz6tFdwnfDdmxuYvr5hUkf8BdangkW48b6hPKwEFhENzngKdvH/oUtMCbxIbS61HStFM0KYY3U0ZYZECKR07ZJA7cbvQ1JqfiC3tLaK8Do6zny7JA/ExI+/kZ+THOeeB6kCsa4liupLm4uImZroJ52BlxEf9VbKM/fcYJHYM2cZFQWXhW/udVmuZpJdMc8KLVgI40H3UVPule5J5J7AYwCK+sSvGsplnkub1vnlMe7yifUxtkoMdCpI+lO8EhT4wjmjliljk0+UDZ2Ikjz/kZHuTWb4gmu7O5a3vGiuwjbxdwjDJ7YHK5wSQMqPzqx8NS03jPUZcBlj0+MNIoxktIxBbtuITqMZCgn1pAbekeIrHSTex3K3LyXN7fTqLeB5T5cMqpIxCgnALKP5V1FrrOmXdzHb2uo2c1xJGJlhSZS5QgENtznBBBz71xHh/ws+rWmg315NIlp9jvzMsFw8Ukhup4pVGVwdu1GzyDkrj2tN4T1T/hJ7C5D239nWV8J4AtzInlwiAxCMQBNmRn7xYnHp0pgdX/bWnNFLJBeQ3AiaNZBA4kKFyAuQucZyPw5rOi8R6NqFwsc4CiE3MokuVVUjNtOYHbJPHz9D6c8VxXhnwjq974R0E3VvaadPb6VYWywl33tslilcygoCrjYQF5wWbJ5rUfwfrUPmyWV3aRzk3xB3sMrPqAuAudh2kx5UtglWOQGxQB28eq6fLaR3Ud/aPbSZ2TLMpRsHBw2cHmp47mCTyvLmjbzQWj2sDvA6keo5FcHovgi4i1O3uNUispYI7+4vPJeeS6K+ZDGgw8i5ZgyscnHB49Ku+DNCms/EGsXUwcWNtLJa6XHJGUMcTsJZiM9VMhCj/ZiXHFAHaUUUUAFFFFAGVrf/H7ov/X6f/RMtatU9Qtkmks5pJRELafzeejHayY/8fq2GUsVBBI6jPSgBaKKKACimyOsaM8jBUUEszHAA9TQjrIivGwZGAKspyCPUUAOooooAKKKKACiiigAooooAKKKKACiiigAooooAxvGNqLzwvqULR+YPJL7MZ37fmx+OMVwBa1abT/D+uymKJYVm0DWoTtk8vbwCx/jUYB7EYOOePWOvWvGNVluNFv5vCut6Jc654deXzEmyiJY2xPyMP4iVORuBBG3OaAN/wAReMj4PsbmPxTHKZIohHp+owKGa8DKA3HRZAeSueQMjPQQfDDTo4dQvGW5s57TUra31F4mUrPLMcEzsmSEy2QRk4KjpVG41zTj4YbT9SuRrvh+Z2gtLuA5mQIeCzZ5dCB8w5I2sAfmxzOowXEVtol/YaiL3U5rdmXVLWMx+Y28BN6pxu2OM7gN231pAelavPpniV9UsvMH9raNKJFns2zLEOSrLjkkEEMncqfUCuLsYrixurnUtOWIWUs7SzxwFhGWHJuIh1Tk/On3o23ZypNYvhfxRdavqLR3QubfUriRbnT7mx3t9rQt++AVtuIiYwWj4YHcQMggek+GFnOoTGXToDdK0a3KQzKDuGD5xUZAfJYH5ssF74wADE8R+G9N1FI9UttStbTVY41ktppifJjHJV2XO1CMt84GMNkYJrEvk1Gzn8O686agI1kMcUFlOu0RMGXznDIQwIJOFYMoYHBJNa/iDT9OvNYKeGdSXSoJnPnNtJtLqcHPld1Ug8uMEE4BBOcQ3lt4itvMfVbASZJb7VYKZI3567EBYfX5aBmNp+nLFqTXl1cz3t2AyLJcS5wCxb5VBAB+bGcbsAfj2GmSyCyvLx0kMlvH5SbiHxvyDx1xj/a6kVzct1p0bKLjV7OxUMA7Sgnj0VR8358VQ1Hxto9tp01pY3SyEM2ZYoH3TDOFXgHI3dMevrQB23wfjaa88R3xBKGeK1Vj3KKWb9ZcfhXpNc38PNEk0HwjY2l1j7awM90fWVzub8icfgK6SmI5bSIEPiLxbpsgHk3BhutvtLF5bfrCf1rz/wCH97f6RCbDRrRJrlmNvIZSSCYmMZkwoyQSM8nOCM4r0K6/0P4jWMxOI9R0+S3PvJE4dR/3zJJ+RrhfEbX/AIS8QX1pYyFYtQEl5ayBwhBZwZEYkEnDNuGMcNjPGKAO11tNYbQXhvr2zjupXIDQWcsi7ccDAbIOe+QK87sNZl0jUIHmaKS0DMFCtjhjiWIgkkqx5Ho4HZjSw3fiDVLeJTrN2Ghy+6CZmySf4toUkcdDnHPWtjUNHvr3Q1mv9VuJ5os7YBHDvlJb+IPGxAxnHT+tAEmhXSQiw08TKV0+9FmkhOd8DvHNA30MYI+qmorTWFbSZ5/LAk1e7luXV22j7OjEAMeyk5z6qGA5IryjVY/EqXd1p+kXk1pNb3Cx7fsnnSBFxJHuA5AXznwQDlSAeRirjNq+h21mdc0u/t7YKiK1yweOdU3KoXcodBuG8KedzgkHAwhno1te6pdXUcnmJYHMjA3GN+SPvPz8kjH1xtXC+ud6y8U6nDB5Wt2sto7HCSELuPfcpGUcY9PeqOmWUo1WISRTTpAG3G2mRihHBwc5QdQRnJrpLmGdLfybGSCS12I7Wmo2xRSGJ4D4ABJ7EE5x60COW1eaG9nlb908LnLkhgpb1C/ejz7E8nv0rR8IW1tonw51e709BGGN5cBmC7zhnxvI4JGMfTFct4l+x2Mplt7a70+cdbYOJYZTn7sbZ+Vv/HfXHWuyl02Sw8EWuk3oVbnULtYpEjOQPMl3uo+ibvyNMBNV1nUtC/snQtEsRdXUenedhl3bxHtQIPmXGSeW528fKc8ObxndJ4jbSZLKEOsH25nWXd+58vd5QA6zbv4em35vaui1+DQ7iO3TxDFpsqNJthW+WNgXPGFD9z7U0R6DFfx2YTS0vTMZ0gAjEnmhAC4XruCEc9cY7UAc8PEOvGy0CWJNHmm1uZFgUNIqwI1tNN8zDdvx5QAIC7snhetVrbxhr92byay0VLi3RrqCJSwj/ewllUGRn53shG3au3I5PJrrLbSNDsLgta6fpttOjfaCY4URgcMvmcDOcO4z6Mw7mqotfC99q9wog0S41SWM+cNkTzPGygHd/EVK4HPBGKAMTTfFWo6ld2ul20lmupO9x58lxaSxCLylhbyzEz53sJ0IIcjaCwz0pLLxdq91qtwItNR9Ot7iW0lkX+BkQnzN5bkFgAE25wwbPatXyPCU2m/ZoLTR7qyhuEQwQQxypFLI4QEqAQpyeT9asrb+GZtVknWHRpNSt48vIFiMsSAFeT1AxkemOKAOYtvGuqmK0S4gsBcahb2M9syhxHD9pdlxJk5bbtGMbdxIXjrVnUfE+u2mrPpttYwX1zZ28dxcmBCFmDySLhdzjy8CMnJ3jPHGMnXlufDU9rZJDDp19aXzrpiG3SOWMhVZ1jbHG0BTgdienNW59E8PMsEE+maSVtMGKN7ePEO9uNoI+Xcw7dSKAM7w9r99eeIrrTtUijtX2yy28AhfLxJIE8wS5KSAhkJAClS4BB611VYkP/COaTqJaH+yLK/vXKkp5cck77uR2LHcffmnWniOyutVGnxCbzzJPHyo25h2b+c/9NFx+NAFH4j6b/a/hgWLWz3UU2oWAliRS2YheQlycdgoYk9gCa5G0i1y31HUF1GHVBbpfW1veXVtHJ5l1bpBIFljKDcdz+Tv2cjLjtXo+sanDpVmJ51kkLyJFHFEuXkdjhVUcDJJ6kgAZJIAJrnX8WzXmvaPp2l2ki/aftD3Rni3NAIJIkdCA4wcyj5ssMYIDA0AZmkReILq7tzeXWrRW0NpPLEu3b5pFw4gEuVzv8rZleDknIrNNr4hj0eWdZ9de7TRba9RS8hzfZfeu3ucBQYvu/7Oea7y/wDEdhY3F3BcGUT23kZjCZL+c5SPYO+WBX6g1Qn8caTa6ne2N6Zbea1iknIYo5kRGCsQqMWHLLgMFLZ4zzQBympza5c6/eLFb6nHBL9utprZobiSNoxFJ5Ugdj5Q3FUICDI3YJzkV0erNeWvgbSYYba7MjJbwzGETB4F2jLFYv3hwQAQuDzyQATVyLxVFNdQ232We2uDfLZSw3IAZWaEyjBQsD8oHfv68VHp3jWx1Cya5t7W+CGzjv4RIqIZ4X4DLlsDB67ivr05oA5zw+nia9GnLc3Opx/Z4b9gXiaFZ3ju9tuJd4LANGAcFtxXkk8mqWnT6/Fo8xun1e4lmS3W5ia2u0eCQuPMkDDlh1BSA7cDI2jmuu0jxhb61qelR6YFa1ukuvNLEM0ckLRjaCpKkfOeQSDxg1eu/FOl2mpfYLmZo7j7SlrhlONzx71Of7p+7npu4oArfD59Qfw7jVmuHmjuZ0je4heJ2iEjeWSrkv8AdxjcScdSTzXS1y7+N9LjfRzKs8cOqrAbaVzGuTMQIxsLeZkkgHCkDPOOcR+F/E1zq+prbTwwohhnlymc5S5eEdT6KD9aAOsooooAKKKKACiiigAooooAKKKKACuV8e+Hp9Wtbe/0hbf+3dOLSWnn8RyZGGicj+FuPxA7ZB6qigD56s4YbzWJLXUdR1Vb2W0imlggiRbe0lifIAB4jPmDaUGN2ORjmq/hbWpfJi0+5sNLjnhhjaUmzJNzBG7xFNpdFOwj+8ynd1JAB9W+IHgKDxJb3c+nyiy1SaERSPz5dwoOQkgHPUD5hyPccVyPhTR7HUtFbw14xnu49Vjklt42ZthyGDlopOc9uAcdeOaQGLdReINdv72/sLKW8srCKLbpwlRJlkjUlZYJCS25iQQTj5cDDdtrS7iKC8mtZr2OLxDOd1ze2k+2W3QcM88IJRmHK5UMCRkhdpxH4i0XWvD97a3l1b/bJ7d1i03UtKUJKAGZlhmtc/OnzMCYznbzgFc1LaPo17bn/hYWg2kU15MXOtW5zbtIw2j96MNCQAqgPg5HPNAzpZtHhgsCj2sF7p8se3zoYvOhmGODPCMkt/00Tn1wOKytM8PhDM3gbxK2nwxkP9meZbq23FRlUBbemCoBDD6AZrYtvCuu6HmXw54pkltCMi11eP7RHgnPEilWHU889ec1xfju50yTV9M/4TTw88Ml7+7+36VIJgXXOJI2QeYxA6qyHjpnByxHSnX/ABpBOtq0ngu6lYg5bUXiJHcbdhP069at+EX1vxRc/aNfi0xNKsrjfbHT3do7yUdGywGUQ5wejMM9FGaPhbwpqeox3I1i/L+GZyGt7R7WGO4njwMCVowAEP8AdHLD7xGSp9MijSKNI4kVI0AVVUYCgdAB2FADqKKKAOR+JMj2Gm6ZrUfH9l6jBPL/ANcXPky/kkrH8KyfinYvLq/hy8XyVCtPbGSVNwUugZcDnn92exrt9b02HWNGvtNus+ReQPA+OoVlIOPfmuMudPufFXwwm0y+UPrdkohkG4jN1AQQc9g+Ac/3ZKALPhDWNB06zZJ9XtlvHJMplmCjgnGM4A/Dmna3qulaoZEs5YZCVI+0QXCjJIxzjrj0NcP4aa11aSFdJsTFv/54RAMg4zv5GMH+XSvSXgOm2yxah4gmQIu5BGqIxUdsEHd+H60AYngHRIJIfEVlrFrBd+VqY+WeJWx/o0GOCWAOD1BqT4g6JpGleA9duLHTLO2kW2bLxQqrYyOMgZq58PJ0uZ/E8sU8lwh1UgSyKAWAt4B2A9PSn/FgsPhx4hKff+ytj68UAcn4bc3322ew0++eRNuJ/kZMFWyCpOWGOOAeSMCrL3zzLPaZjMIY+ZbRkgIfQoeR6449cVk+DftK+G7mR9dGm3fnNsjlkCoWAX723oCe+Onak1LU5tSZYdQnS4dz5azxt+7D+glXGzkcbtoPbnikMsxWsV3fadbsxlimvYgIgNwbB3sCc8DajHn06V3N+4vvHOmWa5KadbyX0voHfMUYP4ecfwrC8C6fFp+ly+ItXut0ccchildQoWAHJkPXcWA6+nQDJz0Pg62nNncapfwmG/1OT7RJG33oo8YijPuqAZH94t60xFPxfoF9qd489iljOJtPm0+RLx2URiQqd64Vs9OV4zheRiqsPhC6hvJphNBIW1i2vhK5PmNFFaxQkMcfeJRzjphuvJFdtRQByvjbw1c65LZyafcR2zlXs7xmyDJZyY8xVx/H8q7SemT61h6t4O1i+1ZZXuoY7WG4uHiliuJA0cMlrLCqJbhQgZTInzbiTtzkZxXo1FAHlui6RqetTXUn2KKwijTRY0LRzRI/2S7eaTCyRo4+QqB8uMkDdwcaaeDtUt7SD7Bc2VveRQ6mglwWG+4lDxnBXkAAZz3xwa7+igDz7SvB+qQ6ul7cNbxj+0IbxkN7LcthIJIj87oCSSykDAAAxxgZ0fGXhCTxDqtvMlysFs1tJDdDJ3Ow+aBhx/BIS/1ArsKKAPMdT8Ea/daGLAXFm3nWhMyrdSwJHePK8ssg2oTKpZxgMQBtzgluOg0vw1eWniddRkktzAJ72XarNuxMYtvbGR5bZ59OtddRQBQ1rS4tWs1glklhaOVJopoSA8TocqwyCPwIIIJBHNUNN8N2WmX9tfi4uJLmGO5jaWZl/emeSJ3Z8KBuzEgGMADjHTD/ABlLf22gyXelJPLdWssU5hhXc80ayKZIwO5ZN4HuRXF+V4qNrf2uqG5upLM2SpIsO5Ll5LlZJWUY5EabVz2wfrQB2eraHpt74h0jUruRkvLQusEYkCrMSM4Zf4tuCw9Dk1h6h4G063sLp2vLloY4LkQw3E8cMMRmYOSZFj3D5lX5mLEY71haVoU732nWkqazH5eualNO2ZUVI5GumjZJOAAwdMlT1bBweK276PVL/wCDskd5DdTatLpm2SNoz5rybccrjO4/SgCzoHhS6S4lvddu3mvW1BL5PLkVwCkHkgMwjQHI3HhF7dcEmR/AWmNpun2YuL1VsbO3soX3IWCwuroxBUqWygzkbT6VkhNcu9Wkt459Vt76W6vYriRlkFtHalJRbtGSNm8HyD8p3ZL5zjhPDF14rvta0uTVo7q2tLpTfSxGPasOxGiMDHHG5milA6kh+wNAHR6T4VtdOv4r0Xd5cXKPcSF5mT52m2byQqgf8sxjGMZPthuveDtN1q7vbq5a4juLqzFkXhcKYwH3q65Bw4bBBOfujis7xPba1da1qn9nXWoQxQ6RvtUhwscl0TKBkkckYTjI6jPasu41TV76eZ1i1qPST9hWYi0mimCkS+cY12h87hEGKjIGSPWgDoLvwXYT3xuI7m8tomltJnt4jHsdrZ0aPJZCwHyKCAwHHYkmrmjeGrPSLwXNtJcNII5IsSMCMPM0p6Ac7mIHt+dec3WraiPC11dzXWsiyt4dWNrPF528SxXUqw+cVG4BY1GN/wAp53ZOK1ru815/FNk9rFqERS4hidGiuJIZ4WhBaQsD5KDc2CMF8rnI6UAemUVwPw5OtNc7taub4ztag3VvcWs6qtwGGWWR/wB33YbYvlIwR799QAUUUUAFFFVdW1C30rS7zUb1ylraQvcTMFLFURSzHA5PANAFqise38S6XJFdPPcfYvspUTreqbcx7vuk78cHnB6ZBHUEVOmt6a+qyaat7Cb2OBLkxbufLfftYHofuN06AZOMjIBo0VnjWtLOnG/GpWX2AHabnz08sHOMbs4zmoLDxFpd9qV1YQ3cX2uCURCNpFBlPkxzboxnLLtlXke9AGvRWbFrmmO1qj3sEM11kQQzSBJJMHHyqeTyO1WY7+zlvpbKK7t3vIlDSQLIDIgPQlc5A5FAFmubtBZPL4lg1JIXtIboSyCZQUCmCNiSD+Nbct9aQ3kVpLdQJdzAmOFpAHcDqVXqfwrm1tYNR8W30YvLKWz2w3EttHMGleRNyjeo6IMIeepAHQHIBX0vwx9oc6la3epaRuBFpAkgcQRnqTHIGVWbgkADAwOuar6j4G1O9kuWPiZ0NyvlzN/Z0JMy91kGNj8ccrkdsV3tFAHnulfDC3trUWt74h168swMC1F15MSj0GwBsdsbunFddo+gaVo246bYwwSMMNLjdIw9C5yx/E1w+sXMFl40lkkubLVJ5L63CWq3skN9ag7F2pGMh4xy5HygqXznHLrXWNdvZbX/AImzQreJqLYS3jPlfZ5gibcg9Qfm3Zz229aAOscN4euGlU50WVsugH/HoxPLD/pmT1H8J56E43gcjI5FeZWPi3Ub+Szea5gjuZ5LBI9K8tT9qgnjiaaYZ+bC+ZL0OAITkHPGbqHiHVJvDeoQ2WolbgaXczXFtbIqPpTxMgSMbfmX5S4+bJO3cuACKAPX6K8wudRvLXXNT1LTtYF1DFHpalkWNo7lZJ3RiSBxwxxtxzjrjFdN431XVNLk0xdLEZN+72K703COdwDFIf8AZXa5I7g/SgDqa5TV5f8AhH/FVtqTcaZqmyyuz2inBxDIfZs+Wffy65tvGGpXekwTzXI0yW8u3hgZmjhijMUarJG8kiP83nCUABSSF46E1jG4/wCErWwk1aNXj1WDRZLiFSQp82OcuBzkDn+VAFjx/a3vhHXP7S0u4S00zUJCxkZCwtrluo6/KJOvQgtkY5FaGgXGnaxbwz6/rN1f30q58j7IhCAE9NsOeevNbFxINPsP+Ef8bKb/AEm4XyI9SkTKSr2W4I/1b9Pn4VjzlTxWcttr3g2SSWELrGgBGZZo4BJdwDbhdygjzFHGWXJIH3e9AG/4FijhuvE6QoEjXVSFUDAA+zwcUnxW3f8ACufEGzO77I2MHHP1qp8LL9tUsddvmMRM+pu+YvukeTFgirfxVYJ8OfELsSqraOSR1A70AeM6PhNPAj0y9aVlkb7fb3MjOW3YCkPuRz1OCOR3GOd7wXpB8V6xd209rAtjBsNzKrMhdGJIiMfZmCkNzjae+4YfoWinxLa6W/h6WYkxIl3ftHJHHFHg5VS/+ubB4GCoPJPGD3dm9vZo/hrwPDHE8Dbbu9Cho7Vj95mJ/wBbOeuOeeXxwChlrUI013WbfR7ZQNI010lvdgAR5FAMVuO2Bw7DsAg/iNdXVPR9Nt9JsI7S0D7FJZndtzyMTlnY92JJJPqauUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFV9QsbTUbZrbULWC6t2IJinjDoSDkcHjg81YooAzp9C0ieO0jn0qwlSzGLZXt0IgHHCAj5fur09B6Vo0UUAFFFFABRRRQAVkeMNMm1rwjrel2rRpcX1jPbRtISFDPGygsQCcZPYGteqGvXN1ZaNe3Wn24ubqCJpI4CceYQM7R7nGB74oA5jXPBW+ezvNJkke8huDNMbm9lVpx5bIP3oDFdoY4AXHLDA3E1ny+BLs2t7a2y2VtBeaRFp5PnvI1u0bzsACVBkVhMFPKHC9OcC43jObUYPN0HyZY7m58mwbyTMblVi3yMBvRQA3y5LgfK3sKp2vjvUL7TIdQt7a0gijisHuIZdzszXLhSEYEABc8Eg7jkcYzQBPbeFNTt7221KK2sTdw3PnPBPqMsyTZhMe7zDFlGUEAYQ8ZGeeLMPhS8F3NdMthDJLq9tqG2JmwkcdrFCyA7R/Ej4HTB7ZIqnL4q1VZZ7exW2MijVbgyXQZwFtZo0VAF29fMxnPGO/Qzr40updY077LAkum3FxDaTfutpglkiEgHmFxuI3LwsZGDywPFAGXdeB9ek0yKw+02kluscYUC7lhEUiztIWKqn73IKgBiApHQ9a1/D/hK60zX1ubjyriGK6urmK4+2yBx5zMxBh27c/NgnfztBwDwJdH1u7tPhfp+szZu547WKedpGJLICPMbPqE3H6iqNv4+ln+177aO1SCF5/McNISrtF9lOwYJ8xZDkZGGQjPUgA0NY8NX13rN3JCbM2l5c2dy88jkTweQyttRdpDA7OCWG0uxwelL4f8AC1zpl/pU7ta4tv7Q87yyct9onWRMcc4C8574xmuevPFGr3Q8q4D2V1Z3l3ayiPCeZjTzOjFQ7gYLrxuPK54PA9C8PSvNoGmyzOXke2iZmY5LEoCSaAL9FFFAGbJrulxzmGS+gSUSSRFGbB3Im9x+C4Y+xrMufGel295bQSGZlublbaKSJN4y1uZwzAcgbRjpnJHGMkZ3iPwBBrV5rFz9teCS/RAhWPJgbaqSsDnkvHHGnbAXvmrd34TkbVzqNlfRwTrqCX0Svb70XbatbFCAwJBVmIIIwcdccgFvw54qsdccwRlobwNOPJZWwwilMbFWwFbnaSATjcM1Jc+JbO01W/s7wNELZICrKC7TNLvwiooLE/uzwMk/hVbSPC/9nXemTfbPM+xfbfl8rG/7RKJPXjbjHfPtTNU8LSXWvtrFrfrBeI8EkAeAyIjRpPGdwDDcGW4cYyMEA80AaK+JdGaATf2jbiIrG+5mwMSSGNOvq4K47EYOK0LO7gvYnktZVljSR4Sy9A6MUcfUMpB9wa4+b4fWtyLMXd20mxLwXIVNouHuHZy3U7Qru7KOcZHPFdL4c0w6PolpYvN9oliXMs+zZ5sjEs77cnG5ixxk4zQBpUVhXniFdKt3uNcs57G1Q4a4GJY19yVyVHuQAO5rYtLmC8tori0mjnt5VDJLGwZXB7gjgigDmfFUceq6mumX0ki6PbWrXt/GhI89SSqRsRzs+WQkd9oHTIPmln478XzrH/ZFtoWmaOYx9ltjbvI8MIX5Bw6ruxjgDAr0vXFLapr8Cj57jRhsPclTMD/6Gv515zpptrTQ9Mk2PO81sytn5SreWCc46gdOMZ3DpSA6L9n37SfCmsvfyrLdya1dySukYjVmJU5CjgcEcV0PxbEv/CtfERtyBOLRmjzyN45XI7jOMjvWb8FRH/wjuqGEAI2pzNx7qhrX+KUpg+H2uyjYClsWG8ZXII6+1MDjNB8beIbTXtMs9duLG8s7qRIHkS1MLo7EKpzvIOWI4x0Ndno8Uek+Mr/TLIFbK5tRf+TuJWKUyMHKjsGyCQOMgnua8osmg8ReJ/DKWrfv2v1kmhIwFEJaRnU+nyIPq1ereHZludZ8R65cssVqkosYXkYACKDO9s9APMaX/vkUAdVRWNbeIbO8YfYIry6jPSaK3fyj7hyApHuCRWi95DEI/tDrC8h2qjsAxOQBj15I/OgCxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTZZEhieWZ1jjRSzOxwFA6knsKdWd4itry80O+ttMnSC9liZIpJBlQSO/B+mcHHXB6UAUHXwrc6FDvGhy6NE5aLIia3RwGJK/wAIIG4nHv71heLNP8KwDTNRv7m3itYFh+x2luluBKFkDr5Z2+ZjJUkI4BA6cnLdJ8HahFrFve3f2YRprA1Jozdy3LbRZPB991BLb2VuwAHHQCqQ8D6xBpk1nC2myi5tYLd2kldfI8qeSQbBsO4EOOPlwV79gDub2DRtPhku76LT7WLEivNMqIuJWBkBY/32Ck+pAzmqq2fhk6vbMtvox1Ro1kgISLziij5WX+LaAOCOBik8S6ZeXd7pF7YLazS2EzyfZ7lyiOGjZMhgrYYZ4O08EjjORgW/g+9TxAb2eK1kt5bqC9Kpeyxi3eONE2rGE2yAbOCSvDYI45AOmN3osNtHp6mz+xNG0flIFMKptyVYD5QCD0PBqw1hpkzXUDWtlI0kKQ3EZjUlohu2I4xyvL4B45OO9cfp/gq403SNChtrbSnnsraeO5jbKxXEkke35iEJIJzkkZwe9a/gHw7c+GdPubK5lhug0iyLdgt5svyAESA5+7tCr8x+QKDyMkA1rfQtItovLt9KsIo9xfbHboo3FNhOAOpT5SfTjpWhFGkUaRxIqRoAqqowFA6ADsKdRQAUUUUAcDquvava3niC7+228em6Zq1lZ+U0A+WGQWjTSPIT0CzSHoMDkk44pT+Mbi5lbGrQWWmtPeiO/QRlXMXleVEGYFTvDu2epEZx616XVDV9KttWhWK8Nz5a54gupYNwIwQ2xhuHscigDzxPGOoyR6bLPqMVrcyNpKpZ7EH2xLl4VmkGRuwPMcDaRgoc5qC48c6smoaidMlS8T7NeyJZylGmt3hkVV3RxoGUYLHazMzY/h6H0Sbw/p01zbTPDLi22eVCJ5BApTlD5IbZlTgg7cggegxq0Acr4C1S61KC9+1ahZahHHIvlTW9xHMwBXJDmNVXOc4wAcEZ9T1EsayoUcEqeuCRTqKAMltOvLbLabfyHnPk3ZMqH2DfeH5ke1YEUiWWpmCwiGjarIxcWUxxaXx6nyyON/fKgMOrKRXa1T1bTLPV7GSz1G3Se3fBKt2I6EEcgjqCMEHpQBzsOovqfiOFm0y/sltrOeO7e6g2IuSm1Vf7r/dJ+UkY64ry3wvJea5aWFjoljFd3PkrM8s5Iht1IVfnYDgkI2FAJOenBNem6h4S1a/sJdJuPFN3/Y0g2OFhUXbR94zPnpjjOzcR/Fnmug8O6Fp3h3TEsNHtVt7ZSWwCSWY9WZjyx9zQBzXwksLzTNF1Wz1I2puotSlDG1QrHjahAUHngEDJ6kZq98UhcH4f60LKNJbowgRRv91n3DaD7ZxVvwpxca//ANhOT/0XHSePRnwnfdP+Wf8A6MWgDzD4ZCNfiasFxZrY3NtZXKfZHGJIHZ4MjGTwVTgjII6HBrp209dCjtbLXp21hjPIdP0izi5uGMhcyyhjhiC3JYhF69SK6nxH4T0vX7q1vLqOWDU7TIt7+1kMVxED1AcdVOTlTkHPSp9C8PWOjPLNAZ7i9mAE15dymaaQDoCx6KOyjA9qAM9IPFWpfPc3llokJ5EFtH9pmA/2pHwgPsEP1NJD4Ulj1iLVJdb1C6u4QFj+0LGVC/xDaqqOfUYI459epooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDB8K/6/Xv+wlJ/6BHTPH5A8J3uc4zEOPeVaf4VGJ9d466lJ/6AlR/EHnwndjgZkhHP/XZKAOiooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAxPDDbpdb9tRkH/jqVB8QQW8KXQBwTJAM/wDbZKm8L587W84/5CMn/oCVF4+48LXH/Xa3H/kZKAOhooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooArWdv5D3LYA82UycHOeAPTjpUes25utPeILuJdDjAPRwe/0q7RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Petechiae (from swabs used to obtain cultures) and papillary excrescences (associated with inflammation).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17588=[""].join("\n");
var outline_f17_11_17588=null;
var title_f17_11_17589="Hailey-Hailey 3";
var content_f17_11_17589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hailey Hailey disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Red, macerated, and cracked axillary plaque in a woman with Hailey-Hailey disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17589=[""].join("\n");
var outline_f17_11_17589=null;
var title_f17_11_17590="Ciprofloxacin (systemic): Patient drug information";
var content_f17_11_17590=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/5/20570?source=see_link\">",
"     see \"Ciprofloxacin (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/11/44216?source=see_link\">",
"     see \"Ciprofloxacin (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9611233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cipro&reg;;",
"     </li>",
"     <li>",
"      Cipro&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9611234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ciproflox&reg;;",
"     </li>",
"     <li>",
"      Auro-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Ciprofloxacin Injection;",
"     </li>",
"     <li>",
"      Ciprofloxacin Intravenous Infusion;",
"     </li>",
"     <li>",
"      Cipro&reg;;",
"     </li>",
"     <li>",
"      Cipro&reg; XL;",
"     </li>",
"     <li>",
"      CO Ciprofloxacin;",
"     </li>",
"     <li>",
"      Dom-Ciprofloxacin;",
"     </li>",
"     <li>",
"      JAMP-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Mar-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Mint-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Mylan-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Novo-Ciprofloxacin;",
"     </li>",
"     <li>",
"      PHL-Ciprofloxacin;",
"     </li>",
"     <li>",
"      PMS-Ciprofloxacin;",
"     </li>",
"     <li>",
"      PRO-Ciprofloxacin;",
"     </li>",
"     <li>",
"      RAN&trade;-Ciproflox;",
"     </li>",
"     <li>",
"      ratio-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Riva-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Sandoz-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Taro-Ciprofloxacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of tendons getting irritated and tearing. The chance is greater in people over the age of 60; heart, kidney, or lung transplant patients; or people taking steroid drugs. Call your doctor right away if you have pain in the back of the ankle or joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you have myasthenia gravis. Very bad effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ciprofloxacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had tendons get irritated or torn when taking this drug or an alike drug in the past.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697757",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care in children younger than 18 years of age. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697297",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low potassium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698530",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking theophylline, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697610",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug 2 hours before or 6 hours after antacids, some didanosine products, multivitamins with minerals, diet aids, or sucralfate.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698369",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tendons may rarely get irritated and tear.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain in back of the ankle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696116",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may crush the tablet and mix with water. Flush feeding tube before and after this drug is given. Stop tube feeding for at least 1 hour before and 2 hours after the dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put liquid suspension down a feeding tube.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may take with meals that have dairy products. Do not take with only dairy products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699444",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature or in a refrigerator. Do not freeze. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11594 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17590=[""].join("\n");
var outline_f17_11_17590=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611233\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611234\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030445\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030447\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030446\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030451\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030452\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030454\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030449\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030450\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030455\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030456\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/7/26740?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/39/36468?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/50/6947?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/20/27971?source=related_link\">",
"      Ciprofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/21/15700?source=related_link\">",
"      Ciprofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/48/38658?source=related_link\">",
"      Ciprofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/5/20570?source=related_link\">",
"      Ciprofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/11/44216?source=related_link\">",
"      Ciprofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_11_17591="Sputum cultures for the evaluation of bacterial pneumonia";
var content_f17_11_17591=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sputum cultures for the evaluation of bacterial pneumonia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17591/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17591/contributors\">",
"     Susan E Boruchoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17591/contributors\">",
"     Melvin P Weinstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17591/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17591/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17591/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17591/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/11/17591/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower respiratory tract infections are common in the general population, occurring with increased frequency in older individuals and those with chronic diseases or compromised immune function. A diagnosis is made by culture of respiratory tract secretions, by isolation of a compatible organism from blood or pleural fluid cultures or by molecular methods.",
"   </p>",
"   <p>",
"    While a positive blood or pleural fluid culture definitively identifies the pathogen, an organism growing from a respiratory specimen is not definitive proof that it is the etiologic agent. Many bacterial species are normal flora or colonizers of the respiratory tract, and although present in respiratory secretions, they may not be responsible for the clinical illness in an individual patient with pneumonia due to another cause. As a result, there is controversy about the diagnostic accuracy of many cultures of respiratory specimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rational approach to specimen collection and the interpretation of results is required if clinically useful information is to be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17591/abstract/1\">",
"     1",
"    </a>",
"    ]. The value and limitations of sputum cultures in patients with suspected bacterial pneumonia, as well as the clinical indications for obtaining sputum cultures in such patients will be reviewed here.",
"   </p>",
"   <p>",
"    Issues related to specimen transport to the laboratory, general approach to Gram stain and culture, and examples of clinical microbiology findings in patients with respiratory tract infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35059?source=see_link\">",
"     \"Microbiology specimen collection and transport\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34791?source=see_link\">",
"     \"Approach to Gram stain and culture results in the microbiology laboratory\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17524?source=see_link\">",
"     \"Clinical microbiology review: Respiratory tract infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the evaluation of patients with possible tuberculosis, Pneumocystis jirovecii (formerly P.carinii) pneumonia, invasive aspergillosis, influenza, and other respiratory viral infections is also discussed separately.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=see_link\">",
"     \"Parainfluenza viruses in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=see_link\">",
"     \"Diagnosis and treatment of adenovirus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXPECTORATED SPUTUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectorated sputum is the most common lower respiratory tract specimen received by the microbiology laboratory. Expectorated sputum is often difficult to assess because many specimens are in fact mostly upper airway specimens and not sputum. The first, and most important, step in evaluation is the Gram stain. Gram stains are useful to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess the suitability of the sputum specimen for further processing and interpretation",
"     </li>",
"     <li>",
"      Predict a likely etiologic agent by identification of a predominant bacterial morphology in an adequate (purulent) specimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several guidelines have been proposed to evaluate the quality of sputum samples. These guidelines have proposed different combinations and cutoffs of the minimum number of squamous epithelial cells (SECs)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polymorphonuclear leukocytes (PMNs) per low power field (LPF, 10X objective) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17591/abstract/2\">",
"     2",
"    </a>",
"    ], but none of these parameters can be considered to be clearly superior. Our laboratory rejects all specimens with more than 10",
"    <span class=\"nowrap\">",
"     SECs/LPF",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef81458 \" href=\"UTD.htm?15/56/16258\">",
"     picture 1",
"    </a>",
"    ), without considering the number of PMNs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17591/abstract/3\">",
"     3",
"    </a>",
"    ]. Rejection criteria have not been evaluated for Legionella, mycobacteria, or dimorphic fungi and our laboratory accepts sputum specimens for diagnosis of these pathogens without screening for cellular content.",
"   </p>",
"   <p>",
"    If a submitted specimen is rejected as unsuitable for culture, the clinician should be notified, and a repeat specimen should be requested. If Gram stains are used for screening, the suitability of each sputum sample should be assessed as soon as possible after the sample arrives in the laboratory in order to minimize delays in acquiring another sample.",
"   </p>",
"   <p>",
"    A good quality sputum Gram stain may or may not be helpful in determining the bacteriologic etiology of pneumonia. Many purulent sputum specimens lack evidence of a single predominant morphologic type, but rather contain multiple organisms. However, a specimen that does demonstrate a predominant organism can be quite useful (",
"    <a class=\"graphic graphic_picture graphicRef75924 \" href=\"UTD.htm?21/0/21507\">",
"     picture 2",
"    </a>",
"    ). In fact, such samples may still provide useful diagnostic information, since some fastidious organisms clearly seen on Gram stain may be overgrown by indigenous respiratory flora on solid media (eg, Streptococcus pneumoniae).",
"   </p>",
"   <p>",
"    The sputum Gram stain has less utility in the diagnosis of atypical pneumonia. In general, patients with atypical pneumonia have mucoid sputum with abundant PMNs and few or no organisms on Gram stain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Legionella infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Collection of expectorated sputum for optimal yield",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to one-third of patients with bacterial pneumonia may be unable to produce a sputum specimen, even under optimal conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17591/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Approaches used to improve the quality of the specimen obtained include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtaining the specimen prior to antibiotic treatment",
"     </li>",
"     <li>",
"      Rinsing the mouth prior to expectoration",
"     </li>",
"     <li>",
"      No food for one to two hours prior to expectoration",
"     </li>",
"     <li>",
"      Inoculation of the culture media immediately after the specimen is obtained or immediately after prompt transport to the microbiology lab",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     When are sputum Gram stains and cultures indicated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is controversy about the utility of sputum specimens in community-acquired pneumonia (CAP). The value of sputum examination and culture in patients with nosocomial pneumonia, especially ventilator-associated pneumonia (VAP), is more universally acknowledged.",
"   </p>",
"   <p>",
"    Special stains of respiratory secretions may be performed for certain organisms when clinically indicated (eg, acid fast stains for mycobacteria, direct fluorescent antibody staining for Pneumocystis jirovecii). These are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Microscopy with staining'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sputum Gram stain and culture have no role in the evaluation of acute bronchitis in otherwise healthy individuals. Similarly, they are not indicated in the initial evaluation of patients with acute exacerbations of chronic obstructive pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=see_link\">",
"     \"Acute bronchitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Community-acquired pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) have issued consensus guidelines for the management of CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17591/abstract/6\">",
"     6",
"    </a>",
"    ]. These guidelines recognize the limitations of sputum Gram stain and culture discussed above.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    guidelines recommend that a pretreatment Gram stain and culture of a sample of expectorated sputum be obtained only if a good quality sputum can be obtained and if appropriate measures are in place for collection, transport, and processing. Under these circumstances, expectorated sputum specimens are recommended for hospitalized patients with signs and symptoms of pneumonia and any of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intensive care unit admission",
"     </li>",
"     <li>",
"      Failure of outpatient antibiotic therapy",
"     </li>",
"     <li>",
"      Cavitary lesions",
"     </li>",
"     <li>",
"      Active alcohol abuse",
"     </li>",
"     <li>",
"      Severe obstructive or structural lung disease",
"     </li>",
"     <li>",
"      Positive urine antigen test for pneumococcus",
"     </li>",
"     <li>",
"      Positive urine antigen test for Legionella (special culture needed)",
"     </li>",
"     <li>",
"      Pleural effusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sputum tests are optional for outpatients and for hospitalized patients who do not meet the above criteria. An endotracheal sputum sample should be obtained from intubated patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Sputum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hospital-acquired (nosocomial) pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sputum Gram stain and culture are indicated for all patients with hospital-acquired pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such specimens may consist of either expectorated sputum or suctioned secretions, depending upon whether the patient is intubated. One study correlated Gram stain and culture results for 504 consecutive sputum samples obtained by endotracheal suctioning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17591/abstract/7\">",
"     7",
"    </a>",
"    ]. A mean of 4.05 organisms were recovered from the 15 percent of specimens with &gt;10 squamous epithelial cells per low power field",
"    <span class=\"nowrap\">",
"     (SEC/LPF),",
"    </span>",
"    compared with 2.35 organisms for specimens with fewer epithelial cells. The yield from culture was low (88 percent either no growth or normal oropharyngeal flora) when no organisms were visible by Gram stain. The authors of this study concluded that a laboratory that rejected endotracheal suctioned specimens with &gt;10",
"    <span class=\"nowrap\">",
"     SEC/LPF",
"    </span>",
"    or no organisms under high power could generate considerable savings for the institution.",
"   </p>",
"   <p>",
"    Sputum culture results cannot be interpreted in the absence of clinical data in patients suspected of having nosocomial pneumonia, especially those who are intubated. In patients suspected of having nosocomial pneumonia, a positive sputum culture in association with the typical signs and symptoms (fever, peripheral leukocytosis, deteriorating oxygenation, change in quantity or character of sputum, or a new infiltrate on chest radiograph) are suggestive of pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Purulent sputum and a culture that grows a predominant organism may be indicative of tracheobronchitis, rather than parenchymal infection, in a patient without the clinical findings described above. Furthermore, in such a patient, a non-purulent specimen growing a predominant organism is not indicative of respiratory tract infection and should not be used as an indication to start antimicrobial therapy. Hospitalized patients become colonized rapidly with enteric gram-negative bacilli, with a frequency that is dictated by the severity of their associated conditions and prior antibiotic exposure. It is often difficult or impossible to determine the clinical significance of these organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SPUTUM CULTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine media used for the isolation and identification of respiratory pathogens include blood agar, chocolate agar, and MacConkey agar:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood agar supports the growth of gram-positive cocci and most gram-negative rods and is especially useful for evaluation of the colony morphology and hemolysis of streptococci.",
"     </li>",
"     <li>",
"      Chocolate agar permits recovery of Haemophilus influenzae and other fastidious organisms that may grow less well on blood agar.",
"     </li>",
"     <li>",
"      MacConkey agar is selective for gram-negative bacteria and allows further classification into lactose positive or negative organisms, based upon their ability to ferment lactose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specialized media is required for culture of atypical pathogens such as Legionella pneumophila. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The laboratory should be notified when respiratory specimens are sent from patients with cystic fibrosis, so that special media and processing can be used to detect pathogens of particular interest in this patient population, such as Burkholderia cepacia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture results are reported in a semiquantitative manner (1+ to 4+ in some laboratories, rare-few-moderate-abundant in others). Most true pathogens are present in at least 3+ (moderate) amounts. When the same organism is detected from respiratory and blood cultures concurrently, it is strongly suggestive that the respiratory tract is the source of the bacteremia. &nbsp;However, the diagnosis of pneumonia must be based on clinical, rather than laboratory, criteria.",
"   </p>",
"   <p>",
"    As stated above, sputum cultures may not yield a specific pathogen. Since the oropharynx and upper airway are virtually always colonized with indigenous flora, cultures of expectorated sputum will often grow mixed flora, even in the absence of bacterial lower respiratory tract infection (",
"    <a class=\"graphic graphic_picture graphicRef66953 \" href=\"UTD.htm?38/44/39621\">",
"     picture 3",
"    </a>",
"    ). For some organisms, the concentration in culture is important, and clinical correlations are critical.",
"   </p>",
"   <p>",
"    The yield of sputum cultures is further diminished if the patient has received antibiotics prior to producing the specimen, which occurs frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17591/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The greatest problem in this regard is with fastidious pathogens, such as S. pneumoniae and H. influenzae. The experienced technologist can select colonies with morphologies consistent with known respiratory pathogens, but their presence, especially in a mixed specimen, does not equate with causality.",
"   </p>",
"   <p>",
"    Organisms can also colonize the respiratory tract, especially in patients with chronic illnesses or recent hospitalization. Thus, any positive sputum culture result must be interpreted in the context of the clinical setting. Some organisms are virtually never pulmonary pathogens, such as Candida spp, coagulase-negative staphylococci, enterococci, gram-positive bacilli other than Nocardia, H. parainfluenzae, and streptococci other than S. pneumoniae, S. pyogenes, S. agalactiae, and S. anginosus. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Specimens obtained via bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy can be used to acquire samples of lower respiratory tract secretions in patients with suspected pneumonia in whom respiratory samples cannot be obtained by expectoration or in whom such samples have been nondiagnostic. Lower respiratory specimens can be obtained by bronchoalveolar lavage, routine brushing, washing, or protected specimen brushing (using a double-sheathed catheter that minimizes bacterial contamination). A variety of quantitative culture methods have been developed to differentiate infection from colonization and to identify pathogenic organisms in the fluid obtained but none of these methods is completely reliable. The utility of quantitative cultures of specimens obtained by bronchoscopy has been highly variable in individual patients and in various studies. The role of bronchoscopic sampling and quantitative cultures, which have been best studied in patients with ventilator-associated pneumonia, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link&amp;anchor=H322290#H322290\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\", section on 'Respiratory sampling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When bronchoscopy is used, it is imperative that specimen handling be optimized, since fastidious organisms may not survive prolonged transport times. In addition, use of a diluent such as bacteriostatic saline in bronchoalveolar lavage or brush specimens can inhibit the growth of microorganisms, possibly leading to false negative results [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17591/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchoscopy for specimen collection is most useful for the diagnosis of infection due to Mycobacterium tuberculosis in patients with negative sputum studies, for Pneumocystis jirovecii (formerly P. carinii) or other fungal or viral pathogens, or for establishing a noninfectious etiology such as malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17591/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53649420\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower respiratory tract infections are common in the general population, occurring with increased frequency in older individuals and those with chronic diseases or compromised immune function. A diagnosis is made by culture of respiratory tract secretions or by isolation of a compatible organism from blood or pleural fluid cultures or by molecular methods. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While a positive blood or pleural fluid culture definitively identifies the pathogen, an organism growing from a respiratory specimen is not definitive proof that it is the etiologic agent. Many bacterial species are normal flora or colonizers of the respiratory tract, and although present in respiratory secretions, they may not be responsible for the clinical illness in an individual patient with pneumonia due to another cause. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Expectorated sputum is the most common lower respiratory tract specimen received by the microbiology laboratory. Expectorated sputum is often difficult to assess because many specimens are in fact mostly upper airway specimens and not sputum. The first, and most important, step in evaluation is the Gram stain. Gram stains are useful to:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assess the suitability of the sputum specimen for further processing and interpretation",
"     </li>",
"     <li>",
"      Predict a likely etiologic agent by identification of a predominant bacterial morphology in an adequate (purulent) specimen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Expectorated sputum'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several guidelines have been proposed to evaluate the quality of sputum samples. These guidelines have proposed different combinations and cutoffs of the minimum number of squamous epithelial cells (SECs)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      polymorphonuclear leukocytes (PMNs) per low power field (LPF, 10X objective), but none of these parameters can be considered to be clearly superior. Our laboratory rejects all specimens with more than 10",
"      <span class=\"nowrap\">",
"       SECs/LPF",
"      </span>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef81458 \" href=\"UTD.htm?15/56/16258\">",
"       picture 1",
"      </a>",
"      ), without considering the number of PMNs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Expectorated sputum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sputum Gram stain and culture are indicated for all patients with hospital-acquired pneumonia, and for certain patients with community-acquired pneumonia. Sputum Gram stain and culture have no role in the evaluation of acute bronchitis in otherwise healthy individuals. Similarly, they are not indicated in the initial evaluation of patients with acute exacerbations of chronic obstructive pulmonary disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'When are sputum Gram stains and cultures indicated?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Culture results are reported in a semiquantitative manner (1+ to 4+ in some laboratories, rare-few-moderate-abundant in others). Most true pathogens are present in at least 3+ (moderate) amounts. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any positive sputum culture result must be interpreted in the context of the clinical setting, since organisms can colonize the upper",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lower respiratory tract. Some organisms are virtually never pulmonary pathogens, such as Candida spp, coagulase-negative staphylococci, enterococci, gram-positive bacilli other than Nocardia, H. parainfluenzae, and streptococci other than S. pneumoniae, S. pyogenes, S. agalactiae, and S. anginosus. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoscopy can be used to acquire samples of lower respiratory tract secretions in patients with suspected pneumonia in whom respiratory samples cannot be obtained by expectoration or in whom such samples have been nondiagnostic. Bronchoscopy for specimen collection is most useful for the diagnosis of infection due to Mycobacterium tuberculosis in patients with negative sputum studies, for Pneumocystis jirovecii (formerly P. carinii) or other fungal or viral pathogens, or for establishing a noninfectious etiology such as malignancy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Specimens obtained via bronchoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17591/abstract/1\">",
"      Reimer LG, Carroll KC. Role of the microbiology laboratory in the diagnosis of lower respiratory tract infections. Clin Infect Dis 1998; 26:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17591/abstract/2\">",
"      Wong LK, Barry AL, Horgan SM. Comparison of six different criteria for judging the acceptability of sputum specimens. J Clin Microbiol 1982; 16:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17591/abstract/3\">",
"      Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc 1975; 50:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17591/abstract/4\">",
"      Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17591/abstract/5\">",
"      Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994; 18:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17591/abstract/6\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17591/abstract/7\">",
"      Morris AJ, Tanner DC, Reller LB. Rejection criteria for endotracheal aspirates from adults. J Clin Microbiol 1993; 31:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17591/abstract/8\">",
"      Rein MF, Mandell GL. Bacterial killing by bacteriostatic saline solutions--potential for diagnostic error. N Engl J Med 1973; 289:794.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7018 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-BD8FC545DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17591=[""].join("\n");
var outline_f17_11_17591=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H53649420\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXPECTORATED SPUTUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Collection of expectorated sputum for optimal yield",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      When are sputum Gram stains and cultures indicated?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bronchitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Community-acquired pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hospital-acquired (nosocomial) pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SPUTUM CULTURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Specimens obtained via bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53649420\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7018\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7018|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/56/16258\" title=\"picture 1\">",
"      Rejected sputum specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/0/21507\" title=\"picture 2\">",
"      Pneumococcus in sputum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/44/39621\" title=\"picture 3\">",
"      Mixed flora on blood agar",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=related_link\">",
"      Acute bronchitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34791?source=related_link\">",
"      Approach to Gram stain and culture results in the microbiology laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=related_link\">",
"      Clinical manifestations and diagnosis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17524?source=related_link\">",
"      Clinical microbiology review: Respiratory tract infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35059?source=related_link\">",
"      Microbiology specimen collection and transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=related_link\">",
"      Parainfluenza viruses in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_11_17592="Interventions for children with reading difficulty";
var content_f17_11_17592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interventions for children with reading difficulty",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17592/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17592/contributors\">",
"     S Sutton Hamilton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17592/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17592/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17592/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17592/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17592/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/11/17592/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reading is critical to the academic, economic, and social success of children. However, many children complete schooling without achieving more than basic literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/1\">",
"     1",
"    </a>",
"    ]. Reading achievement has consistently been a robust predictor of future antisocial behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/2\">",
"     2",
"    </a>",
"    ]. Children with reading difficulties are considerably less likely to graduate high school, and thus are at greater risk for unemployment, underemployment, and incarceration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pediatric clinicians are well positioned to identify children at risk for reading difficulties and children who have unexpected difficulties in learning to read. Early identification and timely intervention for such children improve long-term outcome.",
"   </p>",
"   <p>",
"    Interventions for children with reading difficulty in children will be discussed here. Normal reading development and the epidemiology, etiology, clinical features, and evaluation of reading difficulty are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6409?source=see_link\">",
"     \"Normal reading development and etiology of reading difficulty in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/21/1370?source=see_link\">",
"     \"Clinical features and evaluation of reading difficulty in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General issues related to educational interventions for children with learning disability and the evolution of laws related to special education in the United States also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37306?source=see_link\">",
"     \"Specific learning disabilities in children: Educational management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37480?source=see_link\">",
"     \"Definitions of specific learning disability and laws pertaining to learning disabilities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of terms are used to describe reading problems. Different terms may be used in different settings and by different groups (eg, educators, healthcare providers). Definitions for the terms that are used in this topic review are provided below. A detailed discussion of terminology is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6409?source=see_link&amp;anchor=H3#H3\">",
"     \"Normal reading development and etiology of reading difficulty in children\", section on 'Terminology and conceptual framework'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Reading difficulty",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Reading difficulty\" is defined from a normative perspective (ie, how a child performs in reading compared with peers or educational expectations) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/4\">",
"     4",
"    </a>",
"    ]. Reading difficulty has a number of causes, one of which is reading disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reading disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reading disability is best defined as \"an unexpected difficulty in learning how to read despite adequate intelligence, instruction, and motivation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/4\">",
"     4",
"    </a>",
"    ]. The terms \"dyslexia,\" \"developmental dyslexia,\" \"specific reading disability,\" and \"reading disorder\" also are used to describe this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/5\">",
"     5",
"    </a>",
"    ], although a more specific definition for \"dyslexia\" is provided below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dyslexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"dyslexia\" is used as a synonym for specific reading disability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The International Dyslexia Association defines dyslexia as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    \"Dyslexia is a specific learning disability that is neurological in origin. It is characterized by difficulties with accurate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluent word recognition and by poor spelling and decoding abilities. These difficulties typically result from a deficit in the phonologic component of language that is often unexpected in relation to other cognitive abilities and the provision of effective classroom instruction. Secondary consequences may include problems in reading comprehension and reduced reading experience that can impede the growth of vocabulary and background knowledge.\"",
"   </p>",
"   <p>",
"    This definition also has been adopted by the United States National Institutes of Child Health and Human Development. In the text that follows, \"reading disability\" is used synonymously with \"dyslexia.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with reading disability may require lifelong assistance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/10\">",
"     10",
"    </a>",
"    ]. The optimal management strategy depends upon the individual's age and circumstances. Strategies for preschool children focus on early literacy promotion. Strategies for children who are learning to read but who are slightly behind compared with classmates focus on remediation of the underlying problems in phonologic processing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Strategies for children who are learning to read but who are significantly behind classmates or who have disordered patterns in acquisition of reading skills focus on both remediation and compensation (usually through special education interventions). Strategies for children who have begun to read focus on increasing sight word vocabulary and reading comprehension. Strategies for children in secondary school and beyond focus on accommodation.",
"   </p>",
"   <p>",
"    Effective intervention programs provide children with systematic instruction in five critical areas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phonemic awareness &ndash; The ability to focus on and manipulate phonemes (the smallest units of spoken language) in spoken words",
"     </li>",
"     <li>",
"      Phonics &ndash; Knowledge of relationships between letters and sounds and spelling-sound correspondence, which allows fluent phonologic decoding",
"     </li>",
"     <li>",
"      Fluency &ndash; The ability to read orally with accuracy, speed, and expression",
"     </li>",
"     <li>",
"      Vocabulary &ndash; The storage of word meanings",
"     </li>",
"     <li>",
"      Comprehension &ndash; The ability to think about and extract the information provided in text while reading (ability to construct meaning from the recognized words) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to systematic and structured training exercises in phonemic awareness and phonics, children with reading difficulty require practice in reading stories aloud [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/10\">",
"     10",
"    </a>",
"    ]. Reading practice allows children with reading disability to use their decoding skills while reading words in context and to experience reading for meaning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6409?source=see_link&amp;anchor=H2#H2\">",
"     \"Normal reading development and etiology of reading difficulty in children\", section on 'Normal reading development'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of interventions for reading difficulty has occurred primarily in children beginning to read (eg, in kindergarten and first grade). Phonemic awareness and phonics instruction have been evaluated in a number of randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12\">",
"     12",
"    </a>",
"    ]. Interventions for older children are not well studied, and there are no firm conclusions regarding the best way to teach fluency, vocabulary, and reading comprehension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of reading disability may involve educators, psychologists, and pediatric clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/14\">",
"     14",
"    </a>",
"    ]. Interventions usually are provided by educators within the school system,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depending upon family resources, by private tutors. The information below is provided to help pediatric healthcare clinicians understand the components of effective intervention so that they can help the family make sure the child receives appropriate interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EARLY LITERACY PROMOTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early or precursor literacy skills that correlate with subsequent literacy achievement include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Knowledge of the names and sounds associated with letters (alphabet knowledge)",
"     </li>",
"     <li>",
"      Ability to detect, manipulate, or analyze the auditory aspects of spoken language independent of meaning (phonologic awareness)",
"     </li>",
"     <li>",
"      Rapid automatic naming of letters and digits",
"     </li>",
"     <li>",
"      Rapid automatic naming of objects or colors",
"     </li>",
"     <li>",
"      Writing or writing one's name",
"     </li>",
"     <li>",
"      Ability to remember spoken information for a short period of time (phonologic memory)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Instructional practices that promote early literacy skills include code-focused interventions (ie, increasing phonological awareness), language enhancement interventions, shared reading, parent-home programs, and preschool and kindergarten programs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Code-focused interventions &ndash; Code-focused interventions teach children the relationship between written letters and word sounds (ie, to \"crack the alphabet code\"). Nearly all code-based interventions emphasize phonologic awareness, either in isolation or in combination with other code-focused instruction.",
"     </li>",
"     <li>",
"      Language enhancement &ndash; Language-enhancement interventions are instructional efforts aimed at improving language development in young children. Such interventions enhance a wide range of measures of oral language, including expressive and receptive language skills, phonemic awareness, and verbal intelligence [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Shared reading &ndash; Shared-reading interventions involve reading one-on-one to children with varying degrees of child-reader interaction. Shared reading appears to improve oral language skills and print knowledge, particularly when it takes place frequently and is interactive [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Shared reading by itself does not appear to promote improvement in conventional literacy skills (ie, oral reading fluency, reading comprehension, writing, and spelling) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Parent-home programs &ndash; Parent-home programs are interventions through which the parent promotes literacy in the home setting, typically through parent-child shared reading. Well-known national efforts include Reach Out and Read and Reading is Fundamental. Parent-home programs help to promote oral language skills and cognitive abilities in young children [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preschool and kindergarten programs &ndash; Preschool and kindergarten programs have the largest impact on measures of readiness, a composite of early literacy predictors including alphabet knowledge, print concepts, vocabulary, memory, and phonologic awareness [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     REMEDIATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Content areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;In prereaders and beginning readers, reading interventions focus on remediation of reading skills. Basic skills (ie, phonemic awareness, phonics) are emphasized in the early school years, vocabulary and comprehension as schooling progresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Phonemic awareness",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend instruction in phonemic awareness as the major focus of reading remediation for children with reading difficulty or reading disability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/11,12,17-22\">",
"     11,12,17-22",
"    </a>",
"    ]. Phonemic awareness helps children understand the way letters are used to represent sounds [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Instruction in phonemic awareness includes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phoneme isolation (\"Tell me the first sound in 'paste.'\")",
"     </li>",
"     <li>",
"      Phoneme identity (\"Tell me the sound that is the same in 'bike,' 'boy,' and 'bell.'\")",
"     </li>",
"     <li>",
"      Phoneme categorization (\"Which word does not belong: 'bus,' 'bun,' 'rug'?\")",
"     </li>",
"     <li>",
"      Phoneme blending (\"What word is",
"      <span class=\"nowrap\">",
"       /s/",
"      </span>",
"      <span class=\"nowrap\">",
"       /k/",
"      </span>",
"      <span class=\"nowrap\">",
"       /u/",
"      </span>",
"      <span class=\"nowrap\">",
"       /l/?\"",
"      </span>",
"      [school])",
"     </li>",
"     <li>",
"      Phoneme segmentation (\"How many sounds are there in 'ship'?\")",
"     </li>",
"     <li>",
"      Phoneme deletion (\"What is 'smile' without the",
"      <span class=\"nowrap\">",
"       /s/?\")",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Phonemic awareness instruction is helpful to young readers who are at risk, reading disabled, or progressing normally, but is most helpful to those who are at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12\">",
"     12",
"    </a>",
"    ]. There are few data on the effect of phonemic awareness training programs for children beyond the second grade.",
"   </p>",
"   <p>",
"    A meta-analysis by the National Reading Panel reviewed studies of phonemic awareness instruction compared with alternative methods of training [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12\">",
"     12",
"    </a>",
"    ]. The effect size indicates the extent to which the performance of the treatment group exceeded the performance of the control group, with standard deviation as the unit; values of 0.2, 0.5, and 0.8 were considered small, moderate, and large, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/24\">",
"     24",
"    </a>",
"    ]. The following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phonemic awareness instruction improves phonemic awareness in at-risk, reading-disabled, and normally developing readers (effect sizes of 0.95 [95% CI 0.76-1.14], 0.62 [95% CI 0.48-0.75], and 0.93 [95% CI 0.85-1.01], respectively)",
"     </li>",
"     <li>",
"      Phonemic awareness instruction has a large effect on reading development in at-risk children immediately following training and at follow-up (effect size of 0.86 [95% CI 0.72-1] and 1.33 [95% CI 1.1-1.56], respectively)",
"     </li>",
"     <li>",
"      Phonemic awareness instruction has a small to moderate effect on reading development in reading-disabled children immediately following training and at follow-up (effect size 0.45 [95% CI 0.32-0.57] and 0.28 [95% CI 0.1-0.46], respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Effective elements of phonemic awareness interventions include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/10-13,22\">",
"     10-13,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Teaching children to manipulate phonemes with letters (rather than limiting manipulation to sounds); this allows children to apply the skills to reading and writing",
"     </li>",
"     <li>",
"      Focusing the instruction on one or two types of phoneme manipulation",
"     </li>",
"     <li>",
"      Teaching children in small groups",
"     </li>",
"     <li>",
"      Providing systematic instruction and teaching children how to apply phonemic awareness skills in reading and writing tasks",
"     </li>",
"     <li>",
"      A multisensory approach (eg, asking the children to write letters in the air, trace letters on paper, etc)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Phonics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic (ie, planned and sequential) phonics instruction stresses the acquisition of skills in letter-sound correspondence and the use of these skills to read and spell words [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Explicit, systematic phonics instruction is critical for children beginning to read and those with reading difficulty.",
"   </p>",
"   <p>",
"    The National Reading Panel meta-analysis reviewed studies of systematic phonics instruction compared with nonsystematic or no phonics instruction for school-aged children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12\">",
"     12",
"    </a>",
"    ]. The primary outcome was general literacy, which included decoding, spelling, reading aloud, and reading comprehension. The effect size indicates the extent to which the performance of the treatment group exceeded the performance of the control group, with standard deviation as the unit; values of 0.2, 0.5, and 0.8 were considered small, moderate, and large, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/24\">",
"     24",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systematic phonics instruction was effective in improving general literacy for kindergarten and first-grade children at risk of reading problems (effect size of 0.58 [95% CI 0.4-0.77] and 0.74 [95% CI 0.56-0.91], respectively).",
"     </li>",
"     <li>",
"      Systematic phonics instruction has a small to moderate effect on general literacy for children with reading disability (effect size of 0.32 [95% CI 0.18-0.46]).",
"     </li>",
"     <li>",
"      Systematic phonics instruction was more effective in improving general literacy for normal readers during the first grade than afterward (effect size 0.48 [95% CI 0.38-0.58] versus 0.27 [95% CI 0.12-0.43]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fluency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluency is the ability to read orally with accuracy, speed, and expression. It requires well-developed word-recognition skills and is a critical factor in reading comprehension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12,25,26\">",
"     12,25,26",
"    </a>",
"    ]. We recommend repeated oral reading practice as the most effective method to build reading fluency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. Other terms for repeated oral reading practice include guided-repeated oral reading, paired reading, shared reading, assisted reading, student-adult reading, chorale reading, tape-assisted reading, and partner reading [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/7,12\">",
"     7,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In repeated oral reading, the child reads aloud repeatedly to a teacher, an adult, or a peer, and receives feedback. Guided oral reading has a clear and positive impact on word recognition, fluency, and comprehension at many grade levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/10,12\">",
"     10,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Reading Panel meta-analysis reviewed studies of guided oral reading and unsupervised independent reading at school or home [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12\">",
"     12",
"    </a>",
"    ]. The effect size indicates the extent to which the performance of the treatment group exceeded the performance of the control group, with standard deviation as the unit; values of 0.2, 0.5, and 0.8 were considered small, moderate, and large, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/24\">",
"     24",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guided oral reading has small to moderate effects on reading accuracy (0.55), fluency (0.44), and reading comprehension (0.35).",
"     </li>",
"     <li>",
"      Guided oral reading affects reading ability of nonimpaired readers through at least grade four, and students with various kinds of reading problems throughout high school (the sample sizes were too small to carry out additional analyses).",
"     </li>",
"     <li>",
"      Guided oral reading appears to be effective under a variety of conditions and with minimal special training or materials.",
"     </li>",
"     <li>",
"      There were relatively few studies of unsupervised reading; most failed to find a positive relationship between encouraging reading and either the amount of reading or reading achievement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Vocabulary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vocabulary building is an important aspect of reading comprehension. However, methods of vocabulary instruction are not well standardized, and there are few studies that evaluate the effectiveness of various strategies. The National Reading Panel came to the following conclusions regarding vocabulary instruction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vocabulary can be learned incidentally in the context of storybook reading or from listening to the reading of others",
"     </li>",
"     <li>",
"      Repeated exposure to vocabulary items is important, particularly exposure in contexts outside the classroom",
"     </li>",
"     <li>",
"      Vocabulary instruction before reading a passage that contains the vocabulary words facilitates vocabulary acquisition and comprehension",
"     </li>",
"     <li>",
"      Active engagement in learning tasks facilitates vocabulary acquisition",
"     </li>",
"     <li>",
"      Vocabulary learning is optimized by using multiple methods of instruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Comprehension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions for teaching reading comprehension are not well established [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/7\">",
"     7",
"    </a>",
"    ]. The most effective methods appear to involve teaching vocabulary and strategies that encourage active interaction between the reader and the text [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Reading Panel identified several effective strategies for teaching reading comprehension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comprehension monitoring, in which the reader learns how to monitor his or her understanding during reading and to manage problems in understanding as they arise",
"     </li>",
"     <li>",
"      Cooperative learning, in which readers work together to learn strategies in the context of reading",
"     </li>",
"     <li>",
"      Graphic and semantic organizers that allow the reader to write or draw the meanings and relationships of the ideas that underlie the words in the text",
"     </li>",
"     <li>",
"      Story structure, from which the reader learns to ask and answer who, what, where, when, and why questions about the plot; and in some cases maps out the time line, characters, and events",
"     </li>",
"     <li>",
"      Question answering, in which the reader answers questions posed by the teacher",
"     </li>",
"     <li>",
"      Question generation, in which the reader asks himself or herself questions about the text (who? what? when? where? why? how? what will happen next?)",
"     </li>",
"     <li>",
"      Summarization, in which the reader attempts to identify and write the main or most important ideas that integrate or unite the other ideas or meanings of the text into a coherent whole",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1176819\">",
"    <span class=\"h2\">",
"     Intensity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Students with reading difficulty require &ldquo;intensive&rdquo; instruction. &ldquo;Intensive&rdquo; is not always defined clearly [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/27\">",
"     27",
"    </a>",
"    ]. Intensive instruction can consist of three to five sessions weekly, lasting 30 to 60 minutes each, occurring in a small group setting (ie, three students or less), and provided over the course of several weeks to a year. More severely disabled readers may need intensive instruction over the course of years. The intensity of instruction can be increased by increasing the number of sessions per week, increasing the duration of the sessions, and by reducing the number of sound-symbol correspondences that are taught each week. Low-intensity supplemental tutoring for a few minutes two or three times per week, or instruction provided in groups of 6 to 10, are not likely to result in an adequate response and may not be cost effective in the long run [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intervention programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Orton-Gillingham approach to reading intervention has been used since the 1930s. It is a multisensory, sequential, phonics-based system that teaches the basics of word formation before whole meanings. It emphasizes visual and auditory feedback for sounds and tactile-kinesthetic input for letter formation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/13\">",
"     13",
"    </a>",
"    ]. Several treatment programs that are based on the Orton-Gillingham techniques are commercially available, although few have been tested in methodologically sound studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/13,30\">",
"     13,30",
"    </a>",
"    ]. Examples of commercially available programs include: the Wilson method, Project Read, Alphabetic Phonics, the Herman method, the Slingerland method, Language!, and the Spalding method [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/13,30\">",
"     13,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ACCOMMODATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For students in secondary school, college, and beyond, we suggest educational accommodations, including [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/10,31\">",
"     10,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extra time for reading and test-taking",
"     </li>",
"     <li>",
"      Recording classroom lectures",
"     </li>",
"     <li>",
"      The use of note-takers or a note service",
"     </li>",
"     <li>",
"      Access to syllabi and lecture notes",
"     </li>",
"     <li>",
"      The use of tutors to \"talk through\" and review the content of reading material",
"     </li>",
"     <li>",
"      The use of live readers or audiobooks (available from Recording for the Blind and Dyslexic [",
"      <a class=\"external\" href=\"file://www.rfbd.org/\">",
"       www.rfbd.org",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      The use of a word processor and spell-checker",
"     </li>",
"     <li>",
"      Opportunity to take tests in alternate formats (eg, orally, short essays)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in a separate quiet room",
"     </li>",
"     <li>",
"      Relaxation of the requirement to study a second language",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     UNPROVEN THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of unconventional therapies have been proposed as treatment for reading disability, including optometric training, pharmacotherapy for vestibular dysfunction, chiropractic manipulation, dietary supplementation, and music education [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/7,32\">",
"     7,32",
"    </a>",
"    ]. Such interventions are not supported by high-quality empiric evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/32-37\">",
"     32-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &ldquo;Irlen syndrome&rdquo; is a proposed perceptual disorder that causes distortions when viewing text and contributes to reading difficulty. It is treated with colored lenses (Irlen lenses) or plastic overlays (Irlen overlays). Both the disorder and the intervention are controversial. A randomized trial found no benefit to the use of colored overlays in schoolchildren with reading difficulty (the majority of whom had been diagnosed with Irlen syndrome by an Irlen diagnostician) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/37\">",
"     37",
"    </a>",
"    ]. We do not recommend colored lenses or overlays to treat reading difficulty in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have reading difficulty that resolves during kindergarten typically become normal readers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In contrast, reading disability persists throughout life; it is not a transient \"developmental lag\" [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/40-47\">",
"     40-47",
"    </a>",
"    ]. Many children with reading disability become proficient in reading a set of words that recur in their areas of interest [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/10\">",
"     10",
"    </a>",
"    ]. They also may be able to decode unfamiliar words accurately, but not fluently or automatically [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/7,10,40,45,48\">",
"     7,10,40,45,48",
"    </a>",
"    ]. Even after acquiring decoding skills, reading tends to be slow and laborious.",
"   </p>",
"   <p>",
"    Longitudinal studies demonstrate that although the reading scores of children with reading disability improve as they get older, a gap remains between them and children without reading disability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/40,45,49\">",
"     40,45,49",
"    </a>",
"    ]. Over time, poor readers and good readers tend to maintain their relative positions along the spectrum of reading ability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/49\">",
"     49",
"    </a>",
"    ]. Children with persistent deficits in fundamental reading skills have lower academic performance overall [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among at-risk children in kindergarten and first grade and children in the second through sixth grades, the following characteristics are associated with poor outcome in reading and spelling [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17592/abstract/13,44,50\">",
"     13,44,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor rapid naming",
"     </li>",
"     <li>",
"      Poor verbal ability",
"     </li>",
"     <li>",
"      Poor attention or behavior overall",
"     </li>",
"     <li>",
"      Poor fluency",
"     </li>",
"     <li>",
"      Poor response to intervention",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following resources may provide additional information for parents and clinicians:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"Overcoming Dyslexia\" by Sally Shaywitz, MD (2003)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.ldonline.org/\">",
"       Learning Disabilities Online",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.nationalreadingpanel.org/\">",
"       National Reading Panel Report",
"      </a>",
"      (2000)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://interdys.org/\">",
"       International Dyslexia Association",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.schwabfoundation.org/About-CHSF/Publications/Schwab-Learning.aspx\">",
"       Schwab Foundation",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.readingrockets.org/\">",
"       Reading Rockets",
"      </a>",
"      for K-3 students",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://fcsn.org/index.php\">",
"       Federation for Children with Special Needs",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.rfbd.org/\">",
"       Recording for the Blind and Dyslexic",
"      </a>",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://fcrr.org/\">",
"       Florida Center for Reading Research",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/22/29025?source=see_link\">",
"       \"Patient information: Dyslexia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with reading disability may require lifelong assistance. Strategies for preschool children focus on early literacy promotion. Strategies for children who are learning to read but are slightly behind compared with classmates focus on remediation. Strategies for children who are learning to read but who are significantly behind classmates or who have disordered patterns in acquisition of reading skills focus on both remediation and compensation (usually through special education interventions). Strategies for children who have begun to read focus on increasing sight word vocabulary and reading comprehension. Strategies for children in secondary school and beyond focus on accommodation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Instructional practices that promote early literacy skills include code-focused interventions (ie, increasing phonological awareness), language enhancement interventions, shared reading, parent-home programs, and preschool and kindergarten programs. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Early literacy promotion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Instruction in phonologic processing is the major focus of reading remediation. Direct and systematic phonemic awareness and phonics instruction are beneficial for children with limited exposure to reading before school entry, as well as for those with reading disability. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Phonemic awareness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend systematic instruction in phonemic awareness and phonics for children with reading difficulty or reading disability (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Phonemic awareness'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Phonics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend repeated oral reading practice to improve fluency in children with reading disability (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Fluency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Instruction strategies that require active engagement of the student facilitate acquisition of vocabulary and reading comprehension skills. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Vocabulary'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Comprehension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest educational accommodations for children with reading disability in secondary school and beyond (eg, extra time, audiobooks) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Accommodation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventions such as optometric training, treatment of vestibular dysfunction, chiropractic manipulation, colored lenses or overlays, music education, and dietary supplementation are not supported by high-quality evidence. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Unproven therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/1\">",
"      Murnane RJ. Improving the education of children living in poverty. Future Child 2007; 17:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/2\">",
"      Trzesniewski KH, Moffitt TE, Caspi A, et al. Revisiting the association between reading achievement and antisocial behavior: new evidence of an environmental explanation from a twin study. Child Dev 2006; 77:72.",
"     </a>",
"    </li>",
"    <li>",
"     National Center on Secondary Education and Transition www.ncset.org (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     Fletcher JM, Lyon GR, Fuchs LS, Barnes MA. Learning Disabilities, Guilford Press, New York 2007.",
"    </li>",
"    <li>",
"     Reading disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR&reg;), American Psychiatric Association, Washington, DC 2000. p.429.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/6\">",
"      Vellutino FR, Fletcher JM, Snowling MJ, Scanlon DM. Specific reading disability (dyslexia): what have we learned in the past four decades? J Child Psychol Psychiatry 2004; 45:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/7\">",
"      Shaywitz SE, Shaywitz BA. Dyslexia (specific reading disability). Pediatr Rev 2003; 24:147.",
"     </a>",
"    </li>",
"    <li>",
"     International Dyslexia Association. Definition of dyslexia interdys.org/FactSheets.htm (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/9\">",
"      Lyon GR, Shaywitz SE, Shaywitz BA. A definition of dyslexia. Ann Dyslexia 2003; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/10\">",
"      Shaywitz SE, Gruen JR, Shaywitz BA. Management of dyslexia, its rationale, and underlying neurobiology. Pediatr Clin North Am 2007; 54:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/11\">",
"      Foorman BR, Breier JI, Fletcher JM. Interventions aimed at improving reading success: an evidence-based approach. Dev Neuropsychol 2003; 24:613.",
"     </a>",
"    </li>",
"    <li>",
"     National Reading Panel, National Institute of Child Health and Human Development, National Institutes of Health. Teaching children to read. Reports of the subgroups www.nationalreadingpanel.org/Publications/subgroups.htm (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/13\">",
"      Alexander AW, Slinger-Constant AM. Current status of treatments for dyslexia: critical review. J Child Neurol 2004; 19:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/14\">",
"      Olitsky SE, Nelson LB. Reading disorders in children. Pediatr Clin North Am 2003; 50:213.",
"     </a>",
"    </li>",
"    <li>",
"     National Early Literacy Panel. Developing Early Literacy: Report of the National Early Literacy Panel. National Institute for Literacy, Jessep, MD 2008. www.nifl.gov/earlychildhood/NELP/NELPreport.html (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/16\">",
"      Ohgi S, Loo KK, Mizuike C. Frontal brain activation in young children during picture book reading with their mothers. Acta Paediatr 2010; 99:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/17\">",
"      Torgesen JK, Morgan S, Davis C. The effects of two types of phonological awareness training on word learning in kindergarten children. J Educ Psychol 1992; 84:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/18\">",
"      Ball EW, Blachman BA. Does phoneme awareness training in kindergarten make a difference in early word recognitition and developmental spelling? Read Res Q 1991; 26:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/19\">",
"      Wise BW, Olson RK. Computer-based phonological awareness and reading instruction. Ann Dyslexia 1995; 45:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/20\">",
"      Foorman BR, Francis DJ, Beeler T, et al. Early interventions for children with reading problems: study designs and preliminary findings. Learn Disabil 1997; 8:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/21\">",
"      Lyon GR. Toward a definition of dyslexia. Ann Dyslexia 1995; 45:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/22\">",
"      Oakland T, Black JL, Stanford G, et al. An evaluation of the dyslexia training program: a multisensory method for promoting reading in students with reading disabilities. J Learn Disabil 1998; 31:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/23\">",
"      Schatschneider C, Torgesen JK. Using our current understanding of dyslexia to support early identification and intervention. J Child Neurol 2004; 19:759.",
"     </a>",
"    </li>",
"    <li>",
"     Cohen J. Statistical power for behavioral sciences, 2nd, Lawrence Erlbaum, Mahwah, NJ 1988.",
"    </li>",
"    <li>",
"     Pinnell GS, Pikulski JJ, Wixson KK, et al. Listening to children read aloud, U.S. Department of Education Office of Educational Research and Improvement, Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/26\">",
"      Pikulski JJ, Chard DJ. Fluency: Bridge between decoding and reading comprehension. The Reading Teacher 2005; 58:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/27\">",
"      Shaywitz SE, Morris R, Shaywitz BA. The education of dyslexic children from childhood to young adulthood. Annu Rev Psychol 2008; 59:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/28\">",
"      Vaughn S, Denton CA, Fletcher JM. WHY INTENSIVE INTERVENTIONS ARE NECESSARY FOR STUDENTS WITH SEVERE READING DIFFICULTIES. Psychol Sch 2010; 47:432.",
"     </a>",
"    </li>",
"    <li>",
"     Assisting students struggling with reading: Response to intervention (RtI) and multi-tier intervention in the primary grades. US Department of Education NCEE 2009-4045. National Center for Educational Evaluation and Regional Assistance. file://ies.ed.gov/ncee/wwc/pdf/practice_guides/rti_reading_pg_021809.pdf (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     Multisensory structured Language programs: Content and principles of instruction (1995). www.ldonline.org/article/6332 (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     Shaywitz S. Overcoming dyslexia: A new and complete science-based program for reading problems at any level, Alfred A. Knopf, New York 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/32\">",
"      Cogo-Moreira H, Andriolo RB, Yazigi L, et al. Music education for improving reading skills in children and adolescents with dyslexia. Cochrane Database Syst Rev 2012; 8:CD009133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/33\">",
"      Rawstron JA, Burley CD, Elder MJ. A systematic review of the applicability and efficacy of eye exercises. J Pediatr Ophthalmol Strabismus 2005; 42:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/34\">",
"      Bull L. Sunflower therapy for children with specific learning difficulties (dyslexia): a randomised, controlled trial. Complement Ther Clin Pract 2007; 13:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/35\">",
"      American Academy of Pediatrics, Section on Ophthalmology, Council on Children with Disabilities, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Joint statement--Learning disabilities, dyslexia, and vision. Pediatrics 2009; 124:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/36\">",
"      Handler SM, Fierson WM, Council on Children with Disabilities, et al. Learning disabilities, dyslexia, and vision. Pediatrics 2011; 127:e818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/37\">",
"      Ritchie SJ, Della Sala S, McIntosh RD. Irlen colored overlays do not alleviate reading difficulties. Pediatrics 2011; 128:e932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/38\">",
"      Vellutino FR, Scanlon DM, Small S, Fanuele DP. Response to intervention as a vehicle for distinguishing between children with and without reading disabilities: Evidence for the role of kindergarten and first-grade interventions. J Learn Disabil 2006; 39:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/39\">",
"      Coyne MD, Kame'enui EJ, Simmons DC, Harn BA. Beginning reading intervention as inoculation or insulin: first-grade reading performance of strong responders to kindergarten intervention. J Learn Disabil 2004; 37:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/40\">",
"      Shaywitz SE, Fletcher JM, Holahan JM, et al. Persistence of dyslexia: the Connecticut Longitudinal Study at adolescence. Pediatrics 1999; 104:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/41\">",
"      Scarborough HS. Continuity between childhood dyslexia and adult reading. Br J Psychol 1984; 75 ( Pt 3):329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/42\">",
"      Felton RH, Naylor CE, Wood FB. Neuropsychological profile of adult dyslexics. Brain Lang 1990; 39:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/43\">",
"      Bruck M. Persistence of dyslexics' phonological awareness deficits. Dev Psychol 1992; 28:874.",
"     </a>",
"    </li>",
"    <li>",
"     Vellutino F, Scanlon D, Jaccard J. Toward distinguishing between cognitive and experiential deficits as primary sources of difficulty in learning to read: A two year follow-up of difficult to remediate and readily remediated poor readers. In: Preventing and Remediating Reading Difficulties: Bringing Science to Scale, Foorman BR (Ed), York Press, Timonium, MD 2003. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/45\">",
"      Torgesen JK, Alexander AW, Wagner RK, et al. Intensive remedial instruction for children with severe reading disabilities: immediate and long-term outcomes from two instructional approaches. J Learn Disabil 2001; 34:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/46\">",
"      Bruck M. Word recognition skills of adults with childhood diagnoses of dyslexia. Dev psychol 1990; 26:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/47\">",
"      Hatcher J, Snowling MJ, Griffiths YM. Cognitive assessment of dyslexic students in higher education. Br J Educ Psychol 2002; 72:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/48\">",
"      Grizzle KL. Developmental dyslexia. Pediatr Clin North Am 2007; 54:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17592/abstract/49\">",
"      Francis DJ, Shaywitz SE, Stuebing KK, et al. Developmental lag versus deficit models of reading disabilty: A longitudinal, individual growth curves analysis. J Educ Psychol 1996; 88:3.",
"     </a>",
"    </li>",
"    <li>",
"     Denton C, Mathes P. Intervention for struggling readers. In: Preventing and Remediating Reading Difficulties: Bringing Science to Scale, Foorman BR (Ed), York Press, Timonium, MD 2003. p.229.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 601 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6AD6E7C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17592=[""].join("\n");
var outline_f17_11_17592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Reading difficulty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reading disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dyslexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EARLY LITERACY PROMOTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REMEDIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Content areas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Phonemic awareness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Phonics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fluency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Vocabulary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Comprehension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1176819\">",
"      Intensity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intervention programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACCOMMODATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      UNPROVEN THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/21/1370?source=related_link\">",
"      Clinical features and evaluation of reading difficulty in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37480?source=related_link\">",
"      Definitions of specific learning disability and laws pertaining to learning disabilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6409?source=related_link\">",
"      Normal reading development and etiology of reading difficulty in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/22/29025?source=related_link\">",
"      Patient information: Dyslexia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37306?source=related_link\">",
"      Specific learning disabilities in children: Educational management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_11_17593="Bone disease with hyperthyroidism and thyroid hormone therapy";
var content_f17_11_17593=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bone disease with hyperthyroidism and thyroid hormone therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17593/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17593/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17593/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17593/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17593/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17593/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17593/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/11/17593/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of hyperthyroidism on the skeleton were known before the advent of satisfactory treatment for hyperthyroidism. One of the first reports of hyperthyroid bone disease was in 1891 when von Recklinghausen described the \"worm eaten\" appearance of the long bones of a young woman who died from hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/1\">",
"     1",
"    </a>",
"    ]. With the introduction of antithyroid drugs and radioiodine in the 1940s, clinically apparent hyperthyroid bone disease became less common.",
"   </p>",
"   <p>",
"    However, bone density measurements during the last decade have demonstrated that bone loss is common in patients with overt hyperthyroidism and to a lesser extent in those with subclinical hyperthyroidism, whether caused by nodular goiter or excessive doses of thyroid hormone.",
"   </p>",
"   <p>",
"    Thyroid hormone directly stimulates bone resorption in organ culture [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/2\">",
"     2",
"    </a>",
"    ]. This action may be mediated by a nuclear triiodothyronine (T3) receptor which has been found in rat and human osteoblast cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] and in osteoclasts derived from an osteoclastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/5\">",
"     5",
"    </a>",
"    ]. Experimental studies in mice lacking either the TRalpha or TRbeta receptor suggest bone loss is mediated by TRalpha [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, thyroid hormone may affect bone calcium metabolism either by a direct action on osteoclasts, or by acting on osteoblasts which in turn mediate osteoclastic bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/7\">",
"     7",
"    </a>",
"    ]. TSH may also appear to have a direct effect on bone formation and bone resorption, mediated via the TSH receptor on osteoblast and osteoclast precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/8\">",
"     8",
"    </a>",
"    ]; however, bone loss appeared independent of TSH levels in the experiments with mice lacking specific TR isoforms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased serum interleukin-6 concentrations in hyperthyroid patients may also play a role in thyroid hormone-stimulated bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/9\">",
"     9",
"    </a>",
"    ]. IL-6 stimulates osteoclast production and may be an effector of the action of parathyroid hormone (PTH) on bone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link&amp;anchor=H4#H4\">",
"     \"Hypercalcemia of malignancy\", section on 'Multiple myeloma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERT HYPERTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt hyperthyroidism is associated with accelerated bone remodeling, reduced bone density, osteoporosis, and an increase in fracture rate. The bone density changes may or may not be reversible with therapy. These changes in bone metabolism are associated with negative calcium balance, hypercalciuria and, rarely, hypercalcemia (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone loss is a uniform feature of overt hyperthyroidism. Histomorphometric studies of iliac crest bone biopsies reveal important differences in the effects of thyroid hormone on trabecular and cortical bone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/10\">",
"     10",
"    </a>",
"    ]. Hyperthyroid patients had only a 2.7 percent reduction in trabecular bone volume, but there was a 40 percent increase in osteoclast resorption surfaces in cortical bone and a 32 percent increase in cortical bone porosity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/10\">",
"     10",
"    </a>",
"    ]. There was no change in osteoid volume (ie, no osteomalacia).",
"   </p>",
"   <p>",
"    Three-dimensional reconstructions of the remodeling sequence have shown how these changes occur. In the normal remodeling sequence, osteoclastic resorption and osteoblastic bone formation are synchronized. In overt hyperthyroidism, osteoclastic resorption is stimulated out of proportion to osteoblastic remineralization [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/11\">",
"     11",
"    </a>",
"    ]. As a result, the normal cycle duration of approximately 200 days is halved, and each cycle is associated with a 9.6 percent loss of mineralized bone. In contrast, cycle length approximates 700 days in hypothyroid patients and is associated with a 17 percent increase in mineralized bone.",
"   </p>",
"   <p>",
"    The extent of the reduction in bone density in most studies of hyperthyroid patients ranges from 10 to 20 percent. The extent of the reversibility of bone loss with therapy, however, is unclear. Studies that have looked at changes in bone density after treatment of hyperthyroidism have yielded variable results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two older studies using single photon absorptiometry found a reduction in bone density of 12 to 28 percent in hyperthyroid patients, which normalized after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Several subsequent studies also showed complete recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. A review of different techniques of bone densitometry can be found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link&amp;anchor=H6#H6\">",
"       \"Osteoporotic fracture risk assessment\", section on 'Methods of measurement of BMD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other studies using dual photon absorptiometry reported reductions in bone density of 12 to 13 percent in the lumbar spine in patients with hyperthyroidism. However, recovery was incomplete, with increases in bone density of only 3.7 to 6.6 percent after one year of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. Several other studies have also shown incomplete recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cross-sectional population-based study of 5778 women without and 252 women with a self-reported history of hyperthyroidism, bone density was measured at the ultradistal forearm using DXA technology. Women with a history of hyperthyroidism had a higher prevalence of osteoporosis (adjusted odds ratio 1.5, 95% CI 1.1-2.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The variability in these results is likely due to differences in bone densitometry techniques, site of measurement, patient specific factors (eg, duration of hyperthyroidism prior to treatment), and length of follow up. Taken together, the above data suggest that bone loss is incompletely reversible in some patients, and therefore a past history of hyperthyroidism should be considered during an assessment of clinical risk factors for osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link&amp;anchor=H17#H17\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical risk factor assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fracture risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the variable bone density findings, a history of overt hyperthyroidism is a risk factor for hip fracture later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], which in turn is one of the causes of excess late mortality in previously hyperthyroid patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/25\">",
"     25",
"    </a>",
"    ]. It is therefore reasonable to assume that in some hyperthyroid patients bone density does not return to normal after antithyroid treatment.",
"   </p>",
"   <p>",
"    In a study of 621 patients treated for hyperthyroidism with radioiodine, the risk of spine and forearm fractures was increased. Curiously, the risk was not increased in patients co-treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of low serum TSH concentrations on fracture risk was investigated in a prospective cohort study of 686 white women over age 65 years followed for a mean of 3.7 years. Women with serum TSH concentrations of 0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    or less at baseline were at increased risk for both hip and vertebral fracture (relative risk 3.6 and 4.5, respectively). Exogenous thyroid hormone therapy was not a risk factor for fracture in women with normal serum TSH concentrations, but a history of hyperthyroidism was a risk factor for hip fracture, even after adjustment for serum TSH concentration and bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/27\">",
"     27",
"    </a>",
"    ]. Serum thyroxine was not measured, so the proportion of women with overt and subclinical hyperthyroidism is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptomatic bone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older studies documented the potential for symptomatic bone disease in association with reduced bone density. In one study of 187 patients with hyperthyroidism, as an example, 15 (8 percent) had symptoms. Their features were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All were women and 80 percent were over the age of 50 years",
"     </li>",
"     <li>",
"      Three-quarters had been hyperthyroid for less than a year",
"     </li>",
"     <li>",
"      Two-thirds had a fracture or severe bone pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiographic studies demonstrated generalized osteoporosis with frequent vertebral compression fractures or hypertransparency of the spine in the absence of fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mineral metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased calcium release into the circulation due to the increased bone resorption has effects on mineral metabolism which lead to negative calcium balance in hyperthyroid patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypercalcemia occurs in up to 8 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/28\">",
"       28",
"      </a>",
"      ]. However, increases in the serum ionized calcium concentration are more common [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/29\">",
"       29",
"      </a>",
"      ]. The hypercalcemia suppresses the secretion of PTH, leading to hypercalciuria, which protects against hypercalcemia but leads to a negative calcium balance.",
"     </li>",
"     <li>",
"      Low serum PTH concentrations reduce the conversion of 25-hydroxyvitamin D (calcidiol) to calcitriol&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/30\">",
"       30",
"      </a>",
"      ]. The decline in calcitriol production is compounded by an increase in calcitriol metabolism induced by hyperthyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low serum calcitriol concentrations diminish intestinal calcium (and phosphorous) absorption, resulting in fecal calcium loss. Malabsorption of calcium may be aggravated by steatorrhea and increased gut motility [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Biochemical markers of bone and mineral metabolism are also affected. The serum concentrations of alkaline phosphatase, osteocalcin, and osteoprotegerin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/33\">",
"     33",
"    </a>",
"    ], and fibroblast growth factor-23 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/34\">",
"     34",
"    </a>",
"    ] are increased in overt hyperthyroidism; they may remain high for months after treatment, presumably due to a persistent increase in osteoblastic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Urinary excretion of bone collagen-derived pyridinium cross-links is increased, and falls to normal shortly after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to treating the hyperthyroidism, patients should be advised to have adequate levels of calcium and vitamin D in their diets. One study showed a greater improvement in bone density after resolution of the hyperthyroidism when hyperthyroid women were treated with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    versus methimazole alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NODULAR GOITER AND GRAVES' DISEASE WITH SUBCLINICAL HYPERTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with subclinical hyperthyroidism have normal serum concentrations of free T4 and T3, but subnormal concentrations of thyrotropin (TSH). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"     \"Subclinical hyperthyroidism\"",
"    </a>",
"    .) Any form of hyperthyroidism can be subclinical, but this disorder most commonly occurs in elderly patients with a multinodular goiter or, less often, mild Graves' disease.",
"   </p>",
"   <p>",
"    Symptomatic bone disease is not a feature of subclinical hyperthyroidism. Four sets of observations, however, strongly suggest that this disorder has an adverse effect upon bone density and is a risk factor for osteoporosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased forearm bone density, which correlated inversely with serum free T4 values (although in the normal range), has been documented in women with nodular goiter and subclinical hyperthyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/39\">",
"       39",
"      </a>",
"      ]. In another report, postmenopausal (but not premenopausal) women with nodular goiter and subclinical hyperthyroidism had reduced bone density in the radius and femoral neck, but not lumbar spine [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postmenopausal women with subclinical hyperthyroidism treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      had higher distal forearm bone density as compared with untreated women [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postmenopausal women with subclinical hyperthyroidism treated with radioiodine and followed for two years did not lose bone from the spine or the hip, whereas untreated women lost bone at both sites (4.5 and 2.0 percent, respectively [p&lt;0.02]) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with Graves' hyperthyroidism taking an anti-thyroid drug, those with subclinical hyperthyroidism have higher serum bone alkaline phosphatase concentrations and urinary pyridinoline excretion than those who are euthyroid [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUBCLINICAL HYPERTHYROIDISM DUE TO EXOGENOUS THYROID HORMONE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients treated with T4 have subclinical hyperthyroidism and some have increased bone resorption and reduced bone density. There is no evidence for an increased rate of fracture in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Low bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cross-sectional studies, a smaller number of longitudinal studies, and two meta-analyses have found that patients with exogenous subclinical hyperthyroidism can have the same reduction in bone density as occurs in patients with endogenous subclinical hyperthyroidism, and that careful adjustment of the dose of T4 can minimize this risk.",
"   </p>",
"   <p>",
"    Two early cross-sectional studies in premenopausal women, as an example, demonstrated that suppressive doses of T4 result in reduced density of cortical-rich bone. In one study, 28 premenopausal women with goiter who were taking T4 had, by single photon absorptiometry, a 5 percent reduction in density of the wrist after five years and a 9 percent reduction after 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/44\">",
"     44",
"    </a>",
"    ]. The average T4 dose was 0.171 mg per day, a recommended dose at the time [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/45\">",
"     45",
"    </a>",
"    ]. In a similar study of 31 premenopausal women taking an average dose of 0.175 mg T4 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/46\">",
"     46",
"    </a>",
"    ], bone density of the femoral neck and trochanter, but not the lumbar spine, was reduced.",
"   </p>",
"   <p>",
"    However, with one exception [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/47\">",
"     47",
"    </a>",
"    ], other cross-sectional studies have failed to confirm reduced bone density in T4-treated",
"    <strong>",
"     premenopausal",
"    </strong>",
"    women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/48-54\">",
"     48-54",
"    </a>",
"    ] or in men [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/55\">",
"     55",
"    </a>",
"    ]. The dose in most of these studies was lower than in the initial reports, and the annualized loss of femoral neck density in premenopausal women taking T4 was significantly correlated with the dose [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, most studies have demonstrated that even moderate suppressive doses of T4 can cause bone loss in",
"    <strong>",
"     postmenopausal",
"    </strong>",
"    women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/47-51,56,57\">",
"     47-51,56,57",
"    </a>",
"    ]. However, this is not a uniform finding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/46\">",
"     46",
"    </a>",
"    ], and others have questioned the clinical importance of minor reductions in bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longitudinal studies in patients receiving thyroid hormone replacement have also demonstrated variable bone loss. As an example, in one study of 10 patients with subclinical hyperthyroidism due to T4 therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/59\">",
"     59",
"    </a>",
"    ], the annualized rate of loss of density of the femoral neck was increased four- to fivefold, while loss of the spine was increased two- to threefold; however, only the spinal bone loss was statistically significant. In a three-year study, 14 premenopausal women who had taken an average of 0.147 mg of T4 per day after thyroidectomy for goiter or thyroid cancer were compared with 24 age-matched normal women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/60\">",
"     60",
"    </a>",
"    ]. Spinal bone density fell at a rate of 2.6 percent per year in the T4-treated women, and 0.2 percent per year in the normal women. There was no change in radial bone density. In contrast, in another report 41 women over age 65 who were taking T4 and had a serum TSH concentration of 0.1",
"    <span class=\"nowrap\">",
"     mu/L",
"    </span>",
"    lost no more bone over 5.7 years than did those who were taking T4 but had a serum TSH concentration of 0.1 to 5.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two meta-analyses of the studies of bone density in patients with subclinical hyperthyroidism due to T4 therapy have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. A significant reduction in bone density was found only in postmenopausal women, consistent with the findings in cross-sectional studies. The later meta-analysis also found a reduction in bone density in premenopausal women receiving replacement therapy (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One important caveat affecting the interpretation of these studies is the lack of information on the role of calcitonin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/50,64\">",
"     50,64",
"    </a>",
"    ]. This is a potentially important factor, because surgery, radioiodine therapy, and chronic thyroiditis (which necessitate thyroid hormone replacement) reduce C cell function. No study has satisfactorily separated the effect of calcitonin deficiency from that of concurrent T4 therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other parameters of bone mineral metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in several other measures of bone and mineral metabolism are also consistent with increased bone resorption in subclinical hyperthyroidism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary excretion of bone collagen-derived pyridinium cross-links is increased in postmenopausal women [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A negative correlation has been demonstrated between the serum osteocalcin and TSH concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum carboxy-terminal-I-telopeptide (ICTP) concentrations are high more often than are serum osteocalcin concentrations in postmenopausal women taking suppressive doses of T4 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum ICTP, urine N-terminal telopeptide of type I collagen, and serum osteocalcin were elevated in estrogen deficient postmenopausal women, but not premenopausal women, when T4 dose was carefully titrated to prevent overzealous TSH suppression in patients with thyroid cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fracture rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/27,69\">",
"     27,69",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/70\">",
"     70",
"    </a>",
"    ] studies, patients with subclinical hyperthyroidism due to exogenous thyroid hormone therapy have an increased risk of fracture. The contradictory findings are likely due to differences in the patient populations studied and to the degree of TSH suppression. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study of 17,684 individuals taking thyroxine in Tayside, Scotland, there was no increase in osteoporotic fractures in the 3731 individuals whose TSH was low but detectable (between 0.04 and 0.4",
"      <span class=\"nowrap\">",
"       mU/L),",
"      </span>",
"      while those with undetectable TSH (below 0.03",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      had a twofold increased risk [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 686 women older than 65 years of age, women with a low TSH concentration (&le;0.1",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      had a nearly fourfold increased risk of hip and vertebral fracture compared with women who had normal serum TSH concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 1180 patients taking T4, 59 percent had a suppressed serum TSH concentration (&lt;0.05",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/70\">",
"       70",
"      </a>",
"      ]. Over a five-year period, the overall fracture rate in the women over age 65 years was 2.5 percent in those with suppressed TSH values versus 0.9 percent in those with normal serum TSH values; this difference did not reach statistical significance.",
"     </li>",
"     <li>",
"      In the Cardiovascular Health Study of 3567 individuals over age 65 years, hip fracture incidence was increased (hazard ratio 3.3) in men with subclinical hyperthyroidism, but not women [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/71\">",
"       71",
"      </a>",
"      ]. There were only 29 men with subclinical thyrotoxicosis, and 45 percent were taking thyroid medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, fracture risk appears to be related to the degree of TSH suppression and to specific patient factors (eg, older age) that confer an increased risk of osteoporotic fracture. Use of thyroid hormone itself does not increase the risk of fracture if TSH values remain within the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/27,72\">",
"     27,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prevention and treatment of reduced bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several measures that may prevent loss of bone density:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Titration of suppressive therapy to maintain a slightly low serum TSH concentration (eg, between 0.1 to 0.5",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"     </li>",
"     <li>",
"      Calcium supplementation",
"     </li>",
"     <li>",
"      Estrogen replacement therapy (although the role of estrogen replacement therapy has been diminished since the Women's Health Initiative) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"       \"Postmenopausal hormone therapy: Benefits and risks\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inhibitors of bone resorption (eg, bisphosphonates)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 1997 study demonstrates the benefit of titrating T4 dose. Both lumbar and femoral bone density increased, and serum osteocalcin and urinary excretion of bone collagen-derived pyridinium cross-links decreased when the T4 dose was reduced in postmenopausal women whose initial serum TSH concentration was low [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies are needed to better define the degree of TSH suppression necessary to achieve the desired goal with T4 suppressive therapy. As an example, many authors have recommended that patients with thyroid cancer maintain very low serum TSH concentrations (less than 0.01",
"    <span class=\"nowrap\">",
"     mU/L).",
"    </span>",
"    However, in one report, serum thyroglobulin concentrations did not fall further when serum TSH was suppressed below 0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/74\">",
"     74",
"    </a>",
"    ]. The serum osteocalcin concentration is inversely proportional to the serum TSH concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/66\">",
"     66",
"    </a>",
"    ], and to bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/75\">",
"     75",
"    </a>",
"    ] in overt hyperthyroidism.",
"   </p>",
"   <p>",
"    Adequate dietary calcium intake is essential to ameliorate the adverse effects of thyroid hormone on bone. In a study of 46 postmenopausal women taking suppressive doses of T4, those taking placebo had 5 to 8 percent reductions in bone density over a two-year period, while those given 1000 mg of calcium daily had no measurable bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estrogen replacement therapy is protective when coadministered with thyroid hormone. In one study of 196 women taking thyroid hormone, significant reductions in bone density were found if the T4-equivalent dose was greater than 1.6",
"    <span class=\"nowrap\">",
"     mcg/kg,",
"    </span>",
"    but not at lower doses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/77\">",
"     77",
"    </a>",
"    ]. However, postmenopausal women who also were taking estrogen replacement therapy had no bone loss.",
"   </p>",
"   <p>",
"    Treatment with inhibitors of bone resorption may be useful in patients with continuing bone loss. In short-term studies in humans,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     Pamidronate",
"    </a>",
"    reduces thyroid hormone-mediated increases in measures of bone turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. In one study of patients with thyroid cancer taking suppressive doses of T4, bone density was not reduced as compared with normal subjects, but increased with cyclic pamidronate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcitonin may have limited utility. Calcitonin reduced urinary hydroxyproline excretion and serum calcium in patients with overt hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/80\">",
"     80",
"    </a>",
"    ]. However, intranasal calcitonin with calcium supplements was no more effective than calcium supplements alone in preventing loss of bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/76\">",
"     76",
"    </a>",
"    ], and the improvement in bone density during treatment of overt hyperthyroidism was not augmented by administering intranasal calcitonin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     T4 REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone loss would not be expected to occur when hypothyroidism is treated with oral T4 and the serum TSH concentration does not go below the reference range (ie, if subclinical hyperthyroidism is avoided). In a cross-sectional study, 50 women with primary or radioiodine-induced hypothyroidism receiving long-term therapy had no change in femoral neck or spine bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/82\">",
"     82",
"    </a>",
"    ]. In a longitudinal study, 44 children with congenital hypothyroidism treated and followed for an average of 8.5 years had no change and their bone mineral density did not differ compared to that of age-matched normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Short-term studies, however, are a possible source of confusion. Overtly hypothyroid women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/17,84\">",
"     17,84",
"    </a>",
"    ] treated with T4 for 6 to 12 months have a decrease in bone density, although this seems not to be so for men [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Hypothyroidism, however, is associated with an increase in bone density. A cross-sectional histomorphometric study using iliac crest biopsies, as an example, compared 10 untreated hypothyroid patients with 15 patients receiving thyroid hormone for six months; bone density was lower in the treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/87\">",
"     87",
"    </a>",
"    ]. However, the untreated hypothyroid patients had a mean cortical width that was higher than that of euthyroid subjects. T4 treatment was associated with a transient increase in resorption surfaces and cortical bone porosity, and a decrease in mean cortical width ultimately to levels similar to those in euthyroid subjects. During this period of increased resorption (continuing for two years after initiating T4 therapy) fracture risk may be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment of subclinical hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the loss in bone density during the early treatment of hypothyroidism is due to an increase in remodeling and osteoclast resorption followed by an eventual return to steady-state conditions, then one would not expect a similar reduction in bone density when T4 was administered to patients with subclinical hypothyroidism. Normalization of serum TSH concentrations in postmenopausal women with subclinical hypothyroidism was not associated with a reduction in bone density in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/89\">",
"     89",
"    </a>",
"    ]; however, another study documented increased parameters of bone turnover and a 1.3 percent reduction in bone density after 48 weeks of thyroxine treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is one cross-sectional study that is of concern. Twenty-six premenopausal hypothyroid women with Hashimoto's thyroiditis were treated with an average dose of 0.111 mg per day of T4 for an average of 7.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/91\">",
"     91",
"    </a>",
"    ]. Serum TSH concentrations were normal throughout the study. The density of the femoral trochanter was reduced by 7 percent, but there was no change in the density of the lumbar spine. This single study suggests that T4 replacement therapy may be sufficiently nonphysiologic that it could be associated with increased bone turnover. Euthyroid patients taking T4 have serum T4 concentrations that are on average 1 to 2",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (12.9 to 25.7",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    higher than normal subjects despite normal serum T3 and TSH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is currently little information regarding deiodination of T4 to T3 within bone. It is possible that bone could be responding to the higher serum T4 concentrations achieved with T4 replacement. In support of this hypothesis, a meta-analysis demonstrated reduced bone density in premenopausal women (but not postmenopausal women) receiving replacement T4 therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17593/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt hyperthyroidism and iatrogenic hyperthyroidism result in osteoporosis and fractures. Endogenous or exogenous subclinical hyperthyroidism is associated with reduced bone density, particularly in cortical-rich bone in postmenopausal women. It is not clear, however, that there is an increase in fracture rate.",
"   </p>",
"   <p>",
"    The following recommendations seem prudent at this time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperthyroidism in all patients and endogenous subclinical hyperthyroidism in estrogen-deficient postmenopausal women should be treated to reduce the risk for osteoporosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overt hyperthyroidism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Nodular goiter and graves' disease with subclinical hyperthyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk for osteoporosis in postmenopausal women taking suppressive doses of T4 can be minimized by treatment with the minimal effective suppressive dose of T4 and institution of bisphosphonate therapy where indicated. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Subclinical hyperthyroidism due to exogenous thyroid hormone therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Appropriate replacement therapy of overt hypothyroidism with avoidance of TSH suppression probably does not adversely alter skeletal metabolism. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'T4 replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of subclinical hypothyroidism probably does not decrease bone density. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment of subclinical hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     von Recklinghausen FD. Die Fibr&ouml;se oder deformierende Ostitis, die Osteomalazie und die osteoplastische Carzinose in ihren gegenseitigen Beziehungen, Festchrift Rudolf Virchow (Ed), George Reimer, Berlin 1891. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/2\">",
"      Mundy GR, Shapiro JL, Bandelin JG, et al. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 1976; 58:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/3\">",
"      Rizzoli R, Poser J, B&uuml;rgi U. Nuclear thyroid hormone receptors in cultured bone cells. Metabolism 1986; 35:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/4\">",
"      Sato K, Han DC, Fujii Y, et al. Thyroid hormone stimulates alkaline phosphatase activity in cultured rat osteoblastic cells (ROS 17/2.8) through 3,5,3'-triiodo-L-thyronine nuclear receptors. Endocrinology 1987; 120:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/5\">",
"      Abu EO, Bord S, Horner A, et al. The expression of thyroid hormone receptors in human bone. Bone 1997; 21:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/6\">",
"      Bassett JH, O'Shea PJ, Sriskantharajah S, et al. Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol 2007; 21:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/7\">",
"      Britto JM, Fenton AJ, Holloway WR, Nicholson GC. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994; 134:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/8\">",
"      Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/9\">",
"      Lakatos P, Foldes J, Horvath C, et al. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 1997; 82:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/10\">",
"      Meunier, PJ, S-Bianchi, GG, Edouard, CM, et al. Bony manifestations of thyrotoxicosis. Orthop Clin North Am 1972; 3:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/11\">",
"      Eriksen EF. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 1986; 7:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/12\">",
"      Nielsen HE, Mosekilde L, Charles P. Bone mineral content in hyperthyroid patients after combined medical and surgical treatment. Acta Radiol Oncol Radiat Phys Biol 1979; 18:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/13\">",
"      Linde J, Friis T. Osteoporosis in hyperthyroidism estimated by photon absorptiometry. Acta Endocrinol (Copenh) 1979; 91:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/14\">",
"      Langdahl BL, Loft AG, Eriksen EF, et al. Bone mass, bone turnover, calcium homeostasis, and body composition in surgically and radioiodine-treated former hyperthyroid patients. Thyroid 1996; 6:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/15\">",
"      Langdahl BL, Loft AG, Eriksen EF, et al. Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 1996; 6:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/16\">",
"      Karga H, Papapetrou PD, Korakovouni A, et al. Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf) 2004; 61:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/17\">",
"      Kr&oslash;lner B, J&oslash;rgensen JV, Nielsen SP. Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol (Oxf) 1983; 18:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/18\">",
"      Diamond T, Vine J, Smart R, Butler P. Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med 1994; 120:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/19\">",
"      Toh SH, Claunch BC, Brown PH. Effect of hyperthyroidism and its treatment on bone mineral content. Arch Intern Med 1985; 145:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/20\">",
"      Rosen CJ, Adler RA. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 1992; 75:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/21\">",
"      Grant DJ, McMurdo ME, Mole PA, Paterson CR. Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clin Endocrinol (Oxf) 1995; 43:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/22\">",
"      Svare A, Nilsen TI, Bj&oslash;ro T, et al. Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study. Eur J Endocrinol 2009; 161:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/23\">",
"      Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/24\">",
"      Wejda B, Hintze G, Katschinski B, et al. Hip fractures and the thyroid: a case-control study. J Intern Med 1995; 237:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/25\">",
"      Franklyn JA, Maisonneuve P, Sheppard MC, et al. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 1998; 338:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/26\">",
"      Vestergaard P, Rejnmark L, Weeke J, Mosekilde L. Fracture risk in patients treated for hyperthyroidism. Thyroid 2000; 10:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/27\">",
"      Bauer, DC, Ettinger, B, Nevitt, MC, Stone, KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001; 134:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/28\">",
"      Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990; 19:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/29\">",
"      Frizel D, Malleson A, Marks V. Plasma levels of ionised calcium and magnesium in thyroid disease. Lancet 1967; 1:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/30\">",
"      Jastrup B, Mosekilde L, Melsen F, et al. Serum levels of vitamin D metabolites and bone remodelling in hyperthyroidism. Metabolism 1982; 31:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/31\">",
"      Karsenty G, Bouchard P, Ulmann A, Schaison G. Elevated metabolic clearance rate of 1 alpha,25-dihydroxyvitamin D3 in hyperthyroidism. Acta Endocrinol (Copenh) 1985; 110:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/32\">",
"      Thomas FB, Caldwell JH, Greenberger NJ. Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat. Ann Intern Med 1973; 78:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/33\">",
"      Amato G, Mazziotti G, Sorvillo F, et al. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 2004; 35:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/34\">",
"      Park SE, Cho MA, Kim SH, et al. The adaptation and relationship of FGF-23 to changes in mineral metabolism in Graves' disease. Clin Endocrinol (Oxf) 2007; 66:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/35\">",
"      Cooper DS, Kaplan MM, Ridgway EC, et al. Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Ann Intern Med 1979; 90:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/36\">",
"      Garrel DR, Delmas PD, Malaval L, Tourniaire J. Serum bone Gla protein: a marker of bone turnover in hyperthyroidism. J Clin Endocrinol Metab 1986; 62:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/37\">",
"      MacLeod JM, McHardy KC, Harvey RD, et al. The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover. Clin Endocrinol (Oxf) 1993; 38:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/38\">",
"      Lupoli G, Nuzzo V, Di Carlo C, et al. Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. Gynecol Endocrinol 1996; 10:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/39\">",
"      Mudde AH, Reijnders FJ, Kruseman AC. Peripheral bone density in women with untreated multinodular goitre. Clin Endocrinol (Oxf) 1992; 37:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/40\">",
"      F&ouml;ldes J, Tarj&aacute;n G, Szathmari M, et al. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin Endocrinol (Oxf) 1993; 39:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/41\">",
"      Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 1994; 41:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/42\">",
"      Faber J, Jensen IW, Petersen L, et al. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 1998; 48:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/43\">",
"      Kumeda Y, Inaba M, Tahara H, et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000; 85:4157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/44\">",
"      Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987; 82:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/45\">",
"      Stock JM, Surks MI, Oppenheimer JH. Replacement dosage of L-thyroxine in hypothyroidism. A re-evaluation. N Engl J Med 1974; 290:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/46\">",
"      Paul TL, Kerrigan J, Kelly AM, et al. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988; 259:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/47\">",
"      Franklyn J, Betteridge J, Holder R, et al. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol (Oxf) 1994; 41:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/48\">",
"      Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991; 72:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/49\">",
"      Lehmke J, Bogner U, Felsenberg D, et al. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women. Clin Endocrinol (Oxf) 1992; 36:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/50\">",
"      Gonzalez DC, Mautalen CA, Correa PH, et al. Bone mass in totally thyroidectomized patients. Role of calcitonin deficiency and exogenous thyroid treatment. Acta Endocrinol (Copenh) 1991; 124:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/51\">",
"      St��p&aacute;n JJ, L&iacute;manov&aacute; Z. Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. Bone Miner 1992; 17:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/52\">",
"      Marcocci C, Golia F, Bruno-Bossio G, et al. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 1994; 78:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/53\">",
"      Garton M, Reid I, Loveridge N, et al. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin Endocrinol (Oxf) 1994; 41:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/54\">",
"      Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/55\">",
"      Marcocci C, Golia F, Vignali E, Pinchera A. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res 1997; 12:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/56\">",
"      Kung AW, Lorentz T, Tam SC. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clin Endocrinol (Oxf) 1993; 39:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/57\">",
"      De Rosa G, Testa A, Giacomini D, et al. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre. Clin Endocrinol (Oxf) 1997; 47:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/58\">",
"      M&uuml;ller CG, Bayley TA, Harrison JE, Tsang R. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid 1995; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/59\">",
"      Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990; 113:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/60\">",
"      Pioli G, Pedrazzoni M, Palummeri E, et al. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinol (Copenh) 1992; 126:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/61\">",
"      Bauer DC, Nevitt MC, Ettinger B, Stone K. Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab 1997; 82:2931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/62\">",
"      Faber J, Gall&oslash;e AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994; 130:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/63\">",
"      Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996; 81:4278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/64\">",
"      Schneider P, Berger P, Kruse K, B&ouml;rner W. Effect of calcitonin deficiency on bone density and bone turnover in totally thyroidectomized patients. J Endocrinol Invest 1991; 14:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/65\">",
"      Harvey RD, McHardy KC, Reid IW, et al. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 1991; 72:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/66\">",
"      Ross DS, Ardisson LJ, Nussbaum SR, Meskell MJ. Serum osteocalcin in patients taking L-thyroxine who have subclinical hyperthyroidism. J Clin Endocrinol Metab 1991; 72:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/67\">",
"      Loviselli A, Mastinu R, Rizzolo E, et al. Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy. Thyroid 1997; 7:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/68\">",
"      Mikosch P, Obermayer-Pietsch B, Jost R, et al. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. Thyroid 2003; 13:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/69\">",
"      Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010; 95:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/70\">",
"      Leese GP, Jung RT, Guthrie C, et al. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 1992; 37:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/71\">",
"      Lee JS, Buzkov&aacute; P, Fink HA, et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med 2010; 170:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/72\">",
"      Sheppard MC, Holder R, Franklyn JA. Levothyroxine treatment and occurrence of fracture of the hip. Arch Intern Med 2002; 162:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/73\">",
"      Guo CY, Weetman AP, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (Oxf) 1997; 46:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/74\">",
"      Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 1992; 75:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/75\">",
"      Lee MS, Kim SY, Lee MC, et al. Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J Clin Endocrinol Metab 1990; 70:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/76\">",
"      Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 1996; 81:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/77\">",
"      Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. JAMA 1994; 271:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/78\">",
"      Rosen HN, Moses AC, Gundberg C, et al. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J Clin Endocrinol Metab 1993; 77:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/79\">",
"      Rosen HN, Moses AC, Garber J, et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998; 83:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/80\">",
"      Hendriks JT, Smeenk D. Investigation of bone and mineral metabolism in hyperthyroidism before and after treatment using calcitonin, 47Ca and balance studies. Acta Endocrinol (Copenh) 1979; 91:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/81\">",
"      J&oacute;dar E, Mu&ntilde;oz-Torres M, Escobar-Jim&eacute;nez F, et al. Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. J Clin Endocrinol Metab 1997; 82:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/82\">",
"      Hanna FW, Pettit RJ, Ammari F, et al. Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol (Oxf) 1998; 48:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/83\">",
"      Leger J, Ruiz JC, Guibourdenche J, et al. Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L-thyroxine therapy. Acta Paediatr 1997; 86:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/84\">",
"      Ribot C, Tremollieres F, Pouilles JM, Louvet JP. Bone mineral density and thyroid hormone therapy. Clin Endocrinol (Oxf) 1990; 33:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/85\">",
"      Toh SH, Brown PH. Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study. J Bone Miner Res 1990; 5:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/86\">",
"      Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly men. Arch Intern Med 1995; 155:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/87\">",
"      Coindre JM, David JP, Rivi&egrave;re L, et al. Bone loss in hypothyroidism with hormone replacement. A histomorphometric study. Arch Intern Med 1986; 146:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/88\">",
"      Vestergaard P, Weeke J, Hoeck HC, et al. Fractures in patients with primary idiopathic hypothyroidism. Thyroid 2000; 10:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/89\">",
"      Ross DS. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. Am J Med 1993; 95:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/90\">",
"      Meier C, Beat M, Guglielmetti M, et al. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int 2004; 15:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17593/abstract/91\">",
"      Kung AW, Pun KK. Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine. JAMA 1991; 265:2688.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7882 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17593=[""].join("\n");
var outline_f17_11_17593=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERT HYPERTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bone density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fracture risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptomatic bone disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mineral metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NODULAR GOITER AND GRAVES' DISEASE WITH SUBCLINICAL HYPERTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUBCLINICAL HYPERTHYROIDISM DUE TO EXOGENOUS THYROID HORMONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Low bone density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other parameters of bone mineral metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fracture rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prevention and treatment of reduced bone density",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      T4 REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment of subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_11_17594="Microbiology and therapy of peritonitis in continuous peritoneal dialysis";
var content_f17_11_17594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17594/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17594/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17594/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17594/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17594/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/11/17594/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/11/17594/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/11/17594/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonitis is one of the major complications of peritoneal dialysis (PD) and, despite reductions in overall peritonitis rates, remains the primary reason why patients switch from PD to hemodialysis (HD) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Observational data from a national cohort of incident PD patients starting dialysis in 2000 suggested that 5 percent of patients transferred to HD because of peritonitis during the first year (versus 4.2 for catheter related problems, 3.9 for adequacy issues, and 2.6 for psychosocial issues). Percentages were similar for year two [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/3\">",
"     3",
"    </a>",
"    ]. These authors also noted that the rate of transfer to HD because of peritonitis during year one showed a progressive decline from 1999 to 2001.",
"   </p>",
"   <p>",
"    The overwhelming majority of peritonitis cases are caused by pathogenic bacteria, with a small number of cases being caused by fungi, mostly Candida species. The role of viral infection is uncertain. Although anecdotal cases of viral peritonitis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/4\">",
"     4",
"    </a>",
"    ], viruses are more likely to predispose patients to bacterial peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritonitis is not only a cause of morbidity but can also result in mortality. In one retrospective Spanish study of 565 patients, 41 of 693 episodes of peritonitis resulted in death (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/7\">",
"     7",
"    </a>",
"    ]. The highest mortality was associated with specific organisms, particularly fungus (28 percent of deaths), enteric organisms (19 percent) and Staphylococcus aureus (15 percent). Data from the United States similarly suggest that mortality is related to the specific infectious pathogen; it was less than 5 percent overall in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/8\">",
"     8",
"    </a>",
"    ] and 3.5 percent overall in another [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritonitis is also associated with increased risk of death from non-infectious causes. In a study of 1316 PD patients who died while being treated with PD or within 30 days of transfer to hemodialysis, there was a much greater risk of having had peritonitis within the four months prior to death compared with the rest of the year, even though the immediate cause of death was not attributed to peritonitis in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/10\">",
"     10",
"    </a>",
"    ]. In particular, there was a marked increase in the risk of having had peritonitis in the 30 days prior to death among patients who died of cardiovascular, cerebrovascular or peripheral vascular disease (odds ratio 3.4, 95% CI 2.4-4.6).",
"   </p>",
"   <p>",
"    The microbiology and therapy of peritonitis in patients treated with CAPD will be reviewed here. The approach to the diagnosis of peritonitis, including exclusion of predisposing intraabdominal diseases (such as pancreatitis), is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over the past 20 years, multiple innovations in peritoneal dialysis connectology and the use of prophylactic antibiotics have reduced overall peritonitis rates. Reported peritonitis rates vary widely with reported incidence noted in one review varying from 0.06 episodes per patient year at risk in a Taiwanese program to as high as 1.66 episodes per patient year at risk in a pediatric program in Israel [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology and microbiology of peritonitis among PD patients has varied by location and over time [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]. As an example, a large review of 3366 patients who started CAPD in the first six months of 1989 provided important epidemiologic information on the first episode of peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Almost 50 percent of infections were due to Gram positive organisms and 15 percent to Gram negative organisms",
"     </li>",
"     <li>",
"      Approximately 20 percent were culture negative",
"     </li>",
"     <li>",
"      Polymicrobial infection (either multiple Gram negative organisms or both Gram positive and Gram negative organisms) occurred in 4 percent",
"     </li>",
"     <li>",
"      Fungal infection was found in less than 2 percent",
"     </li>",
"     <li>",
"      Exit site infection was present in 13 percent and a peritoneal fluid leak in 3 percent",
"     </li>",
"     <li>",
"      Hospitalization was required in 31 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent retrospective study is the only review to report the overall epidemiology, changes in incidence, and characteristics of causative organisms in a single center's experience of PD-related peritonitis over a decade-long period (1992 through 2001) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/14\">",
"     14",
"    </a>",
"    ]. Based upon 1108 episodes of peritonitis among 1015 CAPD patients, single Gram positive organisms, single Gram negative organisms, multiple organisms, fungi, and M. tuberculosis caused 45, 15, 1, 2, and 0.1 percent of peritonitis episodes, respectively. Almost 40 percent of episodes were culture-negative, which may have reflected patient noncompliance in providing the first cloudy dialysate prior to antibiotic treatment. The following additional findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of peritonitis significantly decreased over time (0.49 and 0.23",
"      <span class=\"nowrap\">",
"       episodes/patient-year",
"      </span>",
"      in 1992 and 2001, respectively).",
"     </li>",
"     <li>",
"      Among episodes caused by a known organism, the proportion due to single Gram positive organisms decreased from 1992 to 2001 (87 to 70 percent, respectively), while the proportion due to single Gram negative organisms increased (7 to 28 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another epidemiologic study found that CCPD, versus CAPD, was associated with a relatively increased risk of peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the retrospective study evaluated incident PD patients in the years 1994 to 1997, a period prior to the widespread use of prophylactic topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In the United States, subsequent data revealed that 1142 of 3111 patients (37 percent) had 2272 episodes of peritonitis, corresponding to an annual rate of 0.367 episodes of peritonitis per year at risk (or one every 32.7 patient months) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/9\">",
"     9",
"    </a>",
"    ]; this compares to 2886 of 6544 patients (44 percent) who had 6263 episodes of peritonitis, corresponding to an annual rate of 0.434 episodes of peritonitis per year at risk (or one every 27.6 patient months) in Canada. In this database, gram positive organisms accounted for 62 and 61 percent of infections in the United States and Canada, respectively. Gram negative bacteria were responsible for 21 and 24 percent, respectively. Fungal peritonitis caused slightly less than 4 percent in both countries.",
"   </p>",
"   <p>",
"    The ISPD 2010 update of Peritoneal Dialysis related infections recommend that a center&rsquo;s peritonitis rate should be no higher than 1 episode every 18 patient months at risk (0.67",
"    <span class=\"nowrap\">",
"     episodes/year",
"    </span>",
"    at risk) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the rate achieved will depend to some extent on the patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gram positive peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, coagulase-negative staphylococci were the most common cause of peritonitis in CAPD, presumably due to touch contamination or infection via the pericatheter route [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/19\">",
"     19",
"    </a>",
"    ]. Coagulase-negative staphylococci typically cause mild peritonitis that responds rapidly to therapy. Occasionally, infections with coagulase negative staphylococci relapse and, if appropriate antibiotic therapy was given the first time in such cases, a catheter biofilm is usually present, thereby necessitating catheter removal.",
"   </p>",
"   <p>",
"    Another common cause of peritonitis is Staphylococcus aureus, a more virulent pathogen that tends to cause a more severe form of peritonitis and tends to be more resistant to therapy. Although peritonitis with S. aureus may be due to touch contamination, concurrent catheter infection is also a common cause of infection. Patients with S. aureus peritonitis have occasionally presented with a toxic shock-like syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/20\">",
"     20",
"    </a>",
"    ], and severe cases may lead to progressive injury to the peritoneal membrane. One of the reservoirs for S. aureus is the anterior nares, with nasal carriers of S. aureus being at increased risk for S. aureus exit site infections and possibly peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26248?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology and prevention of peritonitis in peritoneal dialysis\", section on 'Staphylococcus aureus nasal carriage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative percentages of peritonitis caused by these two organisms have changed over time [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]. The use of Y systems (or flush before fill) has reduced the incidence of coagulase-negative staphylococcal peritonitis due to touch contamination but has a lesser protective effect against S. aureus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. As a result, there has been a reduction in the overall peritonitis rate, with a relative increase in the incidence of peritonitis due to S. aureus. However, some centers have reported stable rates of S. aureus associated peritonitis, despite the consistent use of Y (or flush before fill) systems [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococci as nosocomial pathogens has risen dramatically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=see_link\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\"",
"    </a>",
"    .) This resistance has been associated with resistance to other antibiotics (including penicillin and aminoglycosides) and can be transferred to staphylococcal strains.",
"   </p>",
"   <p>",
"    There are also case reports of peritonitis due to group B streptococcus in the literature. Affected patients can present with severe systemic symptoms and septic shock within 24 hours after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/24\">",
"     24",
"    </a>",
"    ]. Although rare, these cases illustrate the importance of having patients monitor their blood pressure and report symptomatology early in the course of home therapy for peritonitis. Hypotension is suggestive of more severe disease that usually requires hospitalization.",
"   </p>",
"   <p>",
"    Although enterococcus infections may be due to touch contamination, the organism is frequently from the gastrointestinal tract. As a result, the clinician must always have a high index of suspicion for intra-abdominal pathology in these cases.",
"   </p>",
"   <p>",
"    Streptococci can be oral colonizers, so special attention to oral hygiene and prophylaxis during dental procedures should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gram negative, non-pseudomonas peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram negative peritonitis can be produced by a variety of organisms that may be derived from the bowel, skin, urinary tract, contaminated water, and animal contact. Thus, the history may be important. As examples, peritonitis associated with severe diarrhea has been caused by Campylobacter infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/25\">",
"     25",
"    </a>",
"    ], while peritonitis due to polymicrobial infection or anaerobic Gram negative organisms is more frequently associated with diverticulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/26\">",
"     26",
"    </a>",
"    ]. The outcome of gram-negative, non-pseudomonas peritonitis has similarly poor outcomes as S. aureus peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Escherichia coli is an unusual cause of peritonitis in CAPD. If it occurs, it may be related to occasional transmural migration of bacteria (hence one reason to avoid constipation) and decreased intrinsic peritoneal defenses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pseudomonas peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomonas infections are often difficult to eradicate, are associated with catheter infection, and, in severe cases, may result in damage to the peritoneal membrane. There may also be severe systemic manifestations, such as digital necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some centers, the preventive measures aimed at reducing peritonitis due to touch contamination (flush before fill technology and prophylactic topical antibiotic therapy applied to exit site) have resulted in Pseudomonas infections becoming the most common cause of peritonitis and exit site infections on a percentage basis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report found that the presence or absence of exit site or catheter-related infection was an important determinant of the response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/29\">",
"     29",
"    </a>",
"    ]. The response rate was only 32 percent if such an infection was present versus 73 percent if there was no evidence of catheter-related infection.",
"   </p>",
"   <p>",
"    Pseudomonas bacteria commonly colonize aerators used on faucets. These aerators should be removed to minimize the risk of Pseudomonas peritonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fungal peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal peritonitis is an uncommon cause of peritonitis in peritoneal dialysis patients. The presenting signs and symptoms associated with fungal peritonitis are similar to those seen with bacterial peritonitis. These patients have often had previous antibiotic therapy or peritonitis. The approach to such patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link\">",
"     \"Fungal peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tuberculous peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculous peritonitis usually, but not always [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/30\">",
"     30",
"    </a>",
"    ], presents with a predominance of lymphocytes in the effluent. Suspicion of tuberculous infection should be raised in the patient living in an endemic-area with culture-negative or culture-positive refractory peritonitis, since concurrent bacterial infection may be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Peritonitis can also result from infection with Mycobacterium tuberculosis, kansasii, and fortuitum.",
"   </p>",
"   <p>",
"    Peritonitis due to M. tuberculosis is not necessarily associated with significant long-term morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. In a retrospective study of 10 patients, for example, six continued to receive CAPD after completion of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/32\">",
"     32",
"    </a>",
"    ]. At five years, three of the six patients were still undergoing satisfactory dialytic treatment with peritoneal dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biofilms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the offending organism, the response to therapy may be affected by biofilm growth, which has been associated with antibiotic resistance in in vitro studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A large prospective study has demonstrated biofilms in peritoneal catheters removed from PD patients; furthermore, cultures of scrapings from these biofilms were often positive for S. aureus and coagulase-negative staphylococci [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is sometimes no clear relation between biofilms and clinical peritonitis. One exception may occur in patients with multiple episodes of peritonitis who were likely to have stable biofilms, positive biofilm cultures, and a high incidence of catheter loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26248?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathophysiology and prevention of peritonitis in peritoneal dialysis\", section on 'Biofilms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of any episode of peritonitis impacts the patient's well-being and may influence the ability to continue on peritoneal dialysis. The majority of episodes resolve with outpatient antibiotic treatment alone. Overall cure rates are approximately 75 percent.",
"   </p>",
"   <p>",
"    The principal approach to the management of peritonitis in peritoneal dialysis relies upon appropriate antimicrobial therapy. Additional therapies may include fibrinolytic agents, peritoneal lavage, and catheter removal.",
"   </p>",
"   <p>",
"    To assess the efficacy of the management of peritonitis, a systematic review of 36 randomized controlled trials was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/36\">",
"     36",
"    </a>",
"    ], with 30, 4, 1, and 1 addressing the efficacy of antimicrobials, urokinase, peritoneal lavage, and intraperitoneal immunoglobulins, respectively. In general, no specific antimicrobial regimen was superior, and intermittent and continuous dosing were largely equivalent. Additional findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First generation cephalosporins and glycopeptides had equivalent efficacy (387 patients from three studies, RR 1.84, 95% CI 0.95-3.58).",
"     </li>",
"     <li>",
"      In clinical situations (such as relapsing peritonitis and suspected catheter infection), treatment success was more common with simultaneous catheter",
"      <span class=\"nowrap\">",
"       removal/replacement",
"      </span>",
"      than with urokinase (37 patients in one trial, RR 2.35, 95% CI 1.13-4.91).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trials were limited by suboptimal method quality, inconsistent outcome definitions, and small patient numbers.",
"   </p>",
"   <p>",
"    A working group for the International Society of Peritoneal Dialysis (ISPD) published a series of peritonitis treatment guidelines that were updated in 2010 for the initial approach to a patient with peritonitis and the treatment of specific infections once the culprit organism has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12,18,37-39\">",
"     12,18,37-39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Empiric initial therapy for peritonitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General non-antimicrobial considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the period in which the dialysate remains cloudy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    of dialysate) is usually added to help lyse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevent fibrin clots [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/40\">",
"     40",
"    </a>",
"    ]. Adequate pain control should also be provided as necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36601?source=see_link\">",
"     \"Medical management of the dialysis patient undergoing surgery\"",
"    </a>",
"    .) This can be facilitated by multiple rapid exchanges to remove inflammatory burden and lower the endotoxin load [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/40\">",
"     40",
"    </a>",
"    ]. However, rapid exchanges do not tend to hasten rate of recovery.",
"   </p>",
"   <p>",
"    Additional issues include dwell time and effect on membrane properties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dwell time &mdash; There are two effects of dwell time that influence the dialysis prescription during an episode of peritonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/41\">",
"       41",
"      </a>",
"      ]. The first is that long dwell exchanges (four to six hours), when compared with short dwells (one to two hours), are associated with higher numbers of intra-peritoneal macrophages, a greater percentage of which are functional [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/2\">",
"       2",
"      </a>",
"      ]. The second is that the IgG concentrations in the effluent rise with increasing dwell time.",
"      <br/>",
"      <br/>",
"      As a result, it is recommended that long dwells rather than rapid short dwells be used for the treatment of peritonitis. However, this recommendation must be weighed against the increased protein losses and loss of ultrafiltration associated with episodes of peritonitis. These abnormalities can be associated with fluid absorption from the peritoneum during long dwells, and even volume overload in some cases.",
"     </li>",
"     <li>",
"      Membrane properties &mdash; Peritoneal membrane transport often changes during peritonitis. Infected patients may transiently become rapid transporters, thereby requiring the use of hypertonic glucose or shorter dwells. Alternative agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      , may be helpful in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=see_link\">",
"       \"Rapid transporters on maintenance peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Empiric initial therapy for peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 guidelines recommend that the selection of empiric therapy must cover",
"    <strong>",
"     both",
"    </strong>",
"    Gram positive and Gram negative organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12,18,42\">",
"     12,18,42",
"    </a>",
"    ]. The regimen used should be dependent upon center-specific characteristics, such as the history of sensitivities of organisms that are causing peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, we agree with the working group, which recommended that [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gram positive organisms may be covered by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      or a cephalosporin",
"     </li>",
"     <li>",
"      Gram negative organisms may be covered by a third-generation cephalosporin or an aminoglycoside.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some centers with a high rate of methicillin-resistant organisms,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be used in combination with another drug for Gram negative coverage. By comparison, other centers can successfully use a first-generation cephalosporin (such as cephalothin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ) plus a second drug for Gram negative coverage. As an example, some centers have found that initial empiric therapy consisting of intraperitoneal cefazolin plus oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    was successful in 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Unsuccessful cases resulted from catheter colonization or antimicrobial resistance.",
"   </p>",
"   <p>",
"    The guidelines also state that an aminoglycoside,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    , or carbapenem can provide Gram negative coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]. If local sensitivity patterns permit, quinolones can also be used for empiric coverage of Gram negative organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    can be used as an alternative for cefepime or ceftazidime in the cephalosporin-allergic patient, if an aminoglycoside is not used [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although short-term use of aminoglycosides appears to be safe and does not diminish residual renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/47\">",
"     47",
"    </a>",
"    ], the guidelines state that repeated or prolonged aminoglycoside therapy (eg, longer than two weeks) may be inadvisable if alternative approaches are possible [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]. Alternative approaches for Gram negative coverage include the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Additional regimens, including monotherapy, may also be possible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, similar outcomes were observed among 102 patients randomly assigned to initial treatment with either",
"      <span class=\"nowrap\">",
"       imipenem/cilastatin",
"      </span>",
"      or to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar efficacy was observed in a randomized controlled study that compared intraperitoneal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      plus netilmicin versus cefazolin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      for CAPD peritonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/49\">",
"       49",
"      </a>",
"      ], while another study found similar results with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus netilmicin [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      was found to be effective first line therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Marked clinical improvement should be observed within 48 to 72 hours of initiating therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]. If a cloudy effluent continues after five days of appropriate antibiotic therapy, refractory peritonitis is present and the catheter should be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]. Additional issues surrounding the response to initial empiric therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gram stain reveals yeast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt initiation of antifungal therapy is indicated if the Gram stain reveals yeast or other fungus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12\">",
"     12",
"    </a>",
"    ]. In such cases, one must prepare the patient for possible catheter removal, and if the culture results are positive for yeast, consider prompt catheter removal. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link\">",
"     \"Fungal peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intermittent or continuous intraperitoneal dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of patients with PD-associated peritonitis, the infection is localized to the peritoneum and a few cell layers lining the peritoneal cavity and intraabdominal viscera. In fact, bacteremia almost never occurs.",
"   </p>",
"   <p>",
"    Therefore, in patients undergoing PD, the working group stated that intraperitoneal dosing of antibiotics is preferred to intravenous dosing, given the increased local concentration with intraperitoneal administration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. However, since antibiotics are absorbed if administered in the peritoneum, serum systemic drug levels for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and aminoglycosides must be monitored to facilitate intermittent dosing or prolonged aminoglycoside dosing.",
"   </p>",
"   <p>",
"    The intraperitoneal administration of antibiotics can be either continuous (with antibiotics given in each exchange) or intermittent (given once daily). The working group stated that, with intermittent dosing, the antibiotic must dwell for at least six hours (",
"    <a class=\"graphic graphic_table graphicRef79841 \" href=\"UTD.htm?28/44/29389\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60452 \" href=\"UTD.htm?23/7/23677\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinician must choose between continuous or intermittent dosing. With CAPD, the guidelines state that, for first generation cephalosporins, it was unclear whether continuous is more effective than intermittent dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]. By comparison, there is extensive experience with the efficacy of intermittent dosing of aminoglycosides and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    in CAPD (but less for APD). At our center, we typically start treatment with intermittent therapy, instilling antibiotics during a dwell for greater than six hours. Once established, this would be during the overnight dwell if on CAPD or daytime dwell of APD. Antibiotics are then adjusted pending culture results and clinical response.",
"   </p>",
"   <p>",
"    Less is known concerning the efficacy of different types of dosing with automatic peritoneal dialysis (APD). Given this lack of data, the working group recommended that, with first generation cephalosporins, the safest approach would be to add the antibiotic to each exchange.",
"   </p>",
"   <p>",
"    With respect to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , the committee stated that intermittent dosing can be given in APD. If done, a dosing interval of every four to five days may be adequate, but the optimal interval should be determined by monitoring levels. Redosing is required once serum levels fall to 15",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef74934 \" href=\"UTD.htm?17/5/17499\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Due to lack of data, the approach to the patient on APD can be confusing. At our center, we tend to use the following approach. In the first 24 hours, we use an \"intermittent\" dosing regimen. Specifically, we add antibiotics to their next dwell and advise the patient to have it dwell for at least six hours. If the patient is doing well, we continue the antibiotic regimen having the patient instill antibiotics during the long daytime dwell adjusting as indicated when culture results are available. We monitor the patient's response daily.",
"   </p>",
"   <p>",
"    If a \"continuous regimen\" is used, we usually continue the patient on their current PD prescription and add the antibiotic to the overnight dwell bag, as you would for CAPD dosing (eg, if the patient dialysis dose is four 2 L exchanges and a 2 L last bag fill, then each 5 L bag of fluid would get the same",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    dose of antibiotic [times 5 L] as recommended for each liter of CAPD dwell; the same is true for the last bag fill if an additional bag of fluid is needed).",
"   </p>",
"   <p>",
"    Many centers switch patients to CAPD for the initial three to five days of peritonitis and administer CAPD dosing, but we have seldom found this necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management once culture results and sensitivity are obtained",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial empiric regimen can be adjusted once the culture results are known and a specific organism identified. Therapy is chosen based upon the organism and its sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12,18\">",
"     12,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The minimum length of therapy for peritonitis is two weeks, with three weeks being recommended for more severe infections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Coagulase-negative staphylococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most peritonitis episodes due to a coagulase-negative staphylococcus respond to therapy. This was shown in a review of 232 consecutive cases in which the primary response rate was 95 percent and cure was noted in 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritoneal dialysis programs with a high rate of methicillin resistance (greater than 50 percent) may prefer to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    empirically. With respect to first generation cephalosporins, the committee recommended that continuous dosing may be preferable. In this setting, two weeks of therapy is sufficient, with repeated cell counts and effluent cultures guiding therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]. Among those with relapse or repeat episodes, a three-week course may result in a higher cure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Streptococcus and enterococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcal or enterococcal peritonitis should be treated with intraperitoneal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    . An aminoglycoside (given intraperitoneal once daily) may be added for synergy to treat enterococcal peritonitis. If the organism is ampicillin resistant,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be administered [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococcus (VRE) is susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , ampicillin is the drug of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]. If VRE is resistant to ampicillin, the committee suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    , or",
"    <span class=\"nowrap\">",
"     quinupristin/dalfopristin",
"    </span>",
"    should be administered [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]. However, linezolid is associated with bone marrow suppression after 10 to 14 days, and neurotoxicity may occur with longer therapy.",
"   </p>",
"   <p>",
"    The working group suggested that the duration of therapy should be 14 and 21 days for streptococcus and enterococcus, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the organism is S. aureus, attention must be given to the exit site and catheter tunnel, although a touch contamination may also have been the source. Catheter-related peritonitis is unlikely to be cured without removal of the catheter. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Indications for catheter removal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antimicrobial therapy is based upon sensitivities. The recommended duration of therapy is at least 21 days. If cultures document methicillin-resistance, the patient should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . With intermittent dosing, the patient should receive another vancomycin dose once the trough serum level falls to 15",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Treatment is for three weeks.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    (600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally) can be added, but should be given for only one week and never given as a single agent to avoid resistance. In one retrospective study of 245 consecutive cases of S. aureus peritonitis from China, adjuvant rifampicin therapy, compared with treatment without rifampicin, was associated with a significantly lower risk for relapse or repeat peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At our center, we have elected to redose once the serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    concentration is less than 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    so that the concentration does not become subtherapeutic. If, for example, the serum vancomycin was measured every other day, then a value of 18",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    on day one might be below 15",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    on day three. For patient convenience, we tend not to change from vancomycin to a cephalosporin, even if the patient has a methicillin-sensitive organism. If the S. aureus is resistant to vancomycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    , or",
"    <span class=\"nowrap\">",
"     quinupristin/dalfopristin",
"    </span>",
"    must be administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pseudomonas aeruginosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;With Pseudomonas aeruginosa peritonitis, use of two different acting antibiotics are recommended with a treatment duration of 21 days. A catheter-related infection is also frequently present. In this setting, catheter removal is required, with appropriate antibiotics administered for two weeks while the patient is being hemodialyzed. In a study from Australia, the best outcomes were associated with prompt catheter removal and use of two anti-pseudomonal antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Indications for catheter removal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Occasionally, Pseudomonas aeruginosa peritonitis occurs without a catheter infection. As with a catheter related infection, cure requires the administration of at least two active agents with differing mechanisms of action. One antibiotic can be an oral quinolone, with the second drug being",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"     piperacillin",
"    </a>",
"    . Based upon local sensitivity patterns at our center, we typically use oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and intraperitoneal ceftazidime [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/55\">",
"     55",
"    </a>",
"    ]. The working group recommends that the duration of therapy should be at least 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To avoid P. aeruginosa peritonitis, prompt catheter replacement should occur with recurrent, relapsing, or refractory exit site infections due to this organism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other single gram-negative organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;With a single Gram negative organism other than P. aeruginosa, the chosen antibiotic will depend upon sensitivity, safety, and convenience. Duration of therapy is 14 to 21 days. Although in vitro sensitivity may suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    or other agent is indicated, actual in vivo sensitivity (such as an organism embedded in a biofilm) may be considerably less than that determined in the laboratory. This was shown in a study from Hong Kong, in which the clinical outcomes were reported of 210 consecutive cases of enterobacteriaceae peritonitis (eg, non-pseudomonas Gram negative organisms) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/56\">",
"     56",
"    </a>",
"    ]. There was a primary response and complete cure rate of 85 and 58 percent, respectively. Failure to respond to a single agent, despite in vitro sensitivity, was noted in 39 percent of episodes. Risk of relapse and recurrence was also lower with the use of two antibiotics versus that observed with single agent therapy. Although these findings may not be generalized, consideration should be given to early institution of a second antibiotic in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/57\">",
"     57",
"    </a>",
"    ]. These infections may result from a bowel source, touch contamination, or an exit-site infection.",
"   </p>",
"   <p>",
"    With a Stenotrophomonas infection, therapy is recommended for three to four weeks if the patient is improving. The administration of two drugs to which the organism is sensitive is recommended.",
"   </p>",
"   <p>",
"    An increasing number of episodes of E. Coli peritonitis are due to extended-spectrum beta-lactamase producing organisms, which are effective in inactivating third-generation cephalosporins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    . Peritonitis due to these organisms, which may be due to use of cephalosporins and gastric acid inhibitors, are associated with poor outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/58\">",
"     58",
"    </a>",
"    ]. When a patient with isolated gram negative peritonitis suddenly worsens after initial response to therapy, one has to have a high index of suspicion for this phenomena along with other causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Polymicrobial peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With multiple enteric organisms or mixed",
"    <span class=\"nowrap\">",
"     gram-negative/gram-positive",
"    </span>",
"    organisms, one must consider intra-abdominal disease, such as ischemic bowel or diverticular disease, and a surgical consultation should be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12,18,59\">",
"     12,18,59",
"    </a>",
"    ]. The committee stated that the optimal therapy is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    or an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12\">",
"     12",
"    </a>",
"    ]. With intra-abdominal disease, the catheter may have to be removed.",
"   </p>",
"   <p>",
"    With multiple Gram positive organisms, a contamination or catheter infection is most likely. Appropriate antibiotics should be administered; peritonitis usually resolves without catheter removal, unless the source of infection is the catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Culture negative peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With culture negative peritonitis, a repeat cell count and differential and culture should be obtained after day three with no growth. If the repeat cell count points toward an unresolved infection, special culture techniques should be used to isolate unusual causes of peritonitis, such as fungi and mycoplasma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there is clinical improvement with empiric therapy, the initial therapy is continued. In this setting, treatment is continued for two weeks.",
"   </p>",
"   <p>",
"    If there is inadequate improvement at five days, catheter removal should be strongly considered. Patients should also be evaluated for other catheter-associated infections, intraabdominal disease, tuberculosis or fungal infection, contamination of the dialysate with endotoxin (rare), an adverse reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    , and other possibilities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/60-66\">",
"     60-66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Indications for catheter removal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Fungal peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal peritonitis is often difficult to eradicate, usually requiring early catheter removal. The approach to such patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link\">",
"     \"Fungal peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Mycobacterial peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although mycobacterial peritonitis can be associated with fever, pain, and a cloudy dialysate, infection with this organism should be particularly considered in patients with prolonged symptoms despite antimicrobial therapy or relapsing peritonitis with negative bacterial cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The committee recommended that treatment is based on general protocols for the management of tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"     18",
"    </a>",
"    ]. It should begin with rifampicin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12\">",
"     12",
"    </a>",
"    ]. Given that rifampicin penetration into dialysis fluid may be low, this agent may need to be given intraperitoneally. Pyrazinamide and ofloxacin should be withdrawn after three months, while rifampicin and isoniazid should be continued for 12 to 18 months. Pyridoxine should be given to minimize the risk of neurotoxicity with isoniazid.",
"   </p>",
"   <p>",
"    It is controversial as to whether catheter removal is required. Some investigators feel that approximately one-third of cases of M. tuberculosis infection can be treated without catheter removal; in contrast, atypical mycobacterial infections generally require catheter removal. At our center, we typically remove the catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615480750\">",
"    <span class=\"h3\">",
"     Eosinophilic peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic peritonitis may be related to fungal and viral infections, chemical, non-infectious (culture negative), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    -associated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Usually eosinophilic peritonitis is not due a bacterial infection, but must be treated as such until proven otherwise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\", section on 'Laboratory manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach to the treatment of eosinophilic peritonitis varies depending upon the timing of development:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the eosinophilic peritonitis started just after initiating PD or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      or placing the catheter, we obtain routine bacterial and fungal cultures, and treat for two weeks with both gram positive and gram negative coverage (assuming cultures are negative). If the patient looks well after two weeks, we discontinue antibiotics and follow closely, assuming that eosinophilic peritonitis was due to catheter placement or PD initiation, and will resolve spontaneously. However some clinicians withhold antibiotics from patients who appear clinically well.",
"     </li>",
"     <li>",
"      If the eosinophilic peritonitis occurred de novo and there was no obvious preceding event, we initiate broad spectrum antibiotic coverage as if it were an episode of bacterial peritonitis, while at the same time sending fungal cultures. If the eosinophil",
"      <span class=\"nowrap\">",
"       count/WBC",
"      </span>",
"      does not improve, we consider a CT scan, magnetic resonance imaging study,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other imaging study to look for secondary causes and evaluate the",
"      <span class=\"nowrap\">",
"       abdomen/patient",
"      </span>",
"      for additional causes such as vasculitis, fungal peritonitis, and chemical peritonitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cessation of dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more radical approach that has been suggested for treatment of either acute or relapsing peritonitis is to withhold peritoneal dialysis in an attempt to permit restoration of normal host defenses. Some studies have found that administering one dose of antibiotics and stopping peritoneal dialysis for 48 hours was highly effective, resulting in an 85 percent cure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. However, this option is not commonly utilized for multiple reasons: patients must continue to be dialyzed via some modality; such therapy may be inadequate for more severe peritonitis; and anecdotal observations suggest that withholding peritoneal dialysis in patients with severe peritonitis may enhance the risk of peritoneal sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that peritoneal dialysis",
"    <strong>",
"     not",
"    </strong>",
"    be stopped for more than two days among patients with \"active\" peritonitis. A longer period of cessation may be considered in refractory cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Indications for catheter removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of catheter removal in the appropriate setting can be appreciated from a report of the mortality experience of a single center during 636 episodes of peritonitis in 440 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were 16 deaths associated with peritonitis, leading to a fatality rate of 2.5 percent.",
"     </li>",
"     <li>",
"      Peritonitis with sepsis was the cause of death in 13 patients.",
"     </li>",
"     <li>",
"      The catheter was removed between the fifth and the tenth day in six of the patients who died and after 10 days in seven others. The risk of death was increased in those patients with delayed catheter removal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to minimizing mortality, early catheter removal in patients with refractory peritonitis will also avoid prolonged episodes of peritonitis that could damage the peritoneal membrane.",
"   </p>",
"   <p>",
"    The 2010 guidelines for peritoneal dialysis-related infections recommended that the catheter should be removed in the following conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapsing peritonitis &mdash; This is defined as another episode of peritonitis with the same",
"      <span class=\"nowrap\">",
"       genus/species",
"      </span>",
"      that caused the preceding episode of peritonitis within four weeks after completing the course of antibiotics or one sterile episode.",
"     </li>",
"     <li>",
"      Refractory peritonitis &mdash; This is defined by the failure to respond to appropriate antibiotics within five days.",
"     </li>",
"     <li>",
"      Refractory catheter infections (exit site and tunnel infections) &mdash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"       \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fungal peritonitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following effluent cell counts over time in patients with peritonitis may be of prognostic value. In a study of 565 consecutive episodes of peritonitis, effluent cell count &gt;1000 by the third day of peritonitis was associated with a 64 percent likelihood of treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/73\">",
"     73",
"    </a>",
"    ]. The committee also mentioned that consideration should be given to peritoneal dialysis catheter removal in repeat peritonitis, patients with mycobacterial peritonitis, and multiple enteric organisms who are not responding to therapy.",
"   </p>",
"   <p>",
"    Other indications for catheter removal include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fecal peritonitis or other cause of significant intraabdominal pathology",
"     </li>",
"     <li>",
"      Continually relapsing peritonitis with no obvious cause",
"     </li>",
"     <li>",
"      Peritonitis occurring in association with intraabdominal pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mechanical failure that fails to respond to other maneuvers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Simultaneous catheter removal and a new catheter replacement is usually successful for noninfectious indications of catheter removal and also, in some centers, for some infectious indications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. The committee suggested that this can be done for relapsing peritonitis, if the effluent can first be cleared [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/12\">",
"     12",
"    </a>",
"    ]. By comparison, it was emphasized that simultaneous catheter replacement is not possible for refractory peritonitis and fungal peritonitis. In this setting, a minimum period of three to four weeks is recommended between the time of catheter removal and placement of a new catheter.",
"   </p>",
"   <p>",
"    Limited data exist concerning success with the technique after peritoneal dialysis catheter reinsertion because of catheter removal for severe peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/77\">",
"     77",
"    </a>",
"    ]. Reported success rates range from 30 to 55 percent at follow-up of 20 to 24 months, with overall mortality of 19 to 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/11/17594/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Technique failure was most common in those with increased dialysis vintage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15501152\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritonitis is a major complication of peritoneal dialysis (PD) and is the primary reason why patients switch from PD to hemodialysis (HD). The majority of peritonitis cases are caused by pathogenic bacteria, with a small number of cases being caused by fungi, mostly Candida species. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Historically, coagulase-negative staphylococci were the most common cause of peritonitis in CAPD, presumably due to touch contamination or infection via the pericatheter route. The use of Y systems (or flush before fill) has reduced the incidence of coagulase-negative staphylococcal peritonitis with a relative increase in the incidence of peritonitis due to S. aureus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Gram positive peritonitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gram negative peritonitis can be produced by a variety of organisms from the bowel, skin, urinary tract, contaminated water, and animal contact. The outcome of gram-negative, non-pseudomonas peritonitis has similarly poor outcomes as S. aureus peritonitis. Pseudomonas infections, in particular, are often difficult to eradicate, are associated with catheter infection, and, in severe cases, may result in damage to the peritoneal membrane. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Gram negative, non-pseudomonas peritonitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pseudomonas peritonitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of peritonitis episodes resolve with outpatient antibiotic treatment alone. Overall cure rates are approximately 75 percent. The principal approach to the management of peritonitis in peritoneal dialysis relies upon appropriate antimicrobial therapy. Additional therapies may include fibrinolytic agents, peritoneal lavage, and catheter removal. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment and recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With multiple enteric organisms or mixed",
"      <span class=\"nowrap\">",
"       gram-negative/gram-positive",
"      </span>",
"      organisms, one must consider intra-abdominal disease, such as ischemic bowel or diverticular disease, and a surgical consultation should be obtained. With multiple Gram positive organisms, a contamination or catheter infection is most likely. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Polymicrobial peritonitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With culture negative peritonitis, a repeat cell count and differential and culture should be obtained after day three with no growth. If the repeat cell count points toward an unresolved infection, special culture techniques should be used to isolate unusual causes of peritonitis, such as fungi and mycoplasma. If there is clinical improvement with empiric therapy, the initial therapy is continued. If there is inadequate improvement at five days, catheter removal should be strongly considered. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Culture negative peritonitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catheter removal should also be considered in patients with relapsing, refractory, fungal or mycobacterial peritonitis; in patients who are not responding to therapy; and in the setting of fecal peritonitis, or associated intraabdominal pathology. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Indications for catheter removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients who have had the PD catheter removed due to refractory or fungal peritonitis, a new catheter may be placed after three to four weeks of antimicrobial treatment. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Indications for catheter removal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/1\">",
"      Holley, HL, Piraino, BM. Complications of peritoneal dialysis: Diagnosis and management. Semin Dial 1990; 3:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/2\">",
"      Stablein DM, Nolph KD, Lindblad AS. Timing and characteristics of multiple peritonitis episodes: a report of the National CAPD Registry. Am J Kidney Dis 1989; 14:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/3\">",
"      Guo, A, Mujais, S. Patient and technique survival for patients on PD in the US. In large national cohorts. Kidney Int 2003; 64:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/4\">",
"      Struijk DG, van Ketel RJ, Krediet RT, et al. Viral peritonitis in a continuous ambulatory peritoneal dialysis patient. Nephron 1986; 44:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/5\">",
"      Lewis SL. Recurrent peritonitis: evidence for possible viral etiology. Am J Kidney Dis 1991; 17:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/6\">",
"      Goodship TH, Heaton A, Rodger RS, et al. Factors affecting development of peritonitis in continuous ambulatory peritoneal dialysis. Br Med J (Clin Res Ed) 1984; 289:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/7\">",
"      P&eacute;rez Fontan M, Rodr&iacute;guez-Carmona A, Garc&iacute;a-Naveiro R, et al. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2005; 25:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/8\">",
"      Bunke CM, Brier ME, Golper TA. Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study. Kidney Int 1997; 52:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/9\">",
"      Mujais, S. Microbiology and outcomes of peritonitis in North America. Kidney Int 2006; 70:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/10\">",
"      Boudville N, Kemp A, Clayton P, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol 2012; 23:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/11\">",
"      Piraino B, Bernardini J, Brown E, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 2011; 31:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/12\">",
"      Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/13\">",
"      Port FK, Held PJ, Nolph KD, et al. Risk of peritonitis and technique failure by CAPD connection technique: a national study. Kidney Int 1992; 42:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/14\">",
"      Kim DK, Yoo TH, Ryu DR, et al. Changes in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center's experience over one decade. Perit Dial Int 2004; 24:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/15\">",
"      Oo TN, Roberts TL, Collins AJ. A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis 2005; 45:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/16\">",
"      Kan GW, Thomas MA, Heath CH. A 12-month review of peritoneal dialysis-related peritonitis in Western Australia: is empiric vancomycin still indicated for some patients? Perit Dial Int 2003; 23:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/17\">",
"      Kavanagh D, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999-2002). Nephrol Dial Transplant 2004; 19:2584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/18\">",
"      Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30:393.",
"     </a>",
"    </li>",
"    <li>",
"     Vas, SI. Peritonitis. In: Peritoneal Dialysis, 3rd ed, Nolph, KD (Eds), Kluwer Academic Publishers, Dordrecht 1989. p.261.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/20\">",
"      Gregory MC, Duffy DP. Toxic shock following staphylococcal peritonitis. Clin Nephrol 1983; 20:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/21\">",
"      Luzar MA, Coles GA, Faller B, et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990; 322:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/22\">",
"      Burkart JM, Hylander B, Durnell-Figel T, Roberts D. Comparison of peritonitis rates during long-term use of standard spike versus Ultraset in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1990; 10:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/23\">",
"      Gr&uuml;tzmacher P, Tsobanelis T, Bruns M, et al. Decrease in peritonitis rate by integrated disconnect system in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13 Suppl 2:S326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/24\">",
"      Borra SI, Chandarana J, Kleinfeld M. Fatal peritonitis due to group B beta-hemolytic streptococcus in a patient receiving chronic ambulatory peritoneal dialysis. Am J Kidney Dis 1992; 19:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/25\">",
"      Wood CJ, Fleming V, Turnidge J, et al. Campylobacter peritonitis in continuous ambulatory peritoneal dialysis: report of eight cases and a review of the literature. Am J Kidney Dis 1992; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/26\">",
"      Holley JL, Bernardini J, Piraino B. Polymicrobial peritonitis in patients on continuous peritoneal dialysis. Am J Kidney Dis 1992; 19:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/27\">",
"      Vassa N, Nolph KD, Khanna R. Pseudomonas peritonitis with white blood cell capillary margination and distal digital necrosis in a patient on CAPD. Perit Dial Int 1992; 12:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/28\">",
"      Piraino B, Bernardini J, Florio T, Fried L. Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients. Perit Dial Int 2003; 23:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/29\">",
"      Millikin SP, Matzke GR, Keane WF. Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1991; 11:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/30\">",
"      Lam MF, Tang SC, Lai KN. Tuberculous peritonitis in patients on continuous ambulatory peritoneal dialysis. Int J Artif Organs 2000; 23:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/31\">",
"      Lui SL, Tang S, Li FK, et al. Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2001; 38:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/32\">",
"      Lui SL, Lo CY, Choy BY, et al. Optimal treatment and long-term outcome of tuberculous peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 28:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/33\">",
"      Obst G, Gagnon RF, Harris A, et al. The activity of rifampin and analogs against Staphylococcus epidermidis biofilms in a CAPD environment model. Am J Nephrol 1989; 9:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/34\">",
"      Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother 1990; 34:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/35\">",
"      Dasgupta MK, Costerton JW. Significance of biofilm-adherent bacterial microcolonies on Tenckhoff catheters of CAPD patients. Blood Purif 1989; 7:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/36\">",
"      Wiggins KJ, Johnson DW, Craig JC, Strippoli GF. Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials. Am J Kidney Dis 2007; 50:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/37\">",
"      Keane WF, Alexander SR, Bailie GR, et al. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 1996; 16:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/38\">",
"      Keane WF, Bailie GR, Boeschoten E, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 2000; 20:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/39\">",
"      Troidle L, Gorban-Brennan N, Kliger A, Finkelstein FO. Continuous peritoneal dialysis-associated peritonitis: a review and current concepts. Semin Dial 2003; 16:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/40\">",
"      Voinescu CG, Khanna R. Peritonitis in peritoneal dialysis. Int J Artif Organs 2002; 25:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/41\">",
"      Vlaanderen K, Bos HJ, de Fijter CW, et al. Short dwell times reduce the local defence mechanism of chronic peritoneal dialysis patients. Nephron 1991; 57:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/42\">",
"      Teitelbaum I. Vancomycin for the initial therapy of peritonitis: don't throw out the baby with the bathwater. Perit Dial Int 2001; 21:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/43\">",
"      Lye WC. Empirical treatment of CAPD peritonitis: to each his own? Perit Dial Int 2004; 24:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/44\">",
"      Van Biesen W, Vanholder R, Vogelaers D, et al. The need for a center-tailored treatment protocol for peritonitis. Perit Dial Int 1998; 18:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/45\">",
"      Lima RC, Barreira A, Cardoso FL, et al. Ciprofloxacin and cefazolin as a combination for empirical initial therapy of peritoneal dialysis-related peritonitis: five-year follow-up. Perit Dial Int 2007; 27:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/46\">",
"      Font&aacute;n MP, Cambre HD, Rodr&iacute;guez-Carmona A, et al. Treatment of peritoneal dialysis-related peritonitis with ciprofloxacin monotherapy: clinical outcomes and bacterial susceptibility over two decades. Perit Dial Int 2009; 29:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/47\">",
"      Baker RJ, Senior H, Clemenger M, Brown EA. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/48\">",
"      Leung CB, Szeto CC, Chow KM, et al. Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis--a randomized controlled trial. Perit Dial Int 2004; 24:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/49\">",
"      Lui SL, Cheng SW, Ng F, et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function. Kidney Int 2005; 68:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/50\">",
"      Wong KM, Chan YH, Cheung CY, et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis 2001; 38:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/51\">",
"      Goffin E, Herbiet L, Pouthier D, et al. Vancomycin and ciprofloxacin: systemic antibiotic administration for peritoneal dialysis-associated peritonitis. Perit Dial Int 2004; 24:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/52\">",
"      Szeto CC, Kwan BC, Chow KM, et al. Coagulase negative staphylococcal peritonitis in peritoneal dialysis patients: review of 232 consecutive cases. Clin J Am Soc Nephrol 2008; 3:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/53\">",
"      Szeto CC, Chow KM, Kwan BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases. Clin J Am Soc Nephrol 2007; 2:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/54\">",
"      Siva B, Hawley CM, McDonald SP, et al. Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases. Clin J Am Soc Nephrol 2009; 4:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/55\">",
"      Booranalertpaisarn V, Eiam-Ong S, Wittayalertpanya S, et al. Pharmacokinetics of ceftazidime in CAPD-related peritonitis. Perit Dial Int 2003; 23:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/56\">",
"      Szeto CC, Chow VC, Chow KM, et al. Enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases. Kidney Int 2006; 69:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/57\">",
"      Jain AK, Blake PG. Non-Pseudomonas Gram-negative peritonitis. Kidney Int 2006; 69:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/58\">",
"      Yip T, Tse KC, Lam MF, et al. Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients. Perit Dial Int 2006; 26:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/59\">",
"      Kern EO, Newman LN, Cacho CP, et al. Abdominal catastrophe revisited: the risk and outcome of enteric peritoneal contamination. Perit Dial Int 2002; 22:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/60\">",
"      Seow YY, Iles-Smith H, Hirst H, Gokal R. Icodextrin-associated peritonitis among CAPD patients. Nephrol Dial Transplant 2003; 18:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/61\">",
"      Borr&agrave;s M, Martin M, Fern&aacute;ndez E. Sterile peritonitis outbreak related to icodextrin treatment. Perit Dial Int 2004; 24:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/62\">",
"      Mangram AJ, Archibald LK, Hupert M, et al. Outbreak of sterile peritonitis among continuous cycling peritoneal dialysis patients. Kidney Int 1998; 54:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/63\">",
"      MacGinley R, Cooney K, Alexander G, et al. Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution. Am J Kidney Dis 2002; 40:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/64\">",
"      Foggensteiner L, Baylis J, Moss H, Williams P. Timely initiation of dialysis--single-exchange experience in 39 patients starting peritoneal dialysis. Perit Dial Int 2002; 22:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/65\">",
"      Tintillier M, Pochet JM, Christophe JL, et al. Transient sterile chemical peritonitis with icodextrin: clinical presentation, prevalence, and literature review. Perit Dial Int 2002; 22:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/66\">",
"      Tour&eacute; F, Lavaud S, Mohajer M, et al. Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis. Kidney Int 2004; 65:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/67\">",
"      Johnson CA. Intraperitoneal vancomycin administration. Perit Dial Int 1991; 11:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/68\">",
"      Charney DI, Gouge SF. Chemical peritonitis secondary to intraperitoneal vancomycin. Am J Kidney Dis 1991; 17:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/69\">",
"      Cairns HS, Beckett J, Rudge CJ, et al. Treatment of resistant CAPD peritonitis by temporary discontinuation of peritoneal dialysis. Clin Nephrol 1989; 32:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/70\">",
"      Pagniez DC, MacNamara E, Fortin F, et al. Withdrawal of continuous ambulatory peritoneal dialysis to treat mild peritonitis. BMJ 1988; 297:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/71\">",
"      Burkart, JM. Short, long, or no dwells for PD-associated peritonitis? Semin Dial 1998; 11:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/72\">",
"      Digenis GE, Abraham G, Savin E, et al. Peritonitis-related deaths in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1990; 10:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/73\">",
"      Chow KM, Szeto CC, Cheung KK, et al. Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis. Clin J Am Soc Nephrol 2006; 1:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/74\">",
"      Piraino B. Peritonitis as a complication of peritoneal dialysis. J Am Soc Nephrol 1998; 9:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/75\">",
"      Majkowski NL, Mendley SR. Simultaneous removal and replacement of infected peritoneal dialysis catheters. Am J Kidney Dis 1997; 29:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/76\">",
"      Swartz R, Messana J, Reynolds J, Ranjit U. Simultaneous catheter replacement and removal in refractory peritoneal dialysis infections. Kidney Int 1991; 40:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/77\">",
"      P&eacute;rez-Font&aacute;n M, Rodr&iacute;guez-Carmona A. Peritoneal catheter removal for severe peritonitis: landscape after a lost battle. Perit Dial Int 2007; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/78\">",
"      Cox SD, Walsh SB, Yaqoob MM, Fan SL. Predictors of survival and technique success after reinsertion of peritoneal dialysis catheter following severe peritonitis. Perit Dial Int 2007; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/11/17594/abstract/79\">",
"      Szeto CC, Chow KM, Wong TY, et al. Feasibility of resuming peritoneal dialysis after severe peritonitis and Tenckhoff catheter removal. J Am Soc Nephrol 2002; 13:1040.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1882 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-6E39804395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17594=[""].join("\n");
var outline_f17_11_17594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15501152\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gram positive peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gram negative, non-pseudomonas peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pseudomonas peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fungal peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tuberculous peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biofilms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General non-antimicrobial considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Empiric initial therapy for peritonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gram stain reveals yeast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intermittent or continuous intraperitoneal dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management once culture results and sensitivity are obtained",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Coagulase-negative staphylococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Streptococcus and enterococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pseudomonas aeruginosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other single gram-negative organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Polymicrobial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Culture negative peritonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Fungal peritonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Mycobacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H615480750\">",
"      - Eosinophilic peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cessation of dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Indications for catheter removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15501152\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1882\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1882|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/44/29389\" title=\"table 1\">",
"      IP ABX continuous dosing2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/7/23677\" title=\"table 2\">",
"      IP ABX intermittent dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/5/17499\" title=\"table 3\">",
"      Intermittent IP dosing in APD 2010",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=related_link\">",
"      Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=related_link\">",
"      Epidemiology, prevention and control of vancomycin-resistant enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=related_link\">",
"      Fungal peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36601?source=related_link\">",
"      Medical management of the dialysis patient undergoing surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26248?source=related_link\">",
"      Pathophysiology and prevention of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=related_link\">",
"      Rapid transporters on maintenance peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=related_link\">",
"      Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_11_17595="Drugs that cause uricosuria";
var content_f17_11_17595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs which increase uric acid excretion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Acetohexamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azauridine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorprothixene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dicumarol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Estrogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fenofibrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glyceryl guiacolate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iopanoic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Losartan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meglumine iodipamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pegloticase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylbutazone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probenecid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylates (high doses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium diatrizoate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfinpyrazone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17595=[""].join("\n");
var outline_f17_11_17595=null;
var title_f17_11_17596="Discussing contraception with adolescents";
var content_f17_11_17596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F85698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F85698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Specific tips for counseling adolescents about contraception",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Counseling",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific examples",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tips",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Assessing pregnancy intention or ambivalence",
"       </td>",
"       <td>",
"        <p>",
"         \"What are your thoughts on pregnancy or delaying pregnancy?\"",
"        </p>",
"        <p>",
"         \"At present, in the next couple years, and long-term?\"",
"        </p>",
"        <p>",
"         \"If you were to be pregnant, would that be a good thing or a problem for you?\"",
"        </p>",
"        \"Are you interested starting or continuing birth control?\"",
"       </td>",
"       <td>",
"        <p>",
"         Avoid assuming all adolescents want to contracept",
"        </p>",
"        Adherence failures may indicate ambivalence or an unstated desire to become pregnant",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Assessing birth control methods and options",
"       </td>",
"       <td>",
"        <p>",
"         \"What birth control do you use now?\"",
"        </p>",
"        <p>",
"         \"What kind of birth control does your partner use?\"",
"        </p>",
"        <p>",
"         \"What birth control have you tried or used in the past?\"",
"        </p>",
"        <p>",
"         \"What did you like or not like about that birth control method(s)?\"",
"        </p>",
"        \"Was your method(s) easy to do or take?\"",
"       </td>",
"       <td>",
"        <p>",
"         Don't forget to include boys and men in discussions about pregnancy planning and contraception",
"        </p>",
"        <p>",
"         Women who decline birth control or who are condom only users should be offered Plan B and prenatal multivitamins (This includes young women who have sex with women)",
"        </p>",
"        Consider long-acting reversible contraceptives (intrauterine devices and progestin implants) for superior effectiveness and ease of use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assessing side effects, concerns, and next steps",
"       </td>",
"       <td>",
"        <p>",
"         \"Did you have any problems keeping up with your method?\"",
"        </p>",
"        <p>",
"         \"Did you have any side effects that made you concerned?\"",
"        </p>",
"        \"If you want to try method X, we can always reassess how this is working for you in Y weeks or months.\"",
"       </td>",
"       <td>",
"        <p>",
"         Thorough counseling and education about normal and abnormal side-effects up front may help patients continue on their method",
"        </p>",
"        Encourage patients to call or return to clinic with questions or concerns, rather than just discontinuing a method",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17596=[""].join("\n");
var outline_f17_11_17596=null;
var title_f17_11_17597="Imaging guidelines for newly diagnosed osteosarcoma";
var content_f17_11_17597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for imaging of osteosarcoma from the Children's Oncology Group (all imaging studies are required unless otherwise noted)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        At presentation and prior to surgery/local control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Site",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary and bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary tumor",
"       </td>",
"       <td class=\"indent1\">",
"        MRI with gadolinium (presurgery exam should be performed within four weeks of surgery)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        MRI with gadolinium or CT scan with contrast (recommended for possible bone metastases if diagnosis uncertain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest",
"       </td>",
"       <td class=\"indent1\">",
"        CT; AP and lateral radiographs (recommended at presentation only)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole body",
"       </td>",
"       <td class=\"indent1\">",
"        Technetium bone scintigraphy (with SPECT recommended) and/or FDG-PET",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Baseline after surgery/local control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Site",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Testing and timing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary and bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs within two weeks of surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary tumor",
"       </td>",
"       <td class=\"indent1\">",
"        MRI with gadolinium or CT scan with IV contrast (in patients without significant metallic artifact at primary tumor site) three or four months after local control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        MRI with gadolinium or CT scan with contrast (recommended for possible bone metastases if diagnosis uncertain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Surveillance on chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Site",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Testing and timing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Primary and bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs after three cycles (approximately halfway through postoperative chemotherapy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MRI with gadolinium or CT scan with IV contrast recommended if symptoms or abnormal imaging (and surgical or other intervention contemplated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest",
"       </td>",
"       <td class=\"indent1\">",
"        CT after four cycles (approximately halfway through postoperative chemotherapy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole body",
"       </td>",
"       <td class=\"indent1\">",
"        Technetium bone scintigraphy (add SPECT of lungs if pulmonary metastases suspected) or FDG-PET (if disease positive on prior FDG-PET) at the end of cytotoxic chemotherapy, sooner if symptoms or abnormal imaging (and surgical or other intervention contemplated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Surveillance postchemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Site",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Testing and timing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Primary and bone metastases",
"       </td>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs every three months x 8, then every six months x 6, then every 12 months x 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MRI with gadolinium or CT scan with IV contrast recommended if symptoms or abnormal imaging (and surgical or other intervention contemplated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Chest",
"       </td>",
"       <td class=\"indent1\">",
"        CT every three months x 8, then every six months x 2, then every 12 months x 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AP and lateral radiographs every 12 months x 5 (starting after last scheduled chest CT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole body",
"       </td>",
"       <td class=\"indent1\">",
"        Technetium bone scintigraphy or FDG-PET (if disease positive on prior FDG-PET) if symptoms or abnormal imaging (and surgical or other intervention contemplated)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AP: anterior-posterior; CT: computed tomography scan; FDG-PET: fluorodeoxyglucose positron emission tomography; MRI: magnetic resonance imaging; SPECT: single-photon emission computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Meyer JS, Nadel HR, Marina N, et al. Pediatr Blood Cancer 2008; 51:63.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17597=[""].join("\n");
var outline_f17_11_17597=null;
var title_f17_11_17598="Outcome liver TPL in HDV";
var content_f17_11_17598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Higher survival after liver transplantation with hepatitis D virus than hepatitis B virus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 391px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actuarial survival according to initial type of hepatitis in a large cohort of European patients undergoing liver transplantation. Survival was better in patients with cirrhosis infected with HDV (top curve) than with HBV (bottom curve).",
"    <div class=\"footnotes\">",
"     HDV-C, HDV-related cirrhosis; F-HBV, fulminant HBV; F-HDV, fulminant HDV; HBV-C, HBV-related cirrhosis.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Samuel, D, Muller, Alexander, G, et al, N Engl J Med 1993; 329:1842.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17598=[""].join("\n");
var outline_f17_11_17598=null;
var title_f17_11_17599="RPGN IF Fibrin";
var content_f17_11_17599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence microscopy showing fibrin deposition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy showing intense deposition (bright areas in the upper right portion of the glomerulus) of fibrin within a circumferential crescent surrounding the glomerular tuft in any form of crescentic or rapidly progressive glomerulonephritis, including that due to anti-GBM antibody disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_11_17599=[""].join("\n");
var outline_f17_11_17599=null;
